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ABSTRACT 
Giridhar Murlidharan: Biology of AAV vectors in the central nervous system 
(Under the direction of Aravind Asokan) 
 Adeno-Associated Viruses (AAV) have emerged as the vector platform of choice 
for therapeutic gene transfer towards multiple genetic disorders with neurological 
manifestations. My doctoral thesis was focused on a) evaluating CNS spread, 
transduction profiles, receptor interactions and clearance; and b) understanding the 
physiological and biochemical checkpoints governing AAV biologics in the CNS. In our 
first study, we engineered an AAV4 variant (AAV4.18) that shows expanded tropism 
from ependymal cells to migrating progenitors in the developing brain. AAV4.18 
revealed a striking shift in glycan engagement from 2,3-linked Sialic acid (SA) to 2,8-
linked Polysialic acid (PSA). PSA is an important biomarker of neurogenesis. We also 
report opposing roles of SA and PSA on CNS transduction of AAV4. Overall, 
carbohydrate content can be exploited to regulate viral tropism in the brain. We then 
evaluated a lab-derived chimeric AAV2g9, developed through rational vector design. 
Direct brain injections of AAV2g9 resulted in widespread neuronal transduction with 
reduced glial tropism. As compared to AAV9, AAV2g9 displayed minimal systemic 
leakage and off-target gene expression within peripheral organs. We utilized AAV2g9 
for brain-specific deletion of ubiquitously expressed MIR137 schizophrenia risk gene 
using CRISPR/Cas9 technology. Our approach exemplifies control over AAV tropism at 
both cellular and organ levels to potentially improve vector safety. Lastly, AAV mediated 
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CNS gene therapy requires a deeper understanding of factors affecting transduction 
efficiency and clearance. Dysfunction in aquaporin-4 (AQP4) mediated CSF flux during 
aging or disease is correlated with ineffective solute clearance from the brain. Aged 
mice showed mislocalized AQP4 expression and increased AAV9 deposition following 
intraCSF administration. We further compared wildtype (WT) and AQP4 knockout 
(AQP4-/-) mouse CNS. Minutes after intraCSF administration, AQP4-/- mice exhibited 
highly restricted spread of fluorophore labeled AAV9. Transgene expression was 
markedly increased 2 weeks post AAV9 administrations in AQP4-/- mice. Further, 
AQP4-/- mice showed markedly reduced AAV biodistribution and transgene expression 
in peripheral organs. This suggests that AQP4-deregulation affects CNS spread, 
transduction efficiency and systemic leakage of AAV vectors. We hypothesize that 
altered CSF flux under conditions of aging, CNS disease or injury can impact AAV 
residence time and gene transfer efficiency. 
  
v 
 
To my parents Mr. S. Murlidharan and Mrs. Jaya Murlidharan 
& 
My fiancé Suguna Jairam  
vi 
 
ACKNOWLEDGEMENTS 
 
Coming from an engineering background, I have always been drawn to devising 
elegant solutions for problems. To this end, the spectrum of scientific questions being 
asked and the bandwidth of studies being conducted at the Asokan lab immediately 
resonated with my research interests. As a PhD advisor, Dr. Aravind Asokan offered the 
right mix of effective mentorship and friendly approachability to his students. One of 
Aravind’s key attributes is his ability to inculcate a sense of ownership in his team of 
researchers, for their work. His commitment to train students on conducting day-to-day 
experiments while keeping the big picture in sight at all times, is truly commendable. In 
addition to constantly providing direction to my research, Aravind was very patient and 
equipped me with the skills I required to showcase my findings and connect with various 
audiences. Overall, having known Aravind as his PhD mentee and as a friend, I will 
always try to emulate his scientific perseverance and his ability to think objectively at all 
times. Lastly, I am grateful to him for offering me a position in his lab and advising me 
on issues related to work and life; and his family for treating me, Suguna and Khushi as 
one of their own. 
My special thanks to my thesis committee members Dr. Mark Heise, Dr. Jian Liu, 
Dr. Garret Stuber, Dr. Richard Jude Samulski, Dr. Juan Song and Aravind. Their 
expertise and knowledge in the fields of virology, glycobiology, neuroscience, and gene 
vii 
therapy have enabled me to complete a comprehensive body of research work and 
publish my findings in a timely fashion. I specifically want to thank them for taking time 
off their busy schedules for ensuring my progress during my committee meetings. Their 
ability to critically analyze my experimental findings, to applaud the positives and 
criticize the shortcomings has shaped me into a thorough scientist. They ensured that I 
achieve the important milestones along the way of completion of my PhD. My heartfelt 
thanks to all of them.  
I would also like to thank the curriculum in Genetics and Molecular Biology, our 
program director Dr. Jeff Sekelsky and administrative coordinators John Cornett and 
Cara Marlow for helping me fulfill all the graduate school requirements and ensuring 
smooth completion of my PhD training. 
Growing up, my dad once said achievements are only as valuable as the struggle 
and sacrifice they demand. Coming from a family of academicians on both my parents’ 
sides, I was exposed to hard work, patience and a curiosity to learn from very early on. 
Some of the most vivid memories of my childhood include listening to my mother give 
Indian classical music lessons to kids from the neighborhood, against the backdrop of a 
constant clamor from my dad’s old Remington typing machine, as he wrote articles for 
his weekly columns in newspapers. I truly believe that good parenting by way of setting 
examples goes a long way in one’s life. My parents always strived to put my happiness 
before anything else, and I am deeply grateful to them. What I am today is thanks to the 
efforts and love of my mom and dad. 
I met my fiancé Suguna Jairam during the first year of undergraduate college in 
Tamilnadu, India. She is the love of my life, a constant source of inspiration and an 
viii 
unfaltering support system. As I complete this chapter in my life and embark on a new 
journey, I consider myself lucky to have her by my side.  
While I was undergoing my PhD training here at UNC, Suguna was pursuing 
hers at University of Florida. During one of my visits to Florida in the 4th year of my PhD, 
our friends Sherry and Corky introduced us to a beautiful one month old beagle-mix 
from their pet rescue. Suguna and I did not have to think twice before we decided to 
bring her into our life. Small wonder, bringing ‘Khushi’ home also brought us the most 
happiness. The final stretch of graduate school work was made easy knowing that at 
the end of the day, when I go back home, the happiest being on earth was waiting to 
greet me, every single day.  
The collaborative atmosphere at Asokan lab truly helped cultivate a sense of 
positivity and maximized my productivity. When I joined the Lab, Shen Shen, Nagesh 
Pulicherla and Eric Horowitz were extremely helpful and open to sharing ideas, 
reagents, protocols and techniques. This enabled me to get a head start with my 
various projects and I am really thankful for their gesture. As a junior graduate student 
in lab, I watched Shen successfully cross hurdles, present her findings at scientific 
meetings, publish manuscripts and finally defend her PhD work. The experience was 
both rewarding and a great learning opportunity overall. I would like to specifically thank 
Shen for her friendly and approachable demeanor. 
I am very thankful to other graduate students that overlapped with me during my 
time at Asokan Lab-Erin, Garret, Blake, Vicky, Patrick and Rita have been instrumental 
in keeping the atmosphere at work happy and life outside lab fun! A special mention to 
ix 
Erin and Garret who joined the PhD program along with me in 2011. It has been a 
pleasure making these great friends and grow as a scientist alongside them! 
The postdoctoral scholars Ruth, Sven and Victor have been extremely helpful in 
sharing their knowledge and providing constructive criticisms while I wrote manuscripts 
and designed experiments. Special thanks to Victor for keeping everyone around him 
laughing all the time (one of the funniest people I know); Sven and Cheryl for organizing 
the best movie/game nights at their home; and Ruth for bringing her kids to work from 
time to time! It was wonderful working with these people. 
I would also like to thank the extremely talented set of past and present postbac 
and undergraduate researchers I have had the pleasure of working with over the years- 
Andrew, Sarah, Leo, Joey, Ryan, Sebastian, Lavanya, Travis, Michael, Danny, Rob, 
Dasean, Kelly, Kelsey, Julianne and Becca. A special shout-out to Travis, Lavanya and 
Danny for helping me with animal experiments which were instrumental in completion of 
my manuscripts.  
Lastly, my heartfelt thanks to our director of research, Tara Britt, our lab mom! 
For ensuring everyone’s wellbeing and constantly bringing us amazing food! And to my 
friends and family back home in India and the huge family of friends that I have made in 
the US, for all their love and support. 
I have always aspired to see ‘PhD’ written next to my name. In addition to the 
sense of achievement for this cherished goal, I will leave Asokan lab with some of the 
happiest memories, great friends, and a promise to keep visiting as often as I can. 
Giri Murlidharan 
  
x 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES ......................................................................................................... xii 
LIST OF TABLES .......................................................................................................... xiv 
LIST OF ABBREVIATIONS ............................................................................................xv 
CHAPTER 1: INTRODUCTION ....................................................................................... 1 
1.1 Disorders of the Central Nervous System .............................................................. 1 
1.2 Therapeutic Approaches to CNS disorders ............................................................ 2 
1.3 Recombinant Adeno-Associated Viral Vectors ....................................................... 3 
1.4 Biology of AAV cell entry and implications for CNS gene transfer ......................... 6 
1.5 Clinical routes of AAV administration for CNS applications .................................... 7 
1.5.1 Direct AAV administration into the CNS .......................................................... 7 
1.5.2 Intravenous AAV administration for CNS Gene Transfer .............................. 11 
1.6 AAV transport within the CNS .............................................................................. 13 
1.7 Gene Therapy of CNS Disorders using Recombinant AAV vectors ..................... 16 
1.7.1 Gene therapy of Movement disorders ........................................................... 16 
1.7.2 Gene therapy of CNS disorders arising from metabolic defects .................... 25 
1.8 Safety aspects of AAV-mediated CNS gene therapy ........................................... 36 
CHAPTER 2: EXPLOITING GLYCAN SIGNATURES TO REGULATE  
ADENO-ASSOCIATED VIRAL TROPISM IN THE DEVELOPING BRAIN .................... 45 
2.1 Overview .............................................................................................................. 45 
xi 
2.2 Introduction .......................................................................................................... 46 
2.3 Materials and Methods ......................................................................................... 48 
2.4 Results ................................................................................................................. 52 
2.5 Discussion ............................................................................................................ 59 
CHAPTER 3: LIMITED SYSTEMIC BURDEN AND BRAIN-SPECIFIC 
 GENE DELETION WITH A NOVEL AAV VECTOR...................................................... 72 
3.1 Overview .............................................................................................................. 72 
3.2 Introduction .......................................................................................................... 73 
3.2 MATERIALS AND METHODS ............................................................................. 77 
3.3 RESULTS AND DISCUSSIONS .......................................................................... 82 
CHAPTER 4: AQUAPORIN 4 REGULATES THE PARAVASCULAR  
CLEARANCE OF AAV VECTORS FROM THE BRAIN .............................................. 109 
4.1 Overview ............................................................................................................ 109 
4.2 Introduction ........................................................................................................ 110 
4.3 Materials and Methods ....................................................................................... 112 
4.4 Results ............................................................................................................... 116 
4.5 Discussion .......................................................................................................... 123 
Chapter 5: SYNOPSIS AND FUTURE DIRECTIONS ................................................. 134 
5.1: The Big Picture.................................................................................................. 134 
5.2: Future Directions ............................................................................................... 137 
REFERENCES ............................................................................................................ 145 
  
xii 
LIST OF FIGURES 
 
Figure 1: Schematic representation of AAV genomes ................................................... 39 
Figure 2: Differential spread of CNS transduction from AAV4 or  
AAV9 vectors packaging TdTomato fluorescent reporter transgene  
in neonatal mouse brain ................................................................................................ 40 
Figure 3: Effects of substrate-specific neuraminidases on AAV4/4.18 
 transduction in vitro ...................................................................................................... 64 
Figure 4: Ependymal transduction in the neonatal mouse brain  
by AAV4 and the AAV4.18 mutant. ............................................................................... 65 
Figure 5: The AAV4.18 mutant exhibits selective tropism for migrating progenitors ..... 66 
Figure 6: AAV4.18 particles show enhanced CNS spread. ........................................... 67 
Figure 7: SA and PSA play opposing roles in AAV4 transduction  
within the neonatal mouse brain. ................................................................................... 68 
Figure 8: Removal of PSA expands AAV4 tropism to mature OB neurons. .................. 69 
Figure 9: The AAV4.18 mutant selectively exploits polysialic acid (PSA)  
to transduce migrating progenitors. ............................................................................... 70 
Figure 10: AAV4.18 selectively transduces migrating progenitors expressing 
polysialyated NCAM and GFAP. ................................................................................... 71 
Figure 11. Comparison of transgene (GFP) expression and cellular  
tropisms displayed by AAV9 and AAV2g9 vectors with a ubiquitous  
promoter after ventricular (ICV) injection. ...................................................................... 94 
Figure 12. Comparison of transgene (GFP) expression and cellular  
tropisms displayed by AAV9 and AAV2g9 vectors with cell type-specific  
promoters after ventricular (ICV) injection. .................................................................... 96 
Figure 13. Quantitative assessment of transduction following ICV  
administration of AAV9 and AAV2g9 vectors. ............................................................... 97 
Figure 14. Heparan sulfate interactions are critical towards preferential  
neuronal transduction by AAV2g9 vectors. ................................................................... 98 
Figure 15. CNS transduction profile of a gal-binding AAV9 mutant  
(W503R) and AAV9 following ventricular (ICV) administration. ..................................... 99 
xiii 
Figure 16. CNS transduction profile and cellular tropisms displayed by  
AAV8 and gal-binding AAV8g9 vectors following ventricular (ICV) injection. .............. 101 
Figure 17. Comparison of transgene (GFP) expression and cellular tropism  
displayed by AAV9 and AAV2g9 vectors following intrathecal infusion. ...................... 103 
Figure 18. Comparison of systemic biodistribution and off-target transgene  
(GFP) expression displayed by ICV/IT injected AAV9 and AAV2g9 vectors. .............. 105 
Figure 19. Comparison of blood circulation/pharmacokinetic profiles AAV9  
and AAV2g9 vectors in adult mice post IT administration. .......................................... 107 
Figure 20. CNS-restricted gene disruption of MIR 137 within Cas9  
transgenic mouse using AAV2g9. ............................................................................... 108 
Figure 21. Comparison of AAV vector accumulation within juvenile  
and aging mouse brains. ............................................................................................. 126 
Figure 22. Aged mice display abnormal AAV accumulation and  
altered AQP4 localization in the brain. ........................................................................ 128 
Figure 23. Comparison of AAV vector spread within wildtype and  
aquaporin-4 knockout mouse CNS. ............................................................................ 129 
Figure 24. Comparison of AAV transduction efficiency following  
intraCSF administration in WT and AQP4-/- mouse brains. ........................................ 130 
Figure 25. Comparison of off-target transduction and biodistribution  
of AAV vectors following intracranial administrations in WT and AQP4-/- mice. ......... 132 
Figure 26. Comparison of AQP4 expression in WT and AQP4-/- mouse brain. .......... 133 
  
xiv 
LIST OF TABLES 
 
Table 1. Capsid-receptor interactions, transduction profiles and  
axonal transport properties of some of the well characterized  
Adeno-associated viral serotypes in the mammalian CNS. ........................................... 41 
Table 2. Clinical gene therapy of some neurological disorders using AAV vectors ....... 42 
  
xv 
LIST OF ABBREVIATIONS 
 
6-OHDA 6-hydroxydopamine 
-syn  alpha-synuclein 
-GUSB -glucuronidase 
AADC  L-amino acid decarboxylase 
AAP  Assembly activating protein 
AAT  Alpha-1 Antitrypsin 
AAV  Adeno-associated virus 
A  Amyloid beta 
AD  Alzheimer’s disease 
ALS  Amyotrophic lateral sclerosis 
AQP4  Aquaporin-4 
BBB  Blood-brain barrier 
BDNF  Brain derived neurotrophic factor 
BMT  Bone marrow transplant 
BrdU  5-bromo-2’-deoxyuridine 
CBA  Chicken beta actin 
CBh  Chicken beta hybrid 
CC  Corpus callosum 
CED  Convection-enhanced delivery 
circRNA Circular RNA 
CMV  Cytomegalovirus 
xvi 
CNS  Central nervous system 
CRISPR Clustered regularly interspaced short palindromic repeats 
CSF  Cerebrospinal fluid 
CT  Cortex 
DA  Dopaminergic 
DAB  Diaminobenzidine 
DCX  Doublecortin 
DMEM Dulbecco’s modified eagle’s medium 
DNA  Deoxyribonucleic acid 
DRG  Dorsal root ganglia 
EDTA  Ethylenediaminetretraacetic acid 
Endo-N Endoneuraminidase-N 
EPO  Human erythropoietin 
ERT  Enzyme replacement therapy 
FBS  Fetal bovine serum 
FITC  Fluorescein isothiocyanate 
GABA  Gamma ()-amino butyric acid 
GAD  Glutamic acid decarboxylase 
GAG  Glycosaminoglycans 
Gal  Galactose 
GAN  Giant axonal neuropathy 
GDNF  Glia derived neurotrophic factor 
GFAP  Glial fibrilary acid protein 
xvii 
GFP  Green fluorescent protein 
GLD  Globoid-cell leukodystrophy 
gRNA  Guide RNA 
GUSB  -glucuronidase 
GWAS Genome-wide association study 
HC  Hippocampus 
HD  Huntington’s disease 
HEK293 Human embryonic kidney 293 
HSPG  Heparan sulfate proteoglycans 
HSV  Herpes simplex virus 
hSYN  Human synapsin 
HTL  Hypothalamus 
ICV  Intracerebroventricular 
ISF  Interstitial fluid 
ISTR  Intrastriatal 
IT  Intrathecal 
ITR  Inverted terminal repeats 
IV  Intravenous 
KSHV  Kaposi’s sarcoma associated herpesvirus 
LINCL  Late infantile neuronal ceroid lipofuscinosis 
LSD  Lysosomal storage disorder 
LV  Lateral ventricle 
MEN  Multiple endocrine neoplasia  
xviii 
miR  MicroRNA 
MPS  Mucopolysacharidoses 
MVM  Minute virus of mice 
MWCO Molecular weight cut-off 
NaGlu  N-acetylglucosaminidase 
NCAM Neural cell adhesion molecule 
NCL  Neuronal ceroid lipofuscinosis 
Neu  Neuraminidase 
NeuN  Neuronal antigen N 
NGF  Nerve growth factor 
NHP  Non-human primate 
NTN  Neurturin 
OB  Olfactory bulb 
ORF  Open reading frame 
P0  Postnatal day 0 
PCR  Polymerase chain reaction 
PD  Parkinson’s disease 
PEI   Polyethylenimine 
PET  Positron emission tomography 
PFA  Paraformaldehyde 
PH3  Phospho-histone H3 
PRV  Pseudorabies virus 
PSA  Polysialic acid 
xix 
QPCR  Quantitative polymerase chain reaction 
RMS  Rostral migratory stream 
ROI  Region of interest 
RT PCR Reverse transcription PCR 
SA  Sialic acid 
SEZ  Subependymal zone 
Sc  Self-Complementary 
SMA  Spinal muscular atrophy 
SNPc  Substantia Nigra Pars Compacta 
ss  Single-Stranded 
STN  Subthalamic nucleus 
TBI  Traumatic brain injury 
TdTom TdTomato 
TH  Tyrosine hydroxylase 
THL  Thalamus 
UTR  Untranslated region 
VM  Ventral mesencephalic 
VP  Viral protein 
VTA  Ventral tegmental area 
 
  1 
 
CHAPTER 1: INTRODUCTION1 
1.1 Disorders of the Central Nervous System 
Mammalian central nervous system (CNS) is a complex and precise connectivity 
of intertwining neurons nourished and supported by glial cells- astrocytes, 
oligodendrocytes, and microglia. Smooth functioning of the CNS is orchestrated by 
excitation and inhibition of neuronal firing/action potential i.e. relay of potential 
difference traveling between the cell body (soma) and its projections at the axonal 
terminus/ni. Neurons are decorated with receptors for neurotransmitters like glutamate 
and gamma ()-amino butyric acid (GABA), which are specifically associated with 
excitatory or inhibitory responses (1).  
While timely excitation and inhibition of regional subpopulations of neurons 
controls motor, behavioral, hormonal, sensory and cognitive outcomes; unregulated 
neuronal activity and selective loss of neuronal or glial subgroups has been associated 
with CNS disorders. Such disorders can arise from drug abuse, injuries, genetic, 
epigenetic and environmental factors. Loss of functionality in affected cell types within 
the brain can often be attributed to defects in single genes. For instance, a range of 
                                            
1This chapter includes original publications that appeared in the journal Frontiers in 
Molecular Neuroscience and the book Translational Neuroscience. Full citations are as 
follows: Murlidharan, G., Samulski, R.J., Asokan, A. Biology of adeno-associated viral 
vectors in the central nervous system, Frontiers in Molecular Neuroscience, 2014, 
89:0076. 
Murlidharan, G, Samulski, R.J., Asokan, A. Gene therapy of CNS disorders using 
recombinant AAV vectors, Translational Neuroscience-Fundamental approaches for 
neurological disorders, 2016 (9-32)  
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neurological disorders arise from the inability of cells in the CNS to break down 
metabolic end products (e.g. lysosomal storage disorders (LSDs)). One such example 
of LSDs with fatal manifestations includes Globoid-cell leukodystrophy (GLD) or Krabbe 
disease in which mutations in galactosylceramidase leads to accumulation of the toxin 
‘psychosine’ in the CNS (2). This disease shows early-onset of symptoms like 
demyelination, astrocyte gliosis etc. and progresses to the death of patients within 2 
years of age (3). Other examples of LSDs include Fabry disease, Gaucher disease, 
GM1/GM2 Gangliosidosis, Mucopolysacharidoses disorders, Pompe disease and 
Neuronal Ceroid Lipofuscinosis amongst others (4, 5).   
 Another major class of neurological disorders manifest themselves as loss of 
motor skills e.g. Parkinson’s disease (6), Huntington’s disease (7), epilepsy (8), 
Tourette’s syndrome (9, 10) and amyotrophic lateral sclerosis (ALS) (11); cognitive skills 
e.g. Alzheimer’s disease (11), and Autism (12); or can rarely even be lethal very early 
on in life e.g. Canavan’s disease (13). A common theme among patients suffering from 
such diseases includes difficulties in performing day to day activities amounting to 
exceptional loss in quality of life; disruption of social life; heavy financial burden of 
treatment; and in most cases, absence of curative options. 
 
1.2 Therapeutic Approaches to CNS disorders 
To ameliorate such disease phenotypes, tremendous effort has been directed 
towards pharmacological regulation of events such as neurotransmitter signaling e.g. by 
synthesizing receptor agonists/manipulating receptor domains by genetic 
reprogramming etc. (14). Although successful reversal of pathology is not common, 
  3 
such interventions often provide symptomatic relief for short periods of time and are 
therefore approved for clinical use. Unfortunately, side-effects of pharmacological 
agents; irreversible nature of most genetic alterations; restricted ability of CNS cells to 
replenish themselves; and complicated clinical procedures make CNS disease therapy 
an exceptionally difficult endeavor.  
Gene therapy is being utilized for treating severely debilitating diseases by 
delivering healthy cargo of genetic information to afflicted cell/tissue types. Within the 
CNS, replenishment of biomolecules that are depleted as a result of disease (e.g. 
catabolic enzymes); protection of neurons and glia from premature death; and even 
utilization of cells as bio-factories for production of neurotransmitters and their biological 
co-factors have been demonstrated using gene therapy. Viral vector mediated gene 
therapy offers the ability to perform efficient in vivo gene transfer of therapeutic 
transgenes directed to the CNS. In particular, Adeno-Associated Viruses (AAV) have 
emerged as promising tools for clinical gene transfer in a broad range of genetic 
disorders with neurological manifestations (15). Throughout this chapter, I have 
attempted to bridge the current understanding of the biology of different AAVs with their 
properties such as transduction efficiencies, cellular tropism and transport within the 
CNS. 
 
1.3 Recombinant Adeno-Associated Viral Vectors 
Adeno-associated viruses (AAV) are non-enveloped, helper-dependent 
parvoviruses with an icosahedral capsid architecture ~25 nm in diameter. AAVs 
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package ~4.7 kb genome flanked by ~145 bp inverted terminal repeats (ITRs) on the 5’ 
and 3’ ends (16). The wildtype AAV (wtAAV) genome is a linear single stranded DNA 
consisting of two open reading frames (ORFs). AAV ORFs encode four replication 
proteins (Rep) and three capsid proteins (Cap/VP) and an assembly activating protein 
(AAP) (17). In addition, wtAAV requires co-infection by Adenoviruses or Herpes Simplex 
viruses for successful replication and production of viable AAV particles (16).  
Three advancements have been instrumental in enabling the use of AAV as a 
recombinant vector for gene transfer applications: a) the ability to pseudotype AAV 
vectors by employing AAV capsids of natural or synthetic origin (18-21); b) cloning and 
characterization of adenoviral helper genes that are minimally required for generation of 
infectious AAV particles (22); and c) understanding that inverted terminal repeats (ITRs) 
are the only cis-acting molecular signature for successful packaging of  transgenes 
within an AAV capsids (23). These streamlined components are now used to 
manufacture recombinant AAV (rAAV) vectors packaging a broad spectrum of promoter 
elements and transgene cassettes for different gene transfer applications (24). It is 
noteworthy that due to the aforementioned discoveries, we are now able to manufacture 
AAV vectors with minimal contamination of the wildtype virions. This technology allows 
us to package the transgene of interest into an AAV serotype with desirable properties 
in either single stranded (ss) or self-complementary (sc) configuration (Figure 1). 
Different AAV serotypes exhibit a range of properties pertaining to antigenicity, in 
vivo tropism and receptor interactions based on their capsid structures (17). Capsids of 
different AAV strains bind a spectrum of cell surface glycan receptors and utilize co-
receptors for infection (25). These differences in capsid-receptor interactions play a 
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major role in determining the regional and cellular transduction efficiencies of AAV 
strains across different mammalian organs. Additionally, a recent in vitro genetic screen 
has revealed the type I transmembrane protein, KIAA0319L as an important receptor for 
AAV infection (26). Continued progress in understanding the biology of AAV infection 
over the past two decades has provided the scientific and clinical community with an 
arsenal of AAV strains that offer desirable features for CNS gene transfer (27). In 
addition to natural isolates, several laboratory-derived AAV strains have been 
engineered or evolved for specific CNS gene transfer applications. These efforts have 
yielded novel AAV vectors for targeting a) glioblastoma cells (28); b) rat, mouse and 
human neural stem cells (29); and c) specific regions (piriform cortex and ventral 
hippocampus) of blood-brain barrier (BBB) compromised rats (30).  
In order to showcase differences in CNS transduction profiles of AAV vectors, we 
injected two structurally and functionally distinct strains- AAV4 and AAV9 packaging 
TdTomato (TdTom) fluorescent reporter gene driven by chicken  actin (CBA) promoter 
in the neonatal mouse brain. Intraventricular injections (white arrows, Figure 2) of AAV4 
resulted in TdTom expression (red) close to the site of injection (ependyma) (AAV4-
CBA-TdTom, Figure 2). On the other hand, AAV9 administration resulted in widespread 
TdTom expression across multiple regions of the brain parenchyma (AAV9-CBA-
TdTom, Figure 2). These results suggest that AAV vectors can be utilized to achieve 
either restricted or widespread transgene expression in the CNS. We discuss the 
existing inventory of AAV vectors and their characterization within the CNS later. 
 
  6 
1.4 Biology of AAV cell entry and implications for CNS gene transfer 
Successful transduction by AAV vectors is contingent on many key steps like cell 
surface receptor binding, endocytic uptake, endosomal escape, subsequent nuclear 
entry, capsid uncoating, genome release, second strand synthesis and subsequent 
transcription. Surface exposed regions on the AAV capsids dictate the interactions with 
the host cell surface (25). Cell surface glycans have been identified as the preferred 
primary receptors for many natural AAVs (31). Accordingly, differences in glycan 
architecture have been attributed to variations in the efficiency of gene transfer by AAV 
capsids in different organs. AAV serotypes 1,5 and 6 bind N-linked sialic acid (SA), 
whereas AAV4 is the only natural AAV isolate that binds O-linked SA moieties on 
mammalian cell surfaces (32-34). AAV2, 3 and 6 bind Heparan Sulfate (HS) 
proteoglycans, whereas AAV9 requires N-terminal galactose residues to perform 
successful gene transfer (35-38).  
Direct injection of HS binding AAV2 in the CNS leads to a largely neuronal 
transduction profile, whereas Sialic acid (SA) binding vectors like AAV1 and AAV5 
perform efficient neuronal and some glial transduction (39-41). The preferential 
neuronal tropism of AAV2 was later identified to correlate with the comparatively larger 
availability of Heparan sulfate proteoglycans (HSPGs) on the surface of neurons than 
glia (42, 43). Interestingly, in addition to enabling the neurotropic bias of AAV2, HS 
binding has also been associated with restriction of the CNS volume that is effectively 
targeted by AAV vectors. 
It is now known that the lysine residue at position 531 on AAV6 capsid plays an 
indispensable role in HS binding (44, 45). By creating HS binding and non-binding 
  7 
variants of AAV1 (AAV1E531K) and AAV6 (AAV6K531E) respectively, Arnett and 
colleagues demonstrated antagonistic effect of HS binding on CNS transduction of 
intracranially injected AAVs (46). Supporting these point mutation studies, co-injection 
of safe doses of soluble heparin also led to substantial increase in the CNS transduction 
by AAV2 (47, 48).  
On the other hand, N-terminal galactose binding AAV9 is one of the most 
efficient vectors for CNS gene transfer. AAV9 has been shown to perform extensive 
neuronal and glial transduction from different routes of injection in small and large 
animal models (49-56). In addition to important features on the capsid surfaces, 
efficiency of AAV vector mediated gene transfer can be affected by several post-entry, 
trafficking and genome-related events within the CNS (26). Studies pertaining to some 
of these aspects of AAV biology have been performed within the context of the CNS 
and discussed later. Prior to cell surface binding, the transduction profiles of different 
AAV strains also appear to be affected by the route of CNS administration. These 
aspects are first discussed below.  
 
1.5 Clinical routes of AAV administration for CNS applications 
1.5.1 Direct AAV administration into the CNS 
Direct injections of AAV vectors into the CNS have been used to achieve high 
levels of transgene expression across different animal models (57-60). This strategy of 
AAV vector administration can be broadly classified into intra-cerebrospinal fluid (CSF) 
administration and intra-parenchymal administration. The CSF plays a multi-functional 
role by providing nutrients; molecular and physical cues for important processes like 
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stem cell migration; and removal of interstitial solutes from the brain parenchyma (61, 
62). An extensive characterization of CSF clearance of brain interstitial solutes and its 
effects on intracranially administered AAV biologics can be found in chapter 4 of this 
thesis. The CSF is housed within the subarachnoid space, cerebral ventricles, cisterna 
magna, openings under the cerebellum (foramena), and is in close contact with the 
spinal cord and brain tissue in the rostrocaudal axis (63, 64). Understandably, efficient 
delivery of reporter/therapeutic transgenes to large areas of the CNS has been 
achieved using AAV injections into cerebral ventricles, cisterna magna or intravertebral 
lumbar puncture (65-75).  
Serotypes such as AAV9 and rh.10 exhibit inherently superior ability to spread 
within the brain parenchyma. These vectors have been used to achieve widespread and 
long term expression of corrective transgenes from intra-CSF injections towards 
disease models of spinal muscular atrophy and Krabbe disease (73, 74). On the other 
hand, some AAV vectors exhibit highly cell-specific transduction profiles from intra-CSF 
injections. For instance, intracerebroventricular (ICV) administration of AAV4 leads to 
selective targeting of astrocytes in the ependymal zone surrounding the cerebral 
ventricles (71, 76, 77). The ependyma consists of adult neural stem cells that have the 
ability to perform lifelong migration, differentiation and repopulation of functionally 
defined regions in the brain (78). Due to this natural propensity for ependymal cells, we 
used AAV4 as a platform to engineer a migrating neural progenitor targeting AAV4.18 
vector, as shown in chapter 2. Indeed, targeted delivery of neurogenic cargo, e.g. 
noggin and brain derived neurotrophic factor (BDNF) packaged in AAV4 has shown 
long-term rescue of mouse models of severely debilitating CNS disorders like 
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Huntington’s disease (76, 79). In addition to these in vivo studies, biophysical analysis 
of the AAV4 capsid has revealed distinct structural features and low capsid homology 
among other natural AAV isolates (80, 81). 
Due to the advantages offered by the CSF connectivity of the brain and the 
spinal cord, AAV vector administration has also been extensively characterized through 
intrathecal injections (IT). Traditionally, these injections have been performed by 
exposing the subarachnoid space at the suboccipital cisterna magna region or the 
intravertebral space at lumbar region. In general, applications requiring enhanced 
transduction at the motor, sensory and nociceptive neuronal subpopulations (e.g. within 
dorsal root ganglia (DRG)) utilize lumbar punctures. AAV serotypes 1, 5, 8 and 9 have 
shown extensive transduction in the spinal cord and DRG neurons from IT injections at 
the intravertebral lumbar region (82-84). In an independent study, Snyder and 
colleagues compared IT injections of AAV vectors 1, 6, 8 and 9 for transduction of motor 
neurons in the spinal cord and brain stem, and reported superior transduction properties 
of AAV6 and 9 (85). From studies conducted in large animals like pigs and non-human 
primates (NHPs), a single IT injection of AAV9 has emerged as the candidate procedure 
for clinical correction of motor neuron disorders affecting the different regions of the 
spinal cord (86, 87). As with all these studies, it remains to be seen how vectors 
pseudotyped with these different capsids respond in a human setting and more 
importantly, in manifestations of human brain disease. 
Direct parenchymal injections of AAV vectors in rodents and non-human 
primates have been traditionally used to achieve transduction within, focused, spatio-
functionally distinct regions of the brain (88-90). AAV2 shows minimal ability to spread 
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from the parenchymal site of injection and performs preferential gene transfer in the 
neurons (71). Unlike other capsid-receptor interactions, the high affinity for HSPGs has 
been shown to be detrimental to the spread of AAV2 in the brain parenchyma (48). As 
discussed above, another vector that lacks the ability to spread from the site of 
intracerebral injection is the NHP isolate AAV4 (71). In another study performed in adult 
rats, Burger and colleagues demonstrated that N-linked SA binding AAV1 and AAV5 are 
superior to AAV2 in terms of spread of transduction from a single parenchymal 
microinjection into the hippocampus, substantia nigra, globus pallidus, striatum and 
spinal cord (89). Widespread transgene expression was also achieved by parenchymal 
injections of AAV7, 8 and 9 in rodents (90, 91). On a cellular level, these vectors 
preferentially transduced neurons in the adult rodents from clinically relevant stereotaxic 
injections into the hippocampus, thalamus, cortex and striatum (90). Interestingly, in 
addition to capsid serotype, other parameters like age of the animal also seem to affect 
cellular tropism of AAV vectors from direct brain injections. Using ICV injections of AAVs 
1, 8 and 9, Chakrabarty and colleagues demonstrated, that injections performed on 
postnatal day 0 (P0) leads to preferential neuronal tropism. On the other hand the same 
vectors showed neuronal and astrocytic transduction profiles from injections performed 
on P1 or later (72).  
Against this backdrop of AAV isolates and serotypes that have been extensively 
characterized for their receptor interactions, novel AAV serotypes isolated from human 
beings- AAVhu32, 37, 11, 48R3; and non-human primates- AAVrh.8 and 10 have been 
evaluated in neonatal and adult rodents (55, 92). Preliminary studies have confirmed 
the ability of these vectors to perform transduction comparable to AAV9 in rodents, 
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expanding the AAV vector toolkit for CNS gene transfer. For instance, a recent study 
conducted head to head comparison of AAV 2, 5, 8 and rh.10 for therapeutic delivery of 
functional ‘CLN2’ transgene in a late infantile neuronal ceroid lipofuscinosis (LINCL) 
mouse model. Among different serotypes, AAVrh.10 demonstrated comparatively larger 
spread of transgene expression and restoration of functional levels of the enzyme 
tripeptidyl-peptidase I, originally lost as a result of mutations in the CLN2 gene. 
Improvement in motor activities like gait, balance and grip; and amelioration of seizures 
led to enhanced survival of the treated mice from a single direct brain parenchymal 
injection (93). More recent studies evaluating AAVrh.10 administered through different 
routes in primates have been reviewed in detail in the context of AAV transport within 
the CNS later.  
 
1.5.2 Intravenous AAV administration for CNS Gene Transfer 
Systemic administration of viral vectors has the potential to achieve ubiquitous 
gene transfer of the CNS from a single injection. Additionally, the minimally invasive 
nature of intravenous (IV) injections adds great value to clinical administration of AAV 
vectors via the bloodstream. Two major roadblocks currently impede our ability to utilize 
this technique for therapeutic gene transfer of the CNS. The first major concern is the 
broad biodistribution of AAV vector particles into off-target tissues such as the liver, 
spleen and kidneys during IV administration of AAVs. For instance, IV injections of 
AAV9 achieves exceptional transduction of neurons and glia in rodents and non-human 
primates, but also leads to enrichment of viral genomes (~10 fold or more) in the liver 
and spleen as compared to the brain (94). Careful optimization and use of safe dosages 
of AAV vectors can lead to reduced systemic leakage and associated viral clearance 
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due to neutralizing antibodies (94). Another approach to reduce peripheral organ toxicity 
is the occlusion of blood flow into organs like liver and spleen during IV injections of 
AAVs (95). 
Clearly, the use of such techniques requires meticulous optimization of 
complicated surgical procedures during vector administration before being approved for 
the clinic. However, it should also be noted that several of these techniques are already 
approved for use with other drugs/treatments in the clinical setting. Another important 
problem is the inability of the majority of well-characterized AAV vectors to efficiently 
cross the blood-brain barrier (BBB) and transduce cells within the CNS. In order to 
successfully transduce cells in the CNS, systemically injected virions are thought to 
undergo receptor mediated transcytosis to cross the brain microvasculature. Tight 
junctions in the endothelial cells, astrocytic endfeet and pericytes are collectively 
thought to constitute the BBB (96, 97). Intra-arterial infusion of mannitol leads to 
transient opening of the BBB without eliciting any permanent damage (67). Short-term 
disruption of these checkpoints by administration of mannitol led to effective CNS 
transduction by IV injections of AAV2 which is unable to cross the BBB (67, 98).  
A recent study compared CNS transduction from injections of AAVs 1, 2, 5, 6, 7, 
9, Rh.10, Rh.39 and Rh.43 into the superficial temporal vein of neonatal mice (P1). 
Successful, but differential levels of CNS transduction were reported from all tested 
vectors (except AAVs 2 and 5) (96). Additionally, some leading examples of intravenous 
administration of AAV vectors that have been tested in adult rodents and non-human 
primates include AAVs 8, 9, Rh.8 and Rh.10 (97, 99). These results clearly indicate that 
many AAV serotypes have been associated with a range of cellular and regional CNS 
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gene transfer properties from systemic injections. A better understanding of capsid 
structural motifs that allow certain AAV strains to traverse the blood brain barrier is 
critical. For instance, using directed evolution, Gray and colleagues have engineered 
two AAV capsids capable of crossing seizure compromised-BBB in rats. The original 
library of AAVs from which the candidate capsid was isolated included AAVs 1-6, 8 and 
9. Comparison of the parental and evolved capsid sequences further provided some 
insights into capsid domains possibly involved in CNS transduction after IV 
administration (30). Along similar lines, peptide motifs have been identified that impart 
AAV capsids with the ability to cross the brain microvasculature. IV injection of a peptide 
modified version of the AAV2 packaging glucuronidase was used to achieve 
significant clearance of lysosomal storage burden, leading to cognitive benefits and 
prolonged survival in a mucopolysacharidoses VII mouse model (100). It is noteworthy 
that IV administration of the corrective transgene packaged in AAV9 capsid was unable 
to confer therapeutic benefits. It was later identified using fluorescein labeled Sambucus 
Nigra lectin that enhanced SA depositions in the MPS VII affected mouse CNS might be 
detrimental for AAV9-mediated CNS transduction (100). Such results demonstrate that 
the biology of different AAV strains can be affected by specific disease phenotypes that 
alter the molecular composition(s) of different cell types within the brain.  
 
1.6 AAV transport within the CNS 
Subsequent to vector administration and engagement of cell surface attachment 
factors such as glycans, AAV vectors appear to undergo interstitial as well as 
intracellular transport within the CNS. For instance, recent studies in the primate brain 
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have demonstrated that AAVrh.10 displays distinct transduction patterns following 
different routes of administration (101). Of the five routes tested, delivery to parenchyma 
resulted in more efficient gene transfer than intraventricular or intraarticular routes of 
administration. Another study in marmosets demonstrated that intravenous 
administration of AAVrh.10 is capable of efficient CNS transduction (97). These results 
highlight the potential diversity in AAV vector transport mechanisms not only in the 
context of brain physiology, but also possibly due to vector serotype, receptor usage 
and animal models.  
Although not completely understood, two mechanisms, namely paravascular 
CSF transport and axonal transport appear to play a role in controlling the spread of 
AAV vectors within the CNS. It has been established that the paravascular transport of 
CSF plays a major role in the spread of interstitial fluid (ISF) within the CNS. One of the 
earliest studies demonstrated that proteins accumulate along highly vascularized 
regions of forebrain and brainstem within minutes of ICV injections (102). Further, 
medically induced blood pressure fluctuations have been directly shown to control the 
spread of nanoparticles including AAVs in the brain (103). The brain is distinct from 
other organs in that it lacks lymphatic circulation (104, 105). To understand 
compensatory mechanisms, Iliff and colleagues performed CNS-injections of differently 
sized (between 750 da and 2000 kda) molecular tracers. Using compelling visual 
evidence provided by 2-photon microscopy, the authors concluded that paravascular 
movement of CSF clears solutes from the CNS (62). Specifically, the para-arterial influx 
and the paravenous efflux of subarachnoid CSF drain accumulations of metabolic end 
products and other solutes within the brain parenchyma. These results suggest that 
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mechanisms like the CSF transport can possibly play a role in determining the extent of 
spread of viruses within the CNS. Clearly, understanding the structure-function 
correlates of AAV capsids and host factors that might dictate their ability to spread 
within the CNS will be valuable. 
Another known pathway that viruses utilize to spread within the CNS is axonal 
transport post-entry into host neurons. Viruses can travel long distances by getting 
transported across synaptic connections in various sectors of mammalian central and 
peripheral nervous system (106, 107). Over the years, Herpes simplex virus (HSV) and 
Pseudorabies virus (PRV) have been used to visualize axonal transport and the 
resulting patterns of viral infections in the CNS milieu (108). Although accurate neuronal 
tracing has been achieved using these viruses, a major disadvantage is the loss of gene 
expression and neuronal death observed in the labeled cells between 5 days to 2 weeks 
post infection (109-111). In case of AAVs, both unidirectional and bidirectional axonal 
transport has been observed depending on the viral strain (112, 113). During retrograde 
transport, intact virions are taken up at the axonal projections and are transported to the 
neuronal cell body (soma), where the virus enters the nucleus to carry out transduction. 
Conversely, a successful anterograde transport requires virions to enter the neuronal 
soma and travel along the length of the axon to finally get released at the projections. 
The released virions are then free to transduce new cellular subpopulations in the 
region. 
Understandably, directional axonal transport of AAV can be utilized to achieve 
safe and targeted gene delivery in spatially and functionally distinct neuronal 
subpopulations. For instance, AAV2 specifically undergoes anterograde transport (114, 
  16 
115). On the other hand, AAV6 exhibits exclusive retrograde transport in both rat and 
primate brain (116). In addition, AAV9 has been shown to efficiently travel in both 
anterograde and retrograde directions (117-119). Specifically, Castle and colleagues 
visualized dye-conjugated AAV9 vectors during their anterograde and retrograde 
movements within cultured rat cortical neurons. These studies showed that axonal 
transport of AAV9 occurs in Rab7 positive late endosomal/lysosomal compartments. 
Further, cytoplasmic dynein and kinesin-2 were identified as being critical for successful 
retrograde and anterograde transport, respectively (118, 120).  
The aforementioned strides made in context of AAV biology within in vitro and in 
vivo experimental systems have been instrumental in the field of CNS gene therapy. We 
now focus on therapeutic usage of AAV biologics for CNS disorders. The following 
sections elaborate on the progress made towards AAV mediated therapeutic 
intervention for two major classes of neurological diseases- movement disorders and 
storage disorders. 
 
1.7 Gene Therapy of CNS Disorders using Recombinant AAV vectors 
1.7.1 Gene therapy of Movement disorders 
The timely firing of neurons projecting within corticostriatal, nigrostriatal and 
thalamocortical circuits of the brain orchestrate events leading to motor control. Under 
the umbrella of movement disorders, therapeutic gene transfer using rAAVs has shown 
promise in animal models e.g. Huntington’s disease (HD) and Parkinson’s disease (PD), 
amongst others. For the purpose of this chapter, we will focus on PD and assess the 
use of AAV vectors in understanding and treating the multifactorial CNS disorder.  
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Familial, environmental and idiopathic factors result in selective loss of 
dopaminergic (DA) neurons leading to Parkinsonism (121). PD patients exhibit 
bradykinesia (slow movements), akinesia (no movements) and tremors among other 
symptoms exemplifying disrupted motor function. During normal conditions, DA neurons 
at the basal ganglia (Substantia Nigra Pars Compacta (SNPc) region) send inhibitory 
inputs to the subthalamic nucleus (STN) through enhanced GABA signaling (6). Such 
inhibitory inputs received at the STN are important for the controlled excitation of the 
projections to motor associated regions of the cortex. Detailed descriptions of the 
neuronal subtypes and comprehensive analyses of the circuitry that governs the states 
of normalcy and disease have been reviewed elsewhere (6, 121). On a cellular level, 
PD features loss of DA neurons at the SNPc leading to reduced inhibition of the STN 
causing unregulated inputs reaching motor areas further downstream. Understandably, 
the dysfunction of two major checkpoints i.e. loss of DA neurons/dopamine and 
reduction of GABAergic input to the STN result in disease. Over the years, gene therapy 
research has focused on both of these checkpoints to develop strategies that can 
reverse PD pathology.  
One of the hallmarks of PD is the appearance of aggregated synaptic protein 
alpha-synuclein (-syn) in the surviving dopaminergic neurons (122, 123). Such 
aggregations called ‘Lewy bodies’ are not restricted to PD. A similar phenotype occurs 
in Alzheimer’s disease (AD) where aggregations of the proteins amyloid- and tau 
have been associated with loss of hippocampal neurons resulting in learning and 
memory defects (124). In case of PD, the phosphorylation of the protein -syn at the 
Serine-129 position has been associated with potent disease pathology (125-128). A 
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key mechanistic insight of the association between PD pathology and -syn aggregation 
was provided by the work of Gorbatyuk and colleagues (129). The authors performed 
nigral injections of rats with AAV5 vectors packaging three versions of -syn i.e. wt -
syn, phosphorylated -syn S129A or non-phosphorylated -syn S129D. The enzyme 
TH is a biomarker for DA neurons as it is required for the conversion of L-tyrosine to 
levodopa, a precursor of dopamine (130). The study demonstrated that the AAV 
mediated delivery of S129A mutant was highly toxic to the TH immunopositive (TH+) DA 
neurons resulting in loss of striatal dopamine levels in the brain. Intermediate loss of 
TH+ neurons was also observed due to AAV mediated overexpression of wildtype -
syn. More importantly, the study reported that the unphosphorylated form of -syn 
(S129D) was not toxic to dopaminergic neurons and was incapable of causing PD 
pathology. In summary, this in vivo study utilized AAV vectors to demonstrate that PD 
pathology due to syn aggregation is dependent on its phosphorylation state at the 
S129 position (129).  
The use of AAV vectors to achieve controlled biosynthesis of dopamine in vivo 
has been reported by Li and colleagues (131). Briefly, AAV2 vectors packaging 
dopamine synthesizing enzyme TH, flanked by LoxP loci were generated. In the event 
of Cre-recombination, the transgene expression would be lost, leading to a loss of TH 
gene expression in the transduced neurons. To incorporate temporal control of TH 
expression in their system, the authors packaged 4-hydroxytamoxifen inducible version 
of Cre (CreERTS) into another AAV vector (132). The authors speculated that such AAV 
mediated regulation of TH expression would alter the dopamine levels in both in vitro 
and in vivo settings. Transfection of AAV2 vectors packaging the LoxP flanked-TH 
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transgene led to efficient production of dopamine which was significantly lost after 
subsequent superinfection of AAV2-Cre/CreERTS recombinases in cell culture. This 
confirmed proper functioning of constitutively active and inducible Cre systems in vitro.  
The authors then tested their system in Parkinsonian rats. Specifically, 
neurotoxin 6-hydroxydopamine (6-OHDA) was injected into rat brain to induce lesions in 
the dopaminergic areas of the CNS, generating a Parkinsonian rat model. Such rats 
then received individual/combinations of the above mentioned AAV vectors in the 
striatum and were assessed for biochemical and behavioral outcomes associated with 
PD. Significantly increased dopamine production in the animals that received AAV2 
vectors packaging TH encoding transgene was reported. Subsequent Cre-recombinase 
mediated loss of dopamine production led to significant disruption of motor skills during 
apomorphine-induced rotation tests and spontaneous limb movement tests.  
During low levels of dopamine availability, the compensatory mechanism 
employed by the brain involves conversion of dopamine precursor levodopa into usable 
dopamine using L-amino acid decarboxylase (AADC) enzyme. The Cre-recombinase 
mediated loss of TH expression led to significant reduction of dopamine levels, but did 
not affect the cellular expression of AADC in the rats that received oral levodopa. This 
suggested that the inherent compensatory mechanism of dopamine production is 
unaffected by the AAV treatments. These results demonstrated a system wherein AAV 
gene therapy was used to achieve temporally controlled induction and rescue of PD 
pathology in vivo (131).  
Gene therapy mediated replenishment of the levels of AADC enzyme in the brain 
is a potential strategy to ameliorate PD pathology by way of bolstering the 
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compensatory mechanism for dopamine production. A phase 1 clinical trial reported the 
use of tracer dependent positron emission tomography (PET) to track the spread of 
AADC transgene delivered using AAV2 in 6 PD patients who underwent putaminal 
injections of the vectors (133). The patients were given oral levodopa for continuous 
supply of the enzymatic substrate. PET analysis revealed a 56% increase in the 
bioavailability of AADC for up to 96 weeks post injections. 6 months post injections, the 
authors observed ~46% improved Unified Parkinson’s Disease Rating Scale scores. 
These results show that the AAV vectors can be utilized for potential therapeutic 
intervention for PD pathology, but is also safe and well tolerated in a human disease 
setting (133).  
The combinatorial intracranial delivery of the therapeutic enzyme AADC along 
with oral administration of levodopa is not free of side-effects. Continuous intake of 
levodopa leads to complications associated with loss of impulse control leading to 
uncontrolled motions (Dyskinesia) among other symptoms (134-136). Cederfjall and 
colleagues hypothesized that gene therapy can be used to achieve focused 
biosynthesis of dopamine in therapeutically relevant regions of the brain (137). For this, 
two rate-limiting enzymes involved in the conversion of tyrosine from human diet to 
DOPA (3,4- Dihydroxyphenylalanine) were packaged in the same AAV vector. 
Intrastriatal delivery of AAV5 vectors encoding the transgenes tyrosine hydroxylase 
(TH) and GTP-cyclohydrolase-1 (GCH1) led to efficient production of DOPA and its 
cofactor 5,6,7,8- tetrahydro-L-biopterin (BH4), respectively. The previously discussed 6-
OHDA induced PD rat model was used to assess the efficacy of AAV mediated gene 
therapy.  
  21 
Efficient expression of TH and GCH1 were reported at the striatum and SN. The 
authors speculated anterograde transport of the vector to be responsible for this 
transgene expression profile in the rat brains. AAV treated PD rats in the study exhibited 
supraphysiological levels of BH4 expression along with accumulation of synthesized 
DOPA in the forebrain regions, possibly due to the saturation of available AADC 
enzyme. Furthermore, AAV-treated rats exhibited motor and behavioral benefits from 
PD pathology, not seen in the lesion control animals. Specifically, the motor skills were 
compared using amphetamine-apomorphine induced rotation tests; and corridor and 
staircase tests. Significant therapeutic benefit with forelimb akinesia, sensorimotor 
control and symmetry of movements was reported. In short, widespread biochemical 
reversal of PD pathology (DOPA production) in the AAV5 treated 6-OHDA lesioned rat 
brains resulting in functional recovery of motor control was observed (137). Another 
comprehensive study was recently conducted by the same research group utilizing 
administration of the aforementioned AAV5 vectors. This study surprisingly reported the 
inability of their previous strategy of vector administration used in the PD rat model to 
directly translate therapeutic benefit in higher order mammals. In NHPs, such AAV5 
administration led to increase in the GCH1 levels but not TH levels. It was speculated 
that other important parameters like promoter/enhancer elements were to be optimized 
so as to dissect the molecular basis of the incoherence seen between gene therapy of 
rats and monkeys (138). 
In addition to accentuation of dopamine levels by delivering enzymes that 
partake in its biosynthesis, gene therapy could be used to reverse another aspect of PD 
pathology, neurodegeneration. Gasmi and colleagues have extensively characterized 
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the neuroprotective factor Neurturin (NTN) or Glia derived neurotropic factor (GDNF) 
towards amelioration of PD pathology (139). The authors packaged NTN in AAV2 
vectors and performed intra-striatal injections in a 6-OHDA induced rat model of PD. 
NTN gene expression was reported as early as 2 days post injections and lasted till the 
last time point of the study i.e. 1 year post administration. Further evaluation of the 
kinetics of the AAV gene transfer reported both the bioavailability of the enzyme and the 
expression of the transgene stabilized in 4 weeks post striatal injections. The effect of 
NTN transduction on the dopaminergic neurons was further evaluated at the SN via 
immunostaining for TH. A significant increase (p<0.001) in the neuroprotection of the 
TH-immunopositive (TH+) SN neurons as compared to the control animals was 
reported. Similar promising results were reported during intra-striatal injections of AAV2 
packaging the neurotrophic factor Pleiotrophin (PTN). PTN has a protective and 
nourishing effect towards nigrostriatal dopaminergic neurons lost during PD. Studies 
have shown that PTN expression is associated with differentiation of mesencephalic 
TH+ neurons and neuroprotection of surviving DA neurons during PD (140, 141). To 
utilize such properties of PTN towards gene therapy of PD, intrastriatal delivery of AAV1 
encoding the PTN transgenes was performed by Gombash and colleagues (142). 
Interestingly, this led to restricted transduction of neurons at the striatum and SNPc 
leading to efficient neuroprotection of DA neurons and reversal of PD phenotype in the 
6-OHDA rat model.  
It is clear that the injection of neuroprotective agents like GDNF has a stimulatory 
effect on DA neuronal growth at the site of injection. While functional reversal of PD 
pathology from intrastriatal injections of AAV vectors packaging GDNF has been shown, 
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SN injections of such AAV vectors has been associated with ‘aberrant sprouting’. 
Specifically, intracranial administration of viral vectors packaging GDNF has been 
shown to cause innervation of DA neurons in unspecific regions around the site of 
injection (143). The unprecedented increase of DA synthesizing neurons at random 
projection regions has been associated with counter-beneficial behavioral side-effects in 
the animals (144).  
Fetal ventral mesencephalic (VM) cells are precursors of DA neurons in the 
mammalian CNS. Direct injections of fetal VM tissue implants have shown reversal of 
PD pathology via integration and striatal-innervation of mature DA neurons. Functional 
turnover of dopamine biosynthesis leading to reversal of behavioral pathology in PD 
animal models has been reported from such treatments (145-147). A combination of 
gene and cell therapy strategies was used by Redmond Jr. and colleagues in an 
attempt to augment the benefits individually achieved by both (148). AAV5 vectors 
packaging the GDNF transgene were co-administered with VM tissue grafts into the 
caudate and putamen striatal regions of MPTP induced PD model of NHPs. A head to 
head comparison of the gene and cell therapy based systems individually and in 
tandem was performed. Striatal levels of both DA and GDNF were significantly higher in 
animals that received the dual treatment in comparison to either individual procedure. 
Interestingly, during the phenotypic evaluation conducted over a span of 8 months post-
treatments, the dual treatment did not show a significant increase in the amelioration of 
PD pathology as compared to the singular treatments.  
The authors speculated that these discrepancies in the biochemical and 
functional outcomes could be accounted for by events like downregulated TH 
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expression at innervations of DA termini and aberrant sprouting events in the treated 
NHPs (148). These results indicate that gene and cell therapeutic interventions that are 
autonomously capable of reversing PD pathology do not always complement one 
another. Such results need to be taken into consideration before clinical translation of 
such combinatorial procedures. 
Human erythropoietin (EPO) enhances the production of red blood cells and is 
therefore an unlikely candidate for gene therapy of neurodegenerative disorders in 
CNS. However, recent research has indicated strong neuroprotection of dopaminergic 
neurons achieved by EPO expression in the brain. Mechanistically, the protein is known 
to have anti-inflammatory and anti-apoptotic effects among others leading to protection 
from neuronal loss during experimental neurodegeneration (from hypoxia induced 
ischemia); or toxic insults (e.g. MPTP and 6-OHDA abuse) in vivo. (149-152). In an 
attempt to utilize the aforementioned therapeutic properties of the EPO protein, Xue and 
colleagues packaged human EPO transgene into AAV9 vectors and injected them into 
the rat striatum (153). The authors reported neuroprotection of DA neurons due to 
widespread transduction of EPO in the striatum and SN. The behavioral PD pathology 
was also attenuated in the rats injected with AAV9-EPO, as demonstrated in the rotation 
test and the test for spontaneous use of forelimbs.   
Taken together, such experimental and clinical outcomes have characterized 
three main strategies routinely used in gene therapy of PD i.e. dopamine biosynthesis 
(154); functional growth, protection and innervation of DA neurons (155, 156); and 
neurochemical inhibition of STN (157, 158). Clearly, it is important to restrict the 
aforementioned processes to functionally relevant regions of the brain by choosing the 
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optimal site of injection, dosage and the right AAV serotype during PD gene therapy. 
Other challenges associated with CNS gene therapy in the clinic include neutralizing 
antibodies, long-term bioactivity and aggregation of the protein product. It is important to 
note that none of these concerns have posed serious adverse effects in the last decade 
of research in PD gene therapy (159-163). A comprehensive perspective on gene 
therapy of PD with special focus on predictive animal models, clinical trial design, 
safety, patient selection, and the current limitations has been recently provided by 
Bartus and colleagues (164). 
 
1.7.2 Gene therapy of CNS disorders arising from metabolic defects 
Mammalian cells constantly break down complex biomaterials into simpler end 
products that make up for cellular nutrients or act as transient precursors for 
subsequent metabolic activities. Such biomaterials originate from dietary intake or 
preceding enzymatic degradations. Lysosomes are enzyme rich digestive 
compartments inside a cell that are specifically designed to break-down such buildup. 
Understandably, dysfunctional lysosomes cause steady accrue of undigested enzymatic 
substrates, ultimately leading to cell death. Organs with continuously dividing cells are 
often able to compensate for this loss by replenishing themselves with new cells over 
time. On the other hand, once fully formed, the CNS undergoes very little cell division 
and reorganization. This makes it vulnerable to loss of functional tissue from such 
cellular distress. CNS disorders arising from metabolic storage burden have largely 
been classified as lysosomal storage disorders (LSDs). Another class of disorders 
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called neuronal ceroid lipofuscinosis (NCLs) presents a similar phenotype and 
originates from the inability of the cells to breakdown the metabolite lipofuscins.  
The first association of a metabolic storage disorder with debilitating human 
disease was Pompe’s disease (Glycogen storage disease type II) characterized by 
severe progressive myopathy (165). We are now cognizant of 50 LSDs that affect 
humans, most of which target CNS tissue (5). It is worth mentioning that majority of 
LSDs and NCLs are transmitted in an autosomal recessive fashion, which accounts for 
their rare occurrence in the human population (166). The molecular bases of many such 
disorders have been uncovered in the last few decades and have been reviewed 
elsewhere (5). Such efforts have been important in the development of strategies to 
employ gene therapy towards disease treatment and amelioration. During normal 
conditions, catabolic enzymes utilize specific cellular macromolecules as substrates.  
Typically, LSDs and NCLs occur due to ‘loss of’ or ‘mutations in’ functional genes 
that encode such enzymes. Mucopolysacharidoses (MPS) are a broad range of LSDs 
branching from the common incapability of breaking down mucopolysaccharides 
resulting in fast deterioration of CNS milieu. Pharmacological enzyme replacement 
therapy (ERT) only provides short-lived and localized respite from the cellular buildup 
due to inefficient penetration of CNS tissue and inability of recombinant enzymes to 
cross checkpoints like the blood-brain barrier (BBB) (167). A complete reversal of 
disease pathology demands continuous production and secretion of the lost enzymes in 
both CNS and peripheral organs. AAV gene therapy provides the necessary genomic 
elements to the patient’s functional tissue for biosynthesis of lost enzyme(s) in a cell 
autonomous/non-autonomous fashion. In addition, the combinatorial spread of AAV 
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vectors and the translated protein results in efficient penetration of the disease-afflicted 
CNS and peripheral organs. We have focused our discussion on major MPS disorders 
as case studies outlining progress towards understanding prominent metabolic storage 
disorders affecting the CNS and the use of AAV gene transfer towards their therapy.  
MPS type VII (Sly disease) is a severely debilitating form of LSD that occurs as a 
result of accumulation of glycosaminoglycans (GAGs) due to the deficiency of -
glucuronidase (GUSB) enzyme. The disease symptoms include skeletal deformations, 
mental retardation, loss of sensory skills (vision and hearing), distorted features and a 
short life span (168). In one of the first attempts at utilizing AAV gene therapy towards 
amelioration of MPS VII in a mouse model, AAV2 vectors were engineered to package 
the GUSB transgene. Intravenous delivery of AAV2-GUSB led to reversal of disease 
phenotypes pertaining to bone length, retinal function and vacuole clearance in the MPS 
VII mouse model at an early age of postnatal day 2 (P2) (169, 170). In theory, utilizing 
the blood stream for delivering pharmacological agents to multiple organs is attractive, 
although, it is not always the best route for administration of certain AAV serotypes for 
gene therapy.  
Early studies conducted by Elliger and colleagues concluded that i.v. 
administration of the AAV2 vectors resulted in modest levels of CNS transduction and 
higher transgene expression in the peripheral tissues i.e. heart and liver (171). Recent 
research has demonstrated that AAV2 vectors are unable to cross the BBB (96). 
Therefore, the clearance of GAG accumulation from CNS tissue observed in these initial 
studies using AAV2 is possibly due to secreted enzymes crossing the brain 
microvasculature or entering the parenchyma via aquaporin mediated interstitial fluid 
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clearance (62, 172). Further supporting this argument, direct CNS administration of 
AAV2-GUSB via intrathecal injections in adult mice was demonstrated to achieve 
increased enzyme levels and decreased vacuole formations in the CNS tissue (171). 
This study underscores the importance of pairing an AAV serotype with its optimal route 
of administration for CNS gene therapy applications. Widespread diffusion of the GUSB 
enzyme product in the CNS tissue was achieved by Skorupa and colleagues (173). 
Their report demonstrated that direct injections of AAV2-GUSB into four sites in the 
adult rodent brain namely: striatum, cortex, thalamus and hippocampus achieves 
maximal spread of the enzyme. The authors reported clearance of lysosomal storage 
burden across the complete neuraxis in the ipsilateral hemisphere from such injections 
(173).  
More recently, the use of multiple intracranial injections to achieve efficient 
biodistribution of therapeutic enzyme has been replaced by other strategies that are 
more amenable to clinical translation. To this end, a single striatal injection in the adult 
MPSVII affected rat brain was shown to produce enzyme expression in 10% of the brain 
volume leading to loss of the storage burden for ~16 weeks by Bosch and colleagues 
(174). An alternative strategy towards achieving enhanced levels of transduction is to 
incorporate genetic elements like the promoter and enhancer, from other infectious 
mammalian viruses. The work of Sferra and colleagues demonstrated enhanced 
transduction efficiency of murine -GUSB transgene, when driven by cytomegalovirus 
promoter-enhancer elements. ~50-240% spread of enzyme expression across the CNS, 
resulting in metabolic storage benefit for up to 3 months of age was reported by the 
authors (175).  
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Progressive loss of vision due to retinal degeneration is a characteristic clinical 
phenotype of MPSVII in humans. In an attempt to correct this pathology, AAV2-GUSB 
was injected into adult MPSVII mice via the intravitreal route by Hennig and colleagues 
(176). The enzyme activity was observed in areas of the brain receiving visual inputs 
from the eye e.g. thalamus and tectum. Interestingly, neighboring non-visual areas like 
hippocampus and visual cortex also exhibited GUSB activity. The transduction profile 
suggested the combined role of synaptic vector transmission and diffusion of the 
translated product (176).  
Understandably, expression of the GUSB transgene in large 3-dimensional 
spaces of the CNS is important for rapid lysosomal clearance and associated 
symptomatic benefits from MPSVII. Primate derived AAV strains 7, 8, 9 and rh10 were 
injected into adult mouse brain regions cortex, striatum, thalamus and hippocampus by 
Cearley and colleagues to assess their properties as CNS gene transfer vectors (90). 
The authors reported that all tested serotypes showed preferential transduction of 
neurons and not astrocytes and oligodendrocytes. While AAV7 performed efficient gene 
transfer in cortex, thalamus and hippocampus, AAV9 and AAV Rh.10 outperformed 
other serotypes in spread and transduction of both ipsilateral and contralateral 
hemispheres. Specifically, the assessment of AAV9 injected rodent brains 
demonstrated reversal of lysosomal clearance at 2 months post injections in multiple 
regions of the brain. The authors also observed AAV9 mediated transduction across 
neuronal projections in the hippocampal commissure, providing supportive evidence for 
the vector’s ability to undergo axonal transport to cover large distances in the CNS (90).  
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Although AAV mediated gene therapy in the postnatal in vivo animal models 
successfully reverses clinical manifestations of LSDs, survival of such animals is still 
significantly lower than their wildtype counterparts. In one of the first attempts to 
introduce therapeutic intervention in an in vivo embryonic stage, AAV1 vector encoding 
the GUSB transgene was administered at embryonic day 15.5 (E15.5) by Karolewski 
and colleagues (177). Vector mediated CNS transduction resulting in enzymatic spread 
across the entire brain and spinal cord was observed. Low levels of GUSB activity was 
also observed in peripheral organs like liver, spleen, kidneys and gonads. Interestingly, 
no vector genomes were detected at such off-target locations. The authors further 
discussed that the peripheral leakage of the enzyme was possibly due to uptake of CSF 
metabolites into the venous system. The CNS-specific therapeutic intervention was 
enough to confer benefit from lysosomal storage lesions for up to one year post 
injections and improved the survival comparable to wildtype controls. Surprisingly, some 
of the clinical manifestations like facial and skeletal deformations were not rectified post-
treatment. Such mixed results indicate room for improvement in areas like vector design 
and route of AAV administration (177).  
Some of the most daunting challenges with clinical translation of gene therapy 
are related to surgical procedures during vector administration in the clinic. Major 
advances have been made towards reduction of invasiveness during therapeutic vector 
administration targeting the CNS. Intra-CSF injections like ICV injections, intracisternal 
injections (IC) and intrathecal lumbar puncture (IT) are all viable strategies to achieve 
maximal contact with the CNS tissue from a single dose of administration. In addition, 
viruses are also known to utilize axonal transport to cover long distances via inter-
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synaptic relay. AAV strains have different efficiencies and preferred directionalities of 
movement across neuronal connections (112). In this regard, utilizing regions of heavy 
afferent and efferent ‘wiring’ within the brain can be a useful strategy. A comparative 
assessment of AAVs 1, 9 and Rh.10 injected into a major hub of neuronal projections, 
ventral tegmental area (VTA) was reported by Cearley and colleagues (55). The authors 
compared VTA injections of the AAV vectors to conventional striatal injections. While an 
increase in spread of transduction to distal regions of the brain was reported from all 
three AAV serotypes, the maximal spread was seen in case of AAV9 vectors. The 
authors then used the strategy to deliver GUSB transgene packaged in AAV9 vectors in 
the MPSVII mouse model. The study reported widespread transduction of the 
therapeutic transgene, leading to expanded biodistribution of the enzyme in the entire 
brain from a single 1 ul injection of ~1010 total viral genomes (vg) (55).  
On the behavioral front, MPSVII patients display mental retardation due to 
neuronal and glial cell death. Frisella and colleagues hypothesized that AAV mediated 
GUSB transgene delivery would achieve successful restoration of lost cognitive 
function. To this end, intracranial administration of AAV2-GUSB was performed in the 
MPSVII mice by the authors that led to long-lasting supply of the enzyme in the CNS. 
The authors then utilized the Morris water maze test to show that the mice treated with 
the AAV vector exhibit near wildtype levels of cognitive skills (178). The loss of cognitive 
acumen is often related to dysfunction of the hippocampus e.g. deteriorated learning 
and memory, difficulties in fear conditioning etc.  
Preclinical evaluations of the extent of cognitive benefit seen in MPSVII mice due 
to AAV mediated gene therapy was performed by Liu and colleagues (179). The authors 
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administered AAV5 packaging -GUSB via bilateral intrastriatal injections in adult MPS 
VII mice. AAV5 has been previously demonstrated to be a highly neurotropic vector 
capable of transducing a larger area of the CNS than AAV2 (71). AAV5 mediated 
intrastriatal delivery of the corrective GUSB transgene provided cognitive benefits in 
MPS VII mice as demonstrated in repeated acquisition and performance chamber 
(RAPC) assay. Specifically, the MPSVII affected adult mice underwent RAPC assay 
before and after the vector administration. Post administration, the mice displayed a 
significant reduction in the learning errors and latency period to reach the reward. 
Furthermore, the authors identified a specific loss of glutamate receptor on the surface 
of hippocampal neurons in the MPSVII affected mice. Specifically, 40-60% depletion of 
glutamate receptors GluR1, GluR2 and NR1 was observed in the hippocampal neurons 
which could be linked to the learning deficits. Furthermore, the authors demonstrated 
that the glutamate receptor levels of AAV5-GUSB treated mice was indeed restored 
comparable to the levels of heterozygous littermates, thereby providing the molecular 
basis of the therapeutic benefit (179).  
MPSIIIB/Sanfilippo syndrome is a rare, genetically transmitted LSD where 
patients suffer from intracellular accumulation of glycosaminoglycan heparan sulfate. 
The disorder stems from the deficiency of -N-acetylglucosaminidase (NaGlu) enzyme 
in the CNS. The disease features fast deterioration of CNS and peripheral tissues 
leading to severe mental retardation and premature death in patients (Neufeld and 
colleagues 2001, Metabolic and Molecular basis of inherited diseases). Enzyme 
biosynthesis using gene therapy confers successful protection of neuronal and 
peripheral tissue and provides symptomatic relief in the MPS IIIB mouse model. One of 
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the earliest examples of therapeutic AAV gene transfer was reported by Fu and 
colleagues (180). AAV2 vectors packaging the NaGlu transgene was engineered. The 
transgene was driven by either a constitutive cytomegalovirus (CMV) promoter or a 
neuron specific enolase (NSE) promoter. Successful transduction of AAV2 in human 
MPS IIIB patient fibroblasts and mouse somatic and primary brain cells, resulting in 
significant degradation of GAGs was demonstrated. A low dose (~107) of viral genomes 
of AAV2-NSE-NaGlu was then injected into the adult MPS IIIB mouse brain and 
successful NaGlu expression leading to correction of GAG storage in a broad CNS area 
was observed(180).  
Cressant and colleagues assessed the effects of AAV mediated gene transfer of 
the NaGlu transgene on the behavioral outcomes of MPS IIIB (181). It is now clear that 
certain AAV serotypes like AAV2 have the preferential ability to undergo axonal 
transport in the anterograde direction (115). Regions of extensive synaptic connectivity 
are attractive sites of injection for AAVs packaging corrective transgenes to target a 
large area of the brain from a single injection. In the mammalian CNS, axonal 
projections to multiple regions originate at the caudate putamen. In this report, the 
authors compared putaminal injections of AAV2 and AAV5 vectors in adult 6-week old 
MPS IIIB mice and demonstrated that AAV5 mediated transduction spreads more than 
AAV2 (181). AAV5 binds N-linked sialic acid as cell surface attachment factors whereas 
AAV2 requires the availability of Heparan Sulfate proteoglycans (HSPG) to perform 
successful gene transfer (34, 182).  
The interaction of AAV2 with its cognate receptor (HSPG) is one of the rare 
occurrences where cellular receptor binding is detrimental to the spread of the AAV 
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vectors in the CNS (172). This phenomenon might explain the enhanced ability of AAV5 
vectors to spread and transduce CNS tissue in the distant regions from the site of 
injection. Both AAV vector injections resulted in the enzyme bioavailability above 
untreated controls leading to reversal of disease phenotype in the neurons, microglia 
and perivascular cells. Additionally, a complete reversal of behavioral symptoms from 
both AAV2 and AAV5 treatments was reported (181). The assessment of behavioral 
recovery was performed using a circadian cycle controlled open field test. Parameters 
such as mouse activity during light and dark time periods; explorative and habituated 
navigations, were monitored during the course of the sessions. To summarize, these 
tests provide a fair assessment of the success of gene therapy towards reversal of 
cellular pathology and behavioral outcomes seen in MPS IIIB patients featuring anxiety, 
restlessness, hyper-excitability and aggressiveness (181).  
Many natural and engineered AAV isolates are being discovered with attractive 
properties like the ability to spread and transduce large CNS volumes. In an attempt to 
achieve widespread correction of the MPS IIIB disease pathology in the CNS, AAV2 
mediated NaGlu gene transfer was performed by Fu and colleagues in BBB 
compromised mice in vivo (183). Specifically, the authors utilized intra-arterial injection 
of mannitol post AAV administration that led to transient opening of the BBB. While 
there is no measurable permanent damage inflicted upon the BBB due to this treatment, 
efficient entry of viruses, antibodies and large macromolecules has been widely 
documented due to such treatment (98, 183, 184). The authors demonstrated that 
combined intravascular and intra-cerebrospinal fluid (CSF) vector administration led to 
successful and long term correction of the disease pathology and a significant increase 
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in the lifespan of the mice (from 7.9-11.3 months in untreated mice to 11.1-19.5 months 
in treated mice).  
Simultaneous use of CSF and blood connectivity led to successful gene transfer 
not only in the CNS tissue but in peripheral organs as well. Virtually the entire brain and 
spinal cord tissue are connected with the combination of the CSF and blood vessels. 
The CSF constantly provides nutrients and molecular signals to, and drains interstitial 
fluids from, the brain and spinal cord tissue via the sub-arachnoid space, cerebral 
ventricles, cerebellar foramena and the cisterna magna (61-64). The blood vessels on 
the other hand provide constant supply of oxygenated blood due to the combination of 
arterial influx and venous efflux in the CNS tissue. The authors of this study speculated 
that the success of their therapeutic AAV administration could be attributed the routes of 
administration (183). The transient opening of the BBB clearly assisted the CNS spread 
of AAV vectors. Moving forward, the time span between intra-arterial mannitol infusion 
and the i.v. administration of AAV vectors was optimized by McCarty and colleagues. 
The authors demonstrated that injections performed exactly 8 min after the mannitol 
infusions led to significantly enhanced viral transduction resulting in reversal of the 
disease phenotype in the MPS IIIB mice (98).  
Combinatorial use of other strategies of therapeutic intervention can have a 
synergistic effect on AAV mediated gene therapy of the CNS. Exploring such a 
hypothesis, AAV gene transfer in combination with bone marrow transplant and 
assessment of correction of MPS IIIB was performed by Heldermon and colleagues in 
mice. Specifically, the authors performed intracranial AAV5-NaGlu administration 
with/without the transplant of NaGlu transduced bone marrow cells in the MPS IIIB 
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mouse model. The bone marrow transplant (BMT), by itself, was the least efficacious of 
all three strategies and the report surprisingly concluded an antagonistic effect of the 
combination treatment on survival and motor skills in the disease affected mice (185). 
Such outcomes provide cautious optimism and direction for the future use of AAV 
towards CNS gene therapy of metabolic storage disorders. 
 
1.8 Safety aspects of AAV-mediated CNS gene therapy 
Recombinant AAV vector genomes display inefficient integration into the host 
chromosome and predominantly persist in episomal form (186). This reduces the risk of 
insertional mutagenesis, often associated with other viral vectors like retroviruses (187). 
The vector genomes subsequently require the host cellular machinery to carry out 
second strand synthesis, transcription and translation (188, 189). Safety aspects 
pertaining to persistence of AAV vector genomes have been reviewed elsewhere (27, 
186, 190).  
Another important safety consideration is the observation that rAAV mediated 
overexpression of non-self transgenes can elicit immune responses due to antigen 
presentation of the expressed transgene product. . For instance, direct primate brain 
infusion of AAV1 packaging a humanized Renilla GFP transgene triggered an immune 
response against the translated reporter product (191). Similarly, a cell mediated 
immune response and neuronal loss was observed in rats injected with AAV9 vectors 
packaging the GFP reporter transgene or a human L-amino acid decarboxylase 
transgene (192). More recently, certain AAV serotypes have been shown to undergo 
  37 
systemic leakage resulting in off-target biodistribution in organs like liver and spleen (94, 
97, 101). Crucially, AAV vector engineering can also be employed to design elegant 
solutions to contain peripheral organ accumulation of CNS-targeted AAV biologics. To 
this end, we have engineered and extensively characterized the AAV2g9 vector that 
performs widespread neuronal gene transfer with minimal systemic leakage, peripheral 
tissue biodistribution and systemic tissue gene transfer. These findings have been 
elaborated in the chapter 3 of this thesis.  
These preliminary observations in animal models highlight the need to better 
understand the parameters that determine potential toxicity/biodistribution profiles and 
immune response in AAV-mediated CNS gene transfer. It is also important to 
acknowledge that aspects related to manufacturing, downstream processing and purity 
of AAV vector preparations are critical towards ensuring the safety of AAV vectors. A 
comprehensive comparison of different viral gene transfer vectors for parameters such 
as packaging capacity, host chromosomal integration and other biosafety aspects can 
be found elsewhere (27, 190). 
As of early 2014, 5.3% of world-wide clinical trials involving gene therapy have 
utilized Adeno-associated viruses (AAVs) (109 ongoing trials) (Journal of Gene 
medicine). Only a few of these trials are aimed at treating diseases with CNS 
manifestations. In this chapter, I attempted to provide an overview of various 
parameters that might play a role in determining the success of AAV mediated 
therapeutic gene transfer to the CNS. Interactions of AAV vectors with different primary 
receptors, directional transport and cellular tropisms following different routes of 
administration are summarized in Table 1. Although we were unable to cover every 
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contribution to the field of CNS gene therapy, the information provided not only 
highlights potential gaps in our understanding of AAV-host interactions within the CNS, 
but will assist with continued vector development for CNS-directed gene transfer 
applications in the clinic. 
Some of the prominent applications of AAV mediated CNS gene therapy that are 
currently undergoing various stages of clinical trials as reported in the National Institutes 
of Health’s database (https://clinicaltrials.gov/) have been listed in Table 2. Although we 
were unable to discuss gene therapy of many other CNS disorders and several other 
outstanding scientific contributions; through this chapter, we have attempted to bring 
clarity to the advantages and challenges associated with the therapeutic use of AAV 
vectors in the CNS.   
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Figure 1: Schematic representation of recombinant AAV genomes: The promoter, 
transgene and polyadenylation signal (PolyA) are flanked by inverted terminal repeats 
(ITRs) in single stranded (ss) or self-complementary (sc) configurations.  
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Figure 2: Differential spread of CNS transduction from AAV4 or AAV9 vectors 
packaging TdTomato fluorescent reporter transgene in neonatal mouse brain: P0 
mice were injected with 1x109 vg of AAV4 or AAV9 packaging a CBA-TdTom reporter 
transgene into the left lateral ventricle. At 2 weeks post injections, mice were sacrificed 
and paraformaldehyde fixed brains were sectioned. Brain sections were imaged using a 
Zeiss CLSM 700 confocal laser scanning microscope. Confocal micrographs show 
TdTom transgene expression (red) in 50 m vibratome section of the mouse brain 
(global) and higher magnification images of individual regions in the rostrocaudal axis of 
the brain parenchyma. 
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Table 1. Capsid-receptor interactions, transduction profiles and axonal transport properties of some of 
the well characterized Adeno-associated viral serotypes in the mammalian CNS. 
Serotype Primary 
Receptor 
Intra-CSF or Intra-
parenchymal Administration 
Intravascular Administration Axonal 
Transport 
  Neuronal 
Transduction 
Glial 
Transduction 
Neuronal 
Transduction 
Glial 
Transduction 
 
AAV1 α2,3/α2,6 N-
linked SA 
++ + + + A-,R+ 
AAV2 Heparan 
Sulfate 
+ - - - A+,R- 
AAV4 α2,3 O-
linked SA 
- + - - ? 
AAV5 α2,3 N-
linked SA 
++ + - - ? 
AAV6 α2,3/α2,6 N-
linked 
SA/heparan 
sulfate 
++ - + + A-,R+ 
AAV8 ? ++ ++ ++ ++ A+, R+ 
AAV9 Galactose +++ ++ +++ +++ A+,R+ 
AAVRh.8 ? ++ ++ +++ +++ ? 
AAVRh.10 ? +++ + +++ +++ ? 
? Receptor usage/Axonal transport has not been characterized; + Low levels of transduction; ++ Moderate 
levels of transduction; +++ High levels of transduction; - No transduction; ? A+ or R+ (AAV vector undergoes 
axonal transport in the anterograde (A) or retrograde (R) direction during in vivo characterization) 
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Table 2. Clinical gene therapy of some neurological disorders using AAV vectors. 
Category Disorder Transgene AAV Serotype, 
Route and 
Dosage 
Clinical Status Summary 
Metabolic 
Storage 
Disorders 
Batten’s 
Disease 
Human CLN2 
gene 
AAV2- 
Intracranial 
injections  
Phase 1 
(NCT00151216) 
Expression of CLN2 
transgene to 
replenish the levels 
of tripeptidyl 
transferase-1 
(TPP1) enzyme. 
AAV Rh.10- 
Intracranial 
injections – 2.85 
or 9 X 10^11 vg 
Phase 2 
(NCT01414985) 
Pompe 
Disease 
Human acid 
alpha-
glucosidase 
(GAA) gene 
AAV9- 
Intramuscular 
injections- 
5X10^9 vg 
Phase 1 
(NCT02240407) 
The enzyme GAA 
degrades cellular 
accumulation of 
glycogen which 
leads to severe 
neuromuscular 
pathology.  
AAV1- 
Intramuscular 
injections- 1-
5X10^12 vg 
Phase 2  
(NCT00976352) 
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MPS III A 
(Sanfilippo’s 
type A 
Syndrome) 
Human SGSH 
and SUMF1 
genes 
AAV Rh.10- 
Intracranial 
injections  
Phase 2 
NCT01474343 
Expression of N-
Sulfoglucosamine 
Sulfohydrolase and 
Sulfatase modifying 
factor 1 leads to 
degradation of 
glycosaminoglycans 
(GAGs) 
accumulations in 
the CNS tissue 
Acute 
Intermittent 
Porphyria 
Porphobilinogen 
deaminase 
(PBDG) gene  
AAV5- 
Intravenous 
injections  
Phase 1  
(NCT02082860) 
PBDG enzyme 
deficiency blocks 
heme-biosynthesis 
and causes severe 
neuropathic 
symptoms ranging 
from abdominal 
pain to seizures 
and psychotic 
episodes. 
Movement 
Disorders 
Parkinson’s 
Disease 
Human 
aromatic L-
amino acid 
decarboxylase 
(AADC) 
AAV2- 
Intracranial 
I(Striatal 
injections) – 
9X10^10 – 
3X10^11 vg total 
Phase 1  
(NCT00229736) 
AADC mediated 
conversion of orally 
administered 
levodopa into 
dopamine 
AAV2- 
Intracranial 
(Striatal 
injections) – 
7.5X10^11-
2.3X10^12 vg 
Phase 2  
(NCT01973543) 
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 total 
Glial cell line- 
derived 
neurotrophic 
factor (GDNF) 
AAV2- 
Intracranial 
(Striatal 
injections) – 
9X10^10-
3X10^12 vg total 
Phase 1  
(NCT01621581) 
Neuroprotection of 
dopaminergic 
neurons with GDNF 
Neurotrophic 
factor Neurturin 
(NTN) 
 
AAV2- 
Intracranial 
(Putaminal 
Injections)  
Phase 1 
(NCT00252850) 
Neurturin mediated 
neuroprotection of 
dopaminergic 
neurons 
 AAV2- 
Intracranial 
(Putaminal and 
Substantia Nigral 
injections) – 4-
5X10^11 vg or 
24X10^11 vg 
Phase 1 
(NCT00985517) 
Glutamic acid 
decarboxylase 
(GAD) 
AAV-GAD 
intracranial 
injections 
(Subthalamic 
nucleus) 
Phase 1 
(NCT00195143) 
GAD expression in 
the STN has an 
inhibitory effect due 
to GABA production 
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CHAPTER 2: EXPLOITING GLYCAN SIGNATURES TO REGULATE ADENO-
ASSOCIATED VIRAL TROPISM IN THE DEVELOPING BRAIN2 
2.1 Overview 
Adeno-associated viruses (AAV) are thought to spread through the central 
nervous system (CNS) by exploiting cerebrospinal fluid (CSF) flux and hijacking axonal 
transport pathways. The role of host receptors that mediate these processes is not well 
understood. In the current study, we utilized AAV serotype 4 as a model to evaluate 
whether ubiquitously expressed 2,3-linked sialic acid and the developmentally regulated 
marker, 2,8-linked polysialic acid (PSA) regulate viral transport and tropism in the 
neonatal brain. Modulation of the levels of SA and PSA in cell culture studies using 
specific neuraminidases revealed possibly opposing roles of the two glycans on AAV4 
transduction. Interestingly, upon intracranial injection into lateral ventricles of the 
neonatal mouse brain, a low affinity AAV4 mutant (AAV4.18) displayed a striking shift in 
viral tropism from 2,3-linked SA+ ependymal lining to 2,8-linked PSA+ migrating 
progenitors in the rostral migratory stream and olfactory bulb. In addition, this gain-of-
function phenotype correlated with robust CNS spread of AAV4.18 through 
paravascular transport pathways. Consistent with these observations, altering glycan 
dynamics within the brain by co-administering SA and PSA specific neuraminidases 
resulted in striking changes to the cellular tropisms and transduction efficiencies of both 
                                            
2This chapter includes the original publication that appeared in the journal of virology. 
The full citation is as follows: Murlidharan, G., Corriher, T., Ghashghaei, H.T., Asokan, 
A. Unique glycan signatures regulate adeno-associated virus tropism in the developing 
brain, Journal of Virology, 2015, 89(7):3976-3987 (PMID: 25631075).  
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AAV4 as well as AAV4.18 vectors. We postulate that glycan signatures associated with 
host development can be exploited to redirect AAV vectors to specific cell types in the 
brain.  
 
2.2 Introduction 
Viruses enter the CNS by exploiting a variety of transport pathways that hinge on 
preliminary infection of peripheral nerve endings or through the blood by infecting 
circulating leukocytes or brain endothelial cells. Subsequent spread within the brain is 
achieved by axonal transport and trans-synaptic spread (193). A key step in viral entry 
into the CNS and subsequent directional transport is the recognition of specific cell 
surface membrane glycoproteins as receptors. For instance, polioviruses utilize CD155 
as a receptor (194), while alpha herpesviruses exploit nectin-1 for CNS entry (195), both 
members of the immunoglobulin superfamily. Several membrane-associated 
components have also been implicated in Rabies virus CNS entry (196). Prior to 
engagement of such host membrane proteins, viruses often bind to cell surface glycans 
for attachment. One of the most versatile host glycans that have been exploited as viral 
attachment factors are the family of sialic acids (SA) (197-199). For instance, SA 
receptors have been implicated in the neurovirulence of reovirus and polyomaviruses 
(200, 201). Modulating SA binding affinity has also been shown to influence the 
pathogenicity of the neurovirulent strain of the minute virus of mice (MVM) (25).  
While no natural isolates from brain tissue have been reported thus far, adeno-
associated viruses (AAV), which are helper-dependent parvoviruses, display a broad 
spectrum of CNS tropisms following intracranial or systemic administration in different 
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hosts (71, 89, 90, 92, 96, 97, 172). The cellular tropisms of different AAV strains 
observed in these studies were mostly neuronal, with a few exceptions that can 
transduce astrocytes and glia as well. Similar to their helper viruses such as 
Adenoviridae or Herpesviridae (193), AAV strains undergo interstitial as well as axonal 
transport within the CNS (172). However, the molecular bases of this diversity in AAV 
transport mechanisms and CNS tropisms are not well understood. Within this 
framework, AAV isolates have been shown to utilize three different glycans – SA, 
galactose (GAL) and heparan sulfate (HS) for cell surface attachment (25). In addition, 
several growth factor receptors, transmembrane proteins and integrins have been 
identified as being essential for AAV cell entry (26, 31). Our lab and others have 
recently demonstrated the role of SA and GAL in determining the systemic fate of 
different AAV serotypes in mouse models (38, 202, 203). 
  The African green monkey isolate, AAV serotype 4 is one of the evolutionarily 
and structurally most distinct serotypes known to date and displays selective tropism for 
the ependymal lining following intra-cerebroventricular (ICV) administration in neonatal 
and adult mice (77). In addition, AAV4 particles directly injected into the sub-ventricular 
zone can transduce astrocytes forming glial tubes within the RMS. The functional cell 
surface attachment factor for AAV4 is O-linked α2,3-SA (mucin) (34, 204, 205). We 
previously identified a novel AAV4 mutant (AAV4.18) that displays decreased affinity 
towards 2,3-SA and a transduction-deficient phenotype following systemic 
administration in mice (205). In the current study, we identify a novel glycan that 
differentially regulates the CNS transport and cellular tropism of AAV4 and the lab-
derived mutant strain. Unlike AAV4, which displays restricted tropism for the ependymal 
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lining, the lab-derived AAV4.18 mutant spreads throughout the brain parenchyma and 
can selectively infect migrating progenitors in the rostral and caudal directions from a 
unilateral ICV injection in neonatal mice. Further biochemical characterization of AAV4 
and AAV4.18 in the mouse brain confirmed a switch in receptor specificity from α2,3-
linked SA to α2,8-linked PSA, a well-established marker of neurogenesis. 
 
2.3 Materials and Methods 
Recombinant AAV vector production. Recombinant AAV4 and mutant 
AAV4.18 vectors were generated using an updated triple plasmid transfection method 
(206). Briefly, this involved transfection of (a) the pXR4 helper plasmid (18) or the 
mutant pXR4.18 helper plasmid (205); (b) the adenoviral helper plasmid pXX6-80; and 
(c) pTR-CBA-tdTom or pTR-CBA-Luc plasmids encoding the tdTomato (tdTom) or 
Luciferase (Luc) reporter genes driven by the chicken beta actin (CBA) promoter and 
flanked by inverted terminal repeats (ITRs) derived from the AAV2 genome. Vector 
purification was carried out using cesium gradient ultracentrifugation and viral titers 
obtained by quantitative PCR using a Roche Lightcycler® 480 (Roche Applied 
Sciences, Pleasanton, CA) with primers (IDT Technologies, Ames, IA) designed for the 
CBA promoter (forward, 5’-CGT CAA TGG GTG GAG TAT TT-3’ ; reverse, 5’-GCG 
ATG ACT AAT ACG TAG ATG-3’).  
In order to generate AAV particles packaging thymidine analog 5-bromo-2’-
deoxyuridine (BrdU) labeled genomes, we adapted a modified vector production 
protocol described earlier (207, 208). Briefly, at 1hr post triple plasmid transfection, 
HEK293 producer cells were treated with a 10:1 molar mixture of BrdU and 5-fluoro-2’-
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deoxyuridine at a final concentration of 10μg BrdU/ml of media (Invitrogen, Camarillo, 
CA). Vectors packaging BrdU-labeled genomes were purified and quantified as 
described above.  
 
Cellular transduction assays. CV-1 cells (African green monkey kidney 
fibroblasts) were seeded at a density of 5x104 cells per well in 24-well plates and were 
maintained at 37˚C and 5% CO2. The cells were grown in Dulbecco’s modified eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml 
penicillin, 100 g/ml streptomycin and 2.5 g/ml amphotericin-B (Sigma-Aldrich, St. 
Louis, MO). For transduction assays, cells were first exposed to the different enzymatic 
treatments as described below.  
To cleave long PSA chains, cell cultures were treated with Endoneuraminidase-N 
(ABC Scientific, Los Angeles, CA) diluted to 1:5000 in DMEM supplemented with 10% 
FBS for 12 hrs at 37˚C and 5% CO2. To cleave terminal SA residues, Neuraminidase III 
(Neuraminidase) (Sigma-Aldrich, St. Louis, MO) was diluted to 50 mU/ml in serum-free 
DMEM and cells treated for 3 hrs at 37˚C and 5% CO2. After these treatments, cells 
were washed three times with phosphate-buffered saline (1XPBS) and the media 
replaced with fresh DMEM+10% FBS containing AAV4 or AAV4.18 vectors packaging 
the firefly luciferase transgene, driven by the CBA promoter at a multiplicity of infection 
(MOI) of 1000 viral genomes per cell (vg/cell). Cells were lysed at 24 hours post-
transduction and luciferase transgene expression was quantified using Victor2 
luminometer (PerkinElmer, Waltham, MA) with D-Luciferin as a substrate. 
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Intracerebroventricular (ICV) injections. All animal experiments were carried 
out with Balb/c mice bred and maintained in accordance to NIH guidelines and as 
approved by the UNC Institutional Animal Care and Use Committee (IACUC). Neonatal 
postnatal day 0 (P0) pups were rapidly anesthetized by hypothermia by placing on ice 
for 1 min followed by stereotaxic intraventricular cerebral injections. A Hamilton 700 
series syringe with a 26s gauge needle (Sigma-Aldrich, St. Louis, MO) was attached to 
a KOPF-900 small animal stereotaxic instrument (KOPF instruments, Tujunga, CA) and 
the mice injected unilaterally in their left lateral ventricle with a dose of 1x109 particles 
(volume 3 μl) of AAV4 or AAV4.18 vectors packaging the CBA-tdTom reporter cassette. 
Developing mouse brains (P14) were harvested, post-fixed and immunostained as 
described in detail below. For tracking bromodeoxyuridine (BrdU)-labeled viruses, 
7.4x108 vector genome-containing particles in a volume of 5 µL were injected into the 
left lateral ventricle of P0 mice. Neonatal brains were harvested 2 hours post-injection, 
post-fixed in paraformaldehyde, sectioned and immunostained as described below. For 
recombinant sialidase co-injection experiments, the vectors were mixed with either 5.2 
mU of Neuraminidase type III (Sialidase, Sigma-Aldrich, St. Louis, MO) or 1.45U of 
Endoneuraminidase-N (ABC Scientific, Los Angeles, CA) to a total injection volume of 
4.3μl. All neonatal injections were performed 0.5mm relative to the sagittal sinus, 2mm 
rostral to transverse sinus and 1.5mm deep. Following vector administration, mice were 
revived under a heat lamp and rubbed in the bedding before being placed back with the 
dam. 
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Tissue processing, confocal microscopy and immunofluorescence 
analysis. Two week old mice were sacrificed with an overdose of tribromoethanol 
(avertin) (0.2 ml/10 g of 1.25% solution) followed by transcardial perfusion of 4% 
paraformaldehyde in PBS. The brains were removed and post-fixed for 24 hr and 50μm 
thick sections were obtained using a Leica VT 1000S vibrating blade microtome (Leica 
VT 1000S, Leica Biosystems, IL). Free floating brain sections were blocked in 10% goat 
serum and 1% Triton X (Sigma-Aldrich, St. Louis, MO) in PBS for 1hr prior to overnight 
incubation with primary monoclonal antibodies at 4˚C. The following primary antibodies 
were utilized: rabbit anti- S100β (Sigma, 1:1000), mouse anti-GFAP (Abcam-10062, 
1:1000), rabbit anti-Dcx (Abcam-18723, 1:1000), goat anti-phospho-histone H3 
(Millipore, 1:1000), mouse anti-BrdU (Invitrogen-033900, 1:2500), rabbit anti-NeuN 
(Abcam-104225, 1:750), mouse anti PSA-NCAM (DSHB, 1:750) and mouse anti-
Rc2/Nestin (DSHB, 1:750). Secondary antibodies were raised in goats and conjugated 
to Alexa 488 or Alexa 647 (Abcam, 1:500). For jacalin staining, we followed the blocking 
step with 1.5 hour incubation of free floating mouse brain sections in FITC-Jacalin at 
room temperature (Vectorlabs, Burlingame, CA, 1:40). Jacalin was diluted to a working 
concentration of 20 µg/ml in 3% goat serum in PBS-T. Immunostained brain sections 
were visualized using a Zeiss CLSM 700 confocal laser scanning microscope and 
analyzed with Zen® Black software. Colocalization (%) of tdTomato reporter expression 
with different cell type specific markers were derived from the ratio of the number of 
transduced cells (tdTom+) that were S100β/GFAP/Dcx/PH3+ and the total number of 
transduced cells (tdTom+). Cells were counted in non-overlapping fields of view of 200 
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m2 area in the subependymal zone, rostral migratory stream, olfactory bulb or other 
pertinent regions in the P14 mouse brain. 
 
2.4 Results 
Substrate-specific neuraminidases have differential effects on AAV4 
transduction in vitro. In most mammalian tissues, SA occupies the terminal position 
originating from Asparagine linked (N-) or Serine/Threonine linked (O-) glycoprotein 
glycans. However, in the CNS, sialylated glycans are expressed in two forms, 2,3- or 
2,6-sialylated glycosphingolipids (gangliosides) as well as long polymeric chains of 
2,8-linked PSA bound to neural cell adhesion molecule (NCAM) (209) (Fig. 3A). 
Importantly, the expression of PSA is known to regulate neural plasticity and play an 
indispensable role in embryonic and adult neurogenesis in the mammalian brain (210).  
It is well known that AAV4 utilizes2,3-linked SA as the mammalian cell-surface 
receptor (34). In order to understand whether 2,8-linked PSA on cell surfaces could 
also affect AAV4 transduction, we performed specific neuraminidase treatments to alter 
the relative levels of cell surface SA and PSA in vitro. We chose parental African green 
monkey kidney CV1 cells (precursor to Cos cells) for these experiments due to their 
highly permissive nature towards AAV4 transduction (34). As depicted in Fig. 3A, two 
classes of neuraminidase enzymes were used  - Neuraminidase (Neu), which 
specifically cleaves 2,3/2,6 linkages on SA and Endoneuraminidase-N (Endo-N), 
which targets 2,8 linkages on the polymeric PSA chain. We observed that cleavage of 
SA by Neuraminidase treatment significantly reduced AAV4 transduction (> 1 log order 
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of magnitude reduction in luciferase activity, p < 0.005, Fig. 3B). In contrast, 
Endoneuraminidase-N mediated cleavage of 2,8-linked PSA significantly enhanced 
AAV4 transduction (> 7 fold increase, p < 0.05, Fig. 3C). Taken together, these 
preliminary results suggested that levels of SA and PSA on cell surfaces might 
differentially regulate AAV4 transduction. In contrast to AAV4, we observed no 
significant changes in the in vitro transduction efficiency of AAV4.18 virions arising from 
Neuraminidase or Endoneuraminidase-N treatments (Figs. 3D and E). However, we 
interpreted these results with caution due to the inherently low transduction efficiency of 
the AAV4.18 mutant in these cells. Earlier studies from our lab have demonstrated that 
the mutant AAV4.18 is likely transduction-deficient in vitro due its low binding affinity for 
SA on the cell surface (205).  
 
Ependymal transduction efficiency by AAV4.18 is similar to parental AAV4 
in neonatal mice. Previous studies have demonstrated that ICV administration of AAV4 
results in robust gene transfer in the ependymal cells and astrocytes lining the neonatal 
mouse cerebral ventricles (77). We injected P0 mice with identical titers of AAV4 or 
AAV4.18 packaging the tdTomato (tdTom) reporter gene driven by chicken beta actin 
(CBA) promoter via the ICV route. At 2 weeks post-injection, we carried out confocal 
microscopy analysis of sagittal mouse brain sections. Both vectors displayed efficient 
tdTom expression (tdTom+) in the sub-ependymal zone (SEZ) (Figs. 4A & B, Top row 
panels). In order to further characterize the tdTom+ cells at a cellular level, we 
performed immuno-colocalization with markers for ependymal cells (S100 and primary 
astrocytes (GFAP). As seen in Figs. 4D and E, tdTom+ cells (red) within the SEZ in 
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both AAV4 and AAV4.18 injected mouse brains show significant colocalization with 
S100+ cells (green). Similarly, comparable levels of colocalization of tdTom+ cells 
(red) and the GFAP+ cells (green) were also observed in the SEZs of AAV4 and 4.18 
treated mice (Figs. 4G & H). These observations were further supported by quantitative 
and statistical analyses that showed no significant differences in tdTom+ cells within the 
SEZ (Fig. 4C) or the percentage (%) colocalization with cellular markers (S100and 
GFAP) from AAV4 or AAV4.18 injections (Figs. 4F & I). These results indicate that both 
AAV4 and 4.18 vectors can efficiently transduce neonatal mouse ependyma. Although 
not relevant to the current study focused on the developing brain, it is noteworthy to 
mention that similar ependymal transduction profiles for AAV4 and AAV4.18 vectors 
were observed in adult mouse brains (data not shown). 
 
The AAV4.18 mutant displays expanded tropism for migrating progenitors. 
Neuronal progenitors in the SEZ are known to migrate via the RMS to the OB, where 
they differentiate into interneurons of the granular and periglomerular layers in 
developing and adult rodent brains (78). Confocal microscopy analysis of sagittal 
sections of postnatal mouse brains imaged at 2 weeks post-injection revealed strikingly 
distinct patterns of transduction between AAV4 and AAV4.18 vectors. Notably, AAV4.18 
injected mice showed significantly more tdTom expression in the RMS and OB (~3 and 
6 fold increase respectively, n=4 mice) regions as compared to AAV4 injected mice 
(Top row panels, Figs. 5A & B). We then performed immunostaining for the migrating 
neuroblast marker doublecortin (Dcx) and proliferating cell marker phospho-histone H3 
(PH3) to assess the cell types associated with the tdTom expression in the RMS and 
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OB. As seen in Figs. 5D & E (Middle row panels), tdTom+ cells (red) within the RMS 
and the OB in AAV4.18 injected mouse brains show significantly increased 
colocalization with Dcx+ cells (green) compared to AAV4 injected brains. A similar trend 
showing increased colocalization of tdTom+ expression with the PH3+ cells was 
observed in the RMS and to a lesser level in the OB of 4.18 injected brains (Figs. 5G & 
H; Bottom row panels). These observations were corroborated by quantitative and 
statistical analyses (Figs. 5C, F & I; *p < 0.05).  
 
Mutant AAV4.18 virions display enhanced CNS spread. In order to 
understand the mechanisms underlying the selective tropism of AAV4.18 for progenitors 
and neuroblasts in the postnatal CNS, we tracked the distribution of each AAV vector in 
the mouse brain parenchyma following ICV injections. To achieve this, we injected AAV 
vectors packaging genomes that were labeled with the thymidine analog 
bromodeoxyuridine (BrdU) through ICV injections in neonatal mice. Brains were 
harvested as early as 2 hours post vector administration and immunostained with an 
anti-BrdU antibody to visualize the biodistribution of AAV genomes in the brain 
parenchyma. AAV4 injected mice exhibit robust BrdU staining in the immediate vicinity 
of the site of injection in the SEZ and the outer meninges of the neonatal brain, 
presumably due to CSF transport (Fig. 6A, middle column, arrow). In contrast, the 
AAV4.18 vector shows a remarkably diffuse distribution pattern of BrdU-labeled viral 
particles not only in the SEZ (Fig. 6A, far right column, arrow) but also through the brain 
parenchyma and particularly in the cortical regions (Fig. 6A, far right column, 
arrowhead). Immunostaining analysis of brain sections with the endothelial cell marker 
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CD31 revealed BrdU+ AAV4.18 genomes (green) arranged alongside CD31+ 
processes (red) in the cortical regions of the mouse brain (Fig. 6B, far right column). In 
contrast, AAV4 genomes did not show this phenotype in the cortex (Fig. 6B, middle 
column). It should be noted that despite the expanded spread of the AAV4.18 genomes, 
complete colocalization with endothelial cells was not observed (Fig. 6B, far right 
column, inset). This suggests that the selective tropism for migrating progenitors can, in 
part, be attributed to the ability of AAV4.18 to spread across the neonatal brain 
parenchyma. 
 
           Selective enzymatic removal of PSA expands CNS tropism of AAV4 
vectors. The polysialylated form (PSA, 2,8-linked sialic acid) of neural cell adhesion 
molecule (NCAM) is expressed in migrating progenitor cells of the RMS during OB 
neurogenesis (211). PSA-NCAM plays a pivotal role in mediating rostral migration of 
olfactory bulb precursor cells whereas deficiencies in either PSA or NCAM cause 
accumulation of progenitor cells in the SEZ and RMS resulting in aberrant olfactory 
histogenesis (211, 212). We co-injected Neuraminidase, which selectively cleaves 
terminal SA residues or Endoneuraminidase-N, which cleaves the polymeric PSA chain 
with AAV4 packaging the CBA-tdTom reporter gene in neonatal P0 mice via the ICV 
route. Loss of terminal SA residues due to Neuraminidase treatment was confirmed by 
a significant reduction in fluorescein isothiocyanate (FITC)-labeled jacalin staining in the 
mouse brain (data not shown). Control injections of AAV4 alone resulted in highly 
localized tdTom+ expression in the ependymal lining, which was almost completely 
abrogated in Neuraminidase co-injected mice (Figs. 7A and C, left columns). We 
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observed minimal tdTom+ expression in migrating progenitors within the RMS and OB 
by AAV4, regardless of treatment with Neuraminidase (Figs. 7A and C, middle and 
right columns). Further, no colocalization with PSA-NCAM immunostaining was 
observed (Figs. 7B and D).  In contrast, Endoneuraminidase-N treatments increased 
AAV4 mediated tdTom+ expression in the RMS, but more strikingly in the OB (Fig. 7E, 
middle and right columns) and without affecting ependymal tdTom+ expression. (Fig. 
7E, left column). A concomitant and significant reduction in PSA-NCAM immunostaining 
in the RMS and OB upon Endoneuraminidase-N treatment is also observed (Figs. 7D & 
F). Taken together, these results suggest that 2,8-linked PSA negatively regulates 
AAV4 spread and potentially competes for 2,3-linked SA binding sites on the AAV4 
capsid.  
 To further characterize the expanded transduction profile of AAV4 observed 
following Endoneuraminidase-N co-injections, we carried out immuno-colocalization 
with several cellular markers. As discussed above, PSA-NCAM immunostaining was 
abrogated due to efficient cleavage of PSA residues from such treatments (Fig. 8A) and 
no colocalization with tdTom+ cells was observed as expected. Interestingly, we 
observed that AAV4 mediated transgene expression (tdTom+) significantly colocalized 
with NeuN+ neurons in the OB (Fig. 8B, arrows, far right column). However, we did not 
observe colocalization of tdTom+ cells with the astrocytic marker, GFAP or the radial 
glial marker, RC2/Nestin (Figs. 8C and D). These results indicate that under conditions 
displaying reduced PSA levels, AAV4 can efficiently transduce mature OB neurons. 
This data is consistent with observations from cell culture studies described earlier. 
 58 
 
Thus, it appears that modulation of PSA levels can influence AAV4 tropism in the 
mammalian brain. 
 
The low affinity AAV4.18 mutant displays expanded tropism for migrating 
progenitors by exploiting high PSA levels. In order to dissect the possible 
mechanism underlying the expanded tropism displayed by AAV4.18 from ependymal 
cells towards migrating neuroblasts, we subjected the mutant strain to similar enzymatic 
modulation of SA and PSA levels. Similar to untreated controls (Figs. 9A & B), co-
injection of Neuraminidase III with AAV4.18 did not alter the extent of co-localization 
between tdTom+ and PSA-NCAM+ cells in the RMS or the OB (Figs. 9C & D). In 
contrast, co-administration of Endoneuraminidase-N dramatically altered PSA-NCAM 
staining throughout the mouse brain, particularly within the migrating progenitor 
continuum and completely abrogated tdTom reporter gene expression in AAV4.18 
injected mouse brains (Fig. 9E and F). Taken together, these results support the notion 
that the AAV4.18 has undergone a complete switch in glycan receptor specificity from 
terminal 2,3-linked SA to the polymeric 2,8-linked PSA chain owing to a loss in SA 
binding affinity. In turn, AAV4.18 appears to exploit the PSA glycosylation pattern in the 
developing brain to efficiently transduce migrating progenitors.   
Further characterization of AAV4.18 treated mice co-injected with Neuraminidase 
revealed a striking correlation between the pattern of TdTom+ cells and PSA-NCAM 
staining along the migrating progenitor RMS-OB continuum (Fig. 10A). No apparent 
colocalization was observed with the mature neuronal marker, NeuN in the PSA-NCAM 
labeled region (Fig. 10B). Although, it is noteworthy to mention that some colocalization 
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was observed between tdTom+ and NeuN+ cells in the periphery of OB (data not 
shown). Several tdTom+ cells along the migratory pathway colocalized with the 
astrocyte marker, GFAP; but not the radial glial marker, RC2/Nestin in the RMS as well 
as OB (Figs. 10C and D). Taken together, these results corroborate the notion that 
modulating SA and PSA levels in the brain can be differentially exploited by AAV4 and 
AAV4.18 to attain strikingly distinct transduction patterns targeting the ependymal lining, 
neurons within the OB or migrating progenitors in the RMS and OB regions within the 
neonatal brain.  
 
2.5 Discussion 
Successful infection by parvoviruses such as AAV involves a series of  carefully 
orchestrated events including cell surface receptor binding, endocytic uptake, capsid 
uncoating, nuclear entry and genome release followed by second strand synthesis and 
subsequent transcription. The first step, i.e., parvoviral attachment to the host cell 
surface is mediated by different glycans (25). In the brain, AAV capsid interactions with 
heparan sulfate (HS) have been particularly well-studied. Direct parenchymal injection 
of AAV serotype 2, which utilizes HS as a primary receptor (35), results in a prominently 
neuronal transduction profile (40, 41). Co-injection of soluble heparin has been shown 
to improve the CNS spread and consequently transduction efficiency of AAV2 following 
intracranial injections in rodent models (47, 48). The ability to bind HS also appears to 
restrict the CNS transduction profile of AAV serotype 6 (46). However, this effect can be 
reversed in part by mutating a lysine residue (K531) on the capsid surface, which 
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abolishes HS binding (45, 46). These earlier studies highlight the potential for glycan 
expression patterns to regulate viral spread and tropism in the brain.  
In the current study, we have characterized a novel AAV mutant that selectively 
transduces migrating progenitors in the neonatal mouse brain. This mutant was 
originally discovered from a randomly mutated AAV4 capsid library and characterized 
as an SA-binding deficient mutant. When administered systemically, the AAV4.18 
mutant displays attenuated cardiopulmonary tropism in mice due to the low binding 
affinity towards O-linked 2,3-SA, the cognate receptor for the parental AAV4 serotype 
(205). In the neonatal mouse brain, the natural isolate AAV4 exclusively transduces 
ependymal cells following ventricular injection (77). Interestingly, when injected directly 
into the SEZ, AAV4 can transduce type B astrocytes in the SVZ and glia overlying the 
RMS (77). Our results now show that this dichotomy potentially arises from the high 
binding SA and PSA affinity of AAV4 capsids, which likely restricts transduction to the 
ependymal lining following ICV administration.  
In contrast, the low affinity AAV4.18 mutant can penetrate the ependymal barrier 
into the brain parenchyma following a single ICV injection and selectively transduce 
migrating neuroblasts and proliferating cells, apparently due to interactions with PSA 
alone (Figs. 3-5). It is noteworthy that the enhanced spread of AAV4.18 particles to 
distal regions of the mouse brain does not result in successful transduction of mature 
neurons within these regions. Rather, immunohistochemical analysis suggests that 
AAV4.18 particles that reach the cortex are closely associated with the brain 
microvasculature without actually transducing endothelial cells (Fig. 6). This observation 
suggests that interstitial solutes such as viral particles might exploit paravenous efflux or 
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the ‘glymphatic’ clearance pathway (62). Correspondingly, we postulate that low binding 
affinity AAV4.18 particles are more likely to be affected by interstitial fluid transport 
through white matter tracts and perivascular spaces leading to enhanced penetration of 
brain parenchyma.  
We further expanded these findings by evaluating the effect of selective 
enzymatic removal of 2,3- or 2,8-linked SA from the murine brain by ICV injection of 
substrate-specific neuraminidases. While AAV4 transduction is completely abrogated by 
selective SA removal, AAV4.18 transduction of a subset of cells in the ependymal wall, 
the choroid plexus and PSA-NCAM+ migrating progenitors remains unaffected (Figs. 7 
- 9). This selective requirement of polymeric 2,8-linked PSA chain rather than terminal 
SA residues for AAV4.18 transduction was clearly demonstrated by enzymatic removal. 
Taken together, these results support the notion that AAV4.18 can not only spread 
throughout the brain parenchyma, but also selectively exploit PSA (2,8-linked SA) to 
transduce postnatal migrating progenitors in the mouse forebrain.  
The expanded receptor usage and selective cellular tropism displayed by 
AAV4.18 particles are not a mere coincidence. It is well known that the linear 
homopolymer of alpha 2,8-linked sialic acid (polysialic acid/PSA) plays an indispensable 
role in embryonic and adult neurogenesis. Two regions of the brain, namely OB and 
hippocampal dentate gyrus are persistently neurogenic and undergo constant 
progenitor chain migration into adulthood in rodents (213). Despite multiple differences 
between adult and embryonic neurogeneses, consistent PSA-NCAM expression is a 
feature observed in both of these regions through adulthood (214). The biochemical 
properties of PSA make it a potent negative regulator of cell-cell adhesion. This is 
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important for successful migration of precursor cells during neurogenesis (215). This is 
potentially the reason PSA-NCAM is highly expressed in the neuronal precursor cells 
during olfactory neurogenesis (215). Furthermore, the enzymatic removal of PSA using 
Endoneuraminidase-N treatment disrupts the RMS leading to neuroblast dispersion to 
unspecific regions like cortex and striatum (211). Thus, the selective transduction of 
migrating progenitors by AAV4.18 can be directly attributed to the expression patterns 
of this unique glycan attachment factor that can vary with the developmental stage of 
the host organism.  
Certain gaps still remain in our understanding of the proposed AAV-PSA 
interactions. First, PSA does not appear to functionally influence the tropism or 
transduction efficiency of AAV4 or related mutants in physiological settings other than 
the CNS, such as the heart and lung following intravenous administration (205). It is 
likely that the developing brain provides a unique setting for this novel virus-glycan 
interaction. Secondly, the structural coordinates that mediate PSA recognition by AAV4 
and the mutant virion remain to be determined. Preliminary structural modeling revealed 
altered surface electrostatics for the AAV4.18 mutant in comparison with the parental 
AAV4 strain (data not shown). It is tempting to speculate that manipulation of capsid 
surface charge density might decrease affinity for branched or linear 2,3-linked SA 
glycans, while simultaneously imparting the expanded potential to recognize the 
negatively charged PSA glycopolymer.  
These hypotheses warrant further structural and biophysical analysis outside the 
scope of the current study. Nevertheless, our overall approach helps understand the 
functional implications of altering virus-glycan interactions in the CNS, impact of 
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developmentally regulated or disease-specific glycan expression profiles on virus 
neurotropism. Simultaneously, we provide a roadmap for engineering viruses to favor 
certain glycan architectures for gene transfer applications in the brain.  
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Figure 3: Effects of substrate-specific neuraminidases on AAV4/4.18 transduction 
in vitro (A) Schematic representation of O-linked 3/2,6 Sialic acid (top) and 8 
Polysialic acid (bottom) on mammalian cell surfaces. Legend describes different glycan 
symbols. Black and white arrows represent the cleavage sites of Neuraminidase (Neu) 
and Endoneuraminidase-N (Endo-N) enzymes, respectively. Effects of Neuraminidase 
and Endoneuraminidase-N treatment on AAV4 (B and C) as well as AAV4.18 (D and E) 
are also shown. CV-1 cells pretreated with each enzyme were incubated with AAV4 or 
AAV4.18 vectors packaging a CBA-Luc transgene (MOI = 1000 vg/cell) and luciferase 
activity in relative light units (RLU) measured at 24 hrs post-infection. Error bars 
represent standard deviation (n = 3). (n.s., not statistically significant; *p < 0.05 as 
determined by student t-test).   
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Figure 4: Ependymal transduction in the neonatal mouse brain by AAV4 and the 
AAV4.18 mutant. P0 mice were injected with 1x109 vg of AAV4 (A) or mutant AAV4.18 
(B) packaging a CBA-tdTom transgene into the left lateral ventricle. At 2 weeks post-
injections, mice were sacrificed and paraformaldehyde fixed brains were sectioned and 
immunostained. Brain sections were imaged using a Zeiss CLSM 700 confocal laser 
scanning microscope equipped with 488nm and 555nm excitation filters. Confocal 
micrographs show tdTom transgene expression in red. Global brain sections are 
confocal image stitches of representative 50 um vibratome sagittal sections and SEZ 
regions show tdTom expression in the sub-ependymal zone. (D and E) Immuno-
colocalization of tdTom gene expression (red) with ependymal cells (S100β, green) and 
(G and H) primary astrocytes (GFAP, green) is indicated by yellow pseudocolor within 
the S100β/GFAP merged images. Quantitative assessments of the AAV4 (dark grey 
bars) or AAV4.18 (light grey bars) transduced cells in the dorsal and ventral SEZ are 
indicated by the number of tdTom+ cells (C) and percentage colocalization with S100β+ 
cells (F), or GFAP+ cells (I). Error bars represent standard deviation (n = 4). (n.s., not 
statistically significant; *p < 0.05 as determined by student t-test). Representative 
confocal images are shown. 
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Figure 5: The AAV4.18 mutant exhibits selective tropism for migrating 
progenitors. P0 mice were injected with 1x109 vg of AAV4 (A, D, G) or AAV4.18 (B, E, 
H) packaging the tdTomato reporter transgene driven by a chicken beta actin promoter 
into the left lateral ventricle. Comparison of tdTom expression (red) in sagittal sections 
of the developing mouse brain including the sub-ependymal zone (SEZ), rostral 
migratory stream (RMS) and olfactory bulb (OB) regions are shown. (A, B) Immuno-
colocalization of AAV4 or AAV4.18 mediated gene expression (tdTom, red) with (D, E) 
the migrating neuroblast marker, doublecortin (Dcx+, green) and (G, H) the proliferative 
cell marker, phospho-histone H3 (PH3+, green) are shown. White arrows indicate the 
locations shown at higher magnification (insets) and immunocolocalized regions 
depicted in yellow. Quantitative analysis of the number of tdTom+ cells (C) and 
percentage colocalization with Dcx+ processes (F) and PH3+ cells (I) in the RMS and 
OB regions of AAV4 (dark grey bars) or 4.18 (light grey bars) treated mice are shown. 
Error bars represent standard deviation (n = 4). (n.s., not statistically significant; *p < 
0.05 as determined by student t-test). Representative confocal images are shown. 
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Figure 6: AAV4.18 particles show enhanced CNS spread. P0 mice were injected 
with 7.4x108 vg of AAV4 or AAV4.18 packaging BrdU-labeled genomes into the left 
lateral ventricle. At 2 hours post injections, mice were sacrificed and paraformaldehyde 
fixed brains were sectioned, immunostained and imaged as outlined in methods. (A) 
Global anti-BrdU immunostaining (green) in sagittal sections of the brain obtained from 
mock-treated, AAV4 or AAV4.18 injected mice into the left lateral ventricle (white 
arrows). The positions of the cortical regions shown in higher magnification in B are 
indicated by white arrowheads in A. (B) Immuno-colocalization of BrdU+ viral genome-
containing particles (green) and anti-CD31, endothelial cell marker immunostaining  of 
blood vessels (red) in the cortex. All experiments were carried out in triplicate, 
representative images are shown.  
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Figure 7: SA and PSA play opposing roles in AAV4 transduction within the 
neonatal mouse brain. (A, B) P0 mice were co-injected with mixtures of 1x109 vg of 
AAV4 mixed with PBS (control); (C, D) 3.5 mU of Neuraminidase (cleaves 2,3-/2,6- 
linked sialic acid); or (E, F) 1.45 U of Endoneuraminidase-N (cleaves 2,8 linked 
polysialic acid) into the left lateral ventricle. At 2 weeks post-injections, mice were 
sacrificed and paraformaldehyde fixed brains were sectioned and immunostained. 
TdTom transgene expression patterns (red) and PSA-NCAM immunostaining (green) 
resulting from enzymatic desialylations are shown in the global context or as higher 
magnifications of the RMS and OB regions. White arrows indicate the locations shown 
at higher magnification (insets). All experiments were carried out in triplicate, 
representative images are shown.  
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Figure 8: Removal of PSA expands AAV4 tropism to mature OB neurons.  P0 mice 
were co-injected with 1x109 vg of AAV4 mixed with 1.45 U of Endoneuraminidase-N into 
the left lateral ventricle. At 2 weeks post-injections, mice were sacrificed and 
paraformaldehyde fixed brains were sectioned and immunostained for different cellular 
markers, PSA-NCAM (A), NeuN (B), GFAP (C) and RC2/Nestin (D) with specific 
antibodies as outlined in methods. Sagittal sections of the mouse brain featuring 
progenitor migration in the rostral migratory stream (RMS) and olfactory bulb (OB) and 
immuno-colocalization of tdTom transgene expression (red) with each cellular marker 
(green) are shown. White arrows indicate the locations shown at higher magnification 
(insets) or immunocolocalized regions (shown in yellow). All experiments were carried 
out in triplicate, representative images are shown. 
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Figure 9: The AAV4.18 mutant selectively exploits polysialic acid (PSA) to 
transduce migrating progenitors. (A, B) P0 mice were co-injected with mixtures of 
1x109 vg of AAV4.18 mixed with PBS (control); (C, D) 5.2 mU of Neuraminidase 
(cleaves 2,3- and 2,6- linked sialic acid); or (E, F) 1.45 U of Endoneuraminidase-N 
(cleaves 2,8 linked sialic acid/polysialic acid) into the left lateral ventricle. Post-fixed 
sagittal sections of P14 mouse brains displaying tdTom transgene expression patterns 
resulting from enzymatic desialylation are shown in the global context or as higher 
magnifications of the RMS and OB regions. White arrows indicate the locations shown 
at higher magnification (insets) and immuno-colocalization of tdTom expression (red) 
with PSA-NCAM staining (green) is depicted in yellow (B, D, F). All experiments were 
carried out in triplicate, representative images are shown.  
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Figure 10: AAV4.18 selectively transduces migrating progenitors expressing 
polysialyated NCAM and GFAP.  P0 mice were co-injected with 1x109 vg of AAV4.18 
mixed with 5.2mU of Neuraminidase into the left lateral ventricle. Postfixed P14 mouse 
brains were sectioned and immunostained for different cellular markers, PSA-NCAM 
(A), NeuN (B), GFAP (C) and RC2/Nestin (D) with specific antibodies as outlined in 
methods. Sagittal sections of the mouse brain featuring progenitor migration in the 
rostral migratory stream (RMS) and olfactory bulb (OB) and immuno-colocalization of 
tdTom transgene expression (red) with each cellular marker (green) are shown. White 
arrows indicate the locations shown at higher magnification (insets) or 
immunocolocalized regions (shown in yellow). All experiments were carried out in 
triplicate, representative images are shown. 
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CHAPTER 3: LIMITED SYSTEMIC BURDEN AND BRAIN-SPECIFIC GENE 
DELETION WITH A NOVEL AAV VECTOR 
3.1 Overview 
Gene therapy using recombinant adeno-associated viral (AAV) vectors is 
emerging as a promising approach to treat central nervous system (CNS) disorders 
such as Spinal muscular atrophy, Batten, Parkinson and Alzheimer disease amongst 
others. A critical remaining challenge for CNS-targeted gene replacement, silencing or 
gene editing therapies is to limit potential vector dose-related toxicity in systemic, off-
target organs. Here, we address the latter concern through rational AAV vector design. 
Specifically, we characterize a lab-derived AAV chimeric (AAV2g9), which displays 
favorable CNS attributes derived from both parental counterparts, AAV2 and AAV9. 
This synthetic AAV strain displays preferential, robust and widespread neuronal 
transduction within the brain and decreased glial tropism. Importantly, we observed 
minimal systemic leakage of AAV2g9 compared to AAV9, when administered into the 
cerebral ventricles or by lumbar puncture. Correspondingly, AAV2g9 shows markedly 
decreased sequestration and gene transfer in off-target organs. A single intracranial 
injection of AAV2g9 vectors encoding guide RNAs targeting the schizophrenia risk gene 
MIR137 (encoding miR137) in CRISPR/Cas9 knockin mice resulted in brain-specific 
gene deletion with no detectable events in the liver. Dual glycan binding AAV vectors 
are a promising platform to potentially improve the safety of gene editing, RNAi or gene 
therapies for neurological disorders  
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3.2 Introduction 
The clustered, regularly interspaced, short palindromic repeats (CRISPR)-
associated endonuclease (Cas)9 technology has been utilized for targeted disruption of 
genomic loci in cell culture (216-219), animal studies (220-223), and recently for in vivo 
disease correction (221, 224, 225). Specifically, guide RNA (gRNA) dependent 
recruitment of Cas9 endonuclease (226) can be employed for generating double strand 
breaks in the targeted loci of the host genome (218, 227, 228). The recombinant adeno-
associated viral (rAAV) vector platform offers safe, efficient and tissue specific gene 
transfer systems for therapeutic delivery of CRISP/Cas9 modalities, in vivo (224). 
Understandably, the integration of rAAV and CRISPR/Cas9 technologies can be 
instrumental for gene therapy. However, it is crucial to exercise caution and preempt 
potential side effects before clinical translation of such combinatorial therapeutics. 
Adeno-associated viruses (AAV) are members of the Dependoparvovirus genus 
within the Parvoviridae family (16). These small, non-enveloped viruses package a 
single-stranded DNA genome within an icosahedral (T=1) capsid, approximately 25 nm 
in diameter (17). The topology of the AAV capsid presents a versatile surface for 
interaction with a wide variety of cellular ligands, carbohydrates in particular, which 
serve as attachment factors for viral infection (25). For instance, interactions of AAV 
serotype 2 with the glycosaminoglycan, heparan sulfate (hep) are well known. Other 
natural isolates such as AAV3b and AAV6 have also been shown to bind hep both in 
vitro and in vivo. Further, sialic acids with different linkage specificities and more 
recently, galactose (gal) have been identified as primary receptors for various AAV 
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strains (25, 229). Several of the aforementioned AAV strains are under active 
development as gene therapy vectors for different clinical indications (230, 231). 
The central nervous system (CNS) is comprised of a complex architecture of 
neurons, astrocytes, microglia, endothelium and other cell types. Glycosaminoglycans 
such as hep and chondroitin sulfate as well as sialylated glycans are ubiquitously 
expressed in the mammalian CNS and often tightly regulated during the course of 
neural development (210, 232). Several viral pathogens have evolved to exploit different 
glycosylation patterns within the brain. For instance, hep binding has been implicated in 
the neurovirulence displayed by members of the Alphavirus genus such as sindbis virus 
and equine encephalitis viruses (233, 234). In case of AAV, intracranial injection of a 
hep binding serotype, AAV2, shows restricted, neuronal gene expression (71, 89). 
Controlled co-injection of safe doses of soluble heparin have been shown to enhance 
AAV2 spread and transduction in the CNS (47, 48). Sialic acid binding serotypes such 
as AAV1 or AAV5 appear superior to AAV2 in mediating spread of transgene 
expression in the CNS (89). Widespread transgene expression in the CNS has also 
been demonstrated in case of AAV9, which utilizes gal as a primary attachment 
receptor (37, 90). Studies involving intravascular/intrathecal administration in mouse, 
canine, feline and non-human primate models have provided important insight into the 
CNS tropism of AAV9 and Rh.10 and supported their advancement as candidate 
vectors for clinical trials (54, 56, 66, 94, 235). 
Despite these exciting advances, several gaps exist in our understanding of 
AAV-glycan interactions in the CNS. Within this framework, a specific focus of the 
current study is to understand how glycans such as hep and gal mediate differential 
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AAV-mediated transduction patterns in the CNS. It is known that attachment to heparan 
sulfate (hep) influences the neurotropism of adeno-associated virus (AAV) serotype 2, 
herpes simplex virus, sindbis virus and equine encephalitis viruses amongst other 
examples. Although several natural AAV isolates broadly transduce neurons and glia in 
a hep-independent manner, glycan interactions within the central nervous system (CNS) 
are not well understood. We also systematically evaluated the role of galactose (gal) in 
determining the CNS transduction profile of AAV9 and several lab-derived strains. A 
hep-binding mutant (AAV2i8g9) or co-injection of soluble heparin with AAV2g9 
attenuated neuronal transduction, but redirected transgene expression to glia. Another 
chimeric strain, AAV8g9, which binds gal, but not hep, displayed enhanced CNS 
transduction in both neurons and glia compared to parental AAV8 vectors. Consistent 
with observations that gal binding improves transduction efficiency, a gal-binding AAV9 
mutant was completely attenuated in the brain. Together, these results corroborate 
distinct roles for hep and gal in determining neurotropism and spread of AAV vectors.  
Recombinant AAV vectors have met safety endpoints in several Phase I gene 
therapy clinical trials for treating Hemophilia, Alpha-1 Antitrypsin (AAT) deficiency, 
Alzheimer disease amongst other indications (236-238). Although vector re-dosing 
might be essential in some indications due to loss of gene expression observed in long 
term follow up studies (239), preclinical studies continue to show promise and advance 
with cautious optimism. One concern noted in hemophilia gene therapy clinical trials is 
the potential for vector dose-related hepatotoxicity in patients as evidenced by a rise in 
transaminases (237, 240). Although resolvable by administration of anti-inflammatory 
steroids such as methyl prednisolone, permanent loss in gene expression has been 
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observed (237). The dose and composition of clinical AAV vectors has been shown to 
influence these outcomes in preclinical toxicity studies (241). Accordingly, scientific, 
regulatory and clinical communities alike have established that continued improvements 
in vector design, development and manufacturing are needed (242, 243). 
To date, over a hundred naturally occurring strains of AAV derived from human 
and animal tissues have been isolated (244, 245). Multiple strains ranging from AAV 
serotypes 1 through 9 and Rh.10 are under active development as gene therapy vectors 
for different clinical indications (230, 231). Recent data from clinical gene therapy trials 
to treat Parkinson and Alzheimer disease have provided information that is critical 
towards continued AAV vector development (164, 238). In addition, preclinical studies 
involving intravascular/intrathecal administration in mouse, canine, feline and non-
human primate models have supported the advancement of serotypes such as AAV9 as 
candidates for clinical trials (54, 56, 66, 94, 235). Notably, AAV9 is currently being 
evaluated in Phase I clinical trials for the treatment of Spinal muscular atrophy (SMA) by 
intravascular injection and Giant axonal neuropathy (GAN) through intrathecal injection 
(Clinical trial identifiers NCT02122952, NCT02362438).  
A key observation from preclinical studies is that CNS administration of several 
naturally occurring AAV strains often results in vector sequestration within peripheral 
organs such as the liver and spleen via systemic leakage (94, 101, 235, 246). In the 
current study, we address this potential concern through vector design. Specifically, we 
describe the CNS transduction profile of a rationally engineered, chimeric AAV strain 
(AAV2g9), which harbors the ability to engage either heparan sulfate or galactose as 
receptors for cell entry (37, 206). We demonstrate exceptional CNS transduction 
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efficiency following single bolus injections of AAV2g9 as validated by two routes of 
administration in neonatal and adult rodents. More importantly, we establish potentially 
useful attributes of AAV2g9 for CNS-specific gene therapy applications, namely, 
preferential neuronal tropism, restricted CNS biodistribution and minimal transgene 
expression in off-target peripheral organs.  
Lastly, systemic dissemination of CNS-directed CRISPR/Cas9 modalities can 
result in undesirable genome editing/disruption events in peripheral organs. The 
microRNA (MIR) 137 gene is ubiquitously expressed across mammalian tissue types 
(247). In the CNS, MIR 137 dysfunction has been strongly associated with risk of 
schizophrenia in patient cohorts (248-252). In addition to involvement in SZ, miR137 
also plays an important role in regulation of neurogenesis and neuronal maturation in 
the brain (253, 254). Using AAV2g9, we demonstrate CNS-restricted gRNA mediated 
disruption of miR137 locus within the Cas9 transgenic mouse (222). 
  
3.3 MATERIALS AND METHODS 
Recombinant AAV vector production. An updated triple plasmid transfection 
protocol was used to generate recombinant AAV vectors. . The pXR plasmids 2g9, 8g9, 
2i8g9 and 9W503R have been described earlier (206, 255) All other plasmids used for 
AAV production in this study were obtained from the UNC vector core. Briefly, the 
transfection mixture contained (a) the pXR9 helper plasmid or pXR2g9/2i8g9 helper 
plasmids; (b) the adenoviral helper plasmid pXX6-80; and (c) pTR-CBh-ScGFP, pTR-
hSyn-EGFP, pTR-GFAP-EGFP or pTR-CBA-Luc plasmids encoding the green 
fluorescent protein (GFP) or luciferase (Luc) reporter genes driven by the chicken β 
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hybrid (CBh), human synapsin (hSyn), glial fibrillary acid protein (GFAP) or the chicken 
β actin (CBA) promoters, flanked by inverted terminal repeats (ITRs) derived from the 
AAV2 genome. Vector purification was carried out using iodaxinol gradient 
ultracentrifugation protocol, buffer exchange and concentration using vivaspin2 100 kDa 
molecular weight cut-off (MWCO) centrifugation columns (F-2731-100 Bioexpress, 
Kaysville, UT, USA). Vector genome (vg) titers were obtained by quantitative PCR 
(Lightcycler® 480, Roche Applied Sciences, Pleasanton, CA) using primers designed to 
selectively bind AAV2 ITRs (forward, 5’- AAC ATG CTA CGC AGA GAG GGA GTG G -
3’; reverse, 5’- CAT GAG ACA AGG AAC CCC TAG TGA TGG AG -3’) (IDT 
Technologies, Ames, IA).  
 
Intracerebroventricular (ICV) administration. Animal experiments reported in 
this study were conducted with Balb/C or C57/Bl6 mice bred and maintained in 
accordance to NIH guideline as approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). Postnatal day 0 (P0) Balb/c pups which were rapidly anesthetized 
on ice for 2 min followed by stereotaxic intracerebroventricular (ICV) injections. 
Specifically, AAV9 or AAV2g9 vectors packaging different transgenes were injected into 
the left lateral ventricle (total volume <3 µl) using a Hamilton 700 series syringe with a 
26s gauge needle (Sigma-Aldrich, St. Louis, MO), attached to a KOPF-900 small animal 
stereotaxic instrument (KOPF instruments, Tujunga, CA). All neonatal injections were 
performed 0.5mm relative to the sagittal sinus, 2mm rostral to transverse sinus and 
1.5mm deep. Following vector administration, mice were revived under a heat lamp and 
rubbed in the bedding before being placed back with the dam. 2 weeks post vector 
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administrations (P14) the mouse brains were harvested, post-fixed and immunostained 
as described in detail below. For co-administration of soluble heparin (generously 
provided by Dr. Jian Liu, School of Pharmacy, UNC), AAV vectors (3.5x109 vg) were 
mixed with 1 g of heparin and a total volume of 2-3 l administered per mouse for 30 
min on ice prior to ICV injections in neonatal mice. 
 
Intrathecal (IT) administration. AAV vectors were infused into the mouse 
intrathecal cerebrospinal fluid (CSF) space using Alzet mouse intrathecal catheter and 
pump (Alzet, 0007743, Durect corp. Cupertino, CA, USA). Briefly, the pumps were 
primed with 0.9% NaCl for ~12 hrs followed by AAV vectors. 8 week old C57/Bl6 males 
were anesthetized with intraperitoneal injection of Avertin (1.25%, 2,2,2-tribromoethanol 
in PBS) at 0.23 ml/10 g body weight prior to infusions. A 23 gauge needled was used to 
expose the L5-L6 intervertebral space and the osmotic pump was implanted and 
sutured under the skin. The vector was then infused at the rate of ~8 µl/hr for ~24 hours 
to infuse a total 1x1011 vg of AAV9 and AAV2g9 vectors packaging the CBh-ScGFP 
transgene. 3 weeks post administration of the vectors, the mice were sacrificed, post-
fixed in paraformaldehyde, sectioned and immunostained as described below. Another 
cohort of 8 week old Balb/C mice was injected via IT bolus injections with AAV9 and 
AAV2g9 vectors as described elsewhere (256). Briefly, equal titers of vectors packaging 
the CBA-Luc transgene cassette (total volume 4-5 µl) was free-hand injected into the L5 
and L6 intervertebral space. The injections were carried out an angle of 20-30 degrees 
from spinal column using the 30G disposable needle attached to 50 µl Luer-hub 
Hamilton syringe (Sigma-Aldrich, St. Louis, MO).  
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Vector genome biodistribution and pharmacokinetic analyses. Cohorts of 
neonatal and adult mice used for biodistribution studies were sacrificed 3 days post 
vector administration via the ICV or IT bolus routes. The genomic DNA was extracted 
from the tissue lysates and blood using the DNeasy® kit (Qiagen, Valencia, CA). To 
calculate viral genome copy numbers QPCR was performed with primers specific to 
luciferase transgene 5’-AAAAGCACTCTGATTGACAAATAC-3’ and 5’-
CCTTCGCTTCAAAAAATGGAAC-3’. The vector genome copy numbers were 
normalized to mouse lamin B2 locus as the housekeeping gene using the primers 5’-
GGACCCAAGGACTACCTCAAGGG-3’ and 5’- AGGGCACCTCCATCTCGGAAAC-3’. 
The vector biodistribution was represented as the ratio of vector genomes per cell 
recovered in the peripheral organs to the CNS site of injection (brain or the spinal cord). 
For pharmacokinetic studies, the vector genome copy numbers were calculated from 
total DNA isolated from 10 l blood. 
 
Tissue processing, immunofluorescence and confocal microscopy. 
Neonatal and adult mouse cohorts were sacrificed 2 weeks and 3 weeks post vector 
administrations respectively. The mice were overdosed with tribromoethanol (avertin) 
(0.2 ml/10 g of 1.25% solution) via the intraperitoneal route. This was followed by 
transcardial perfusions of PBS and 4% paraformaldehyde in PBS. The organs were 
removed and post-fixed for 24 hr prior to sectioning. Briefly, 50 μm thick sections were 
obtained using a Leica VT 1200S vibrating blade microtome (Leica Biosystems, IL). The 
spinal cords were cryo-sectioned by UNC animal histopathology core. The sections of 
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mouse organs from various treatments were blocked in 10% goat serum (Sigma-
Aldrich, St. Louis, MO) and 1% Triton X (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hr. 
This was followed by overnight incubation with primary monoclonal antibodies at 4˚C. 
The primary antibodies utilized as a part of this study are as follows: Rabbit anti-GFP 
(Life-Technologies- G10362, 1:750) mouse anti-GFAP (Abcam-10062, 1:1000), rabbit 
anti-NeuN (Abcam-104225, 1:750), chicken anti-GFP (Abcam-13970 1:750). Secondary 
antibodies were raised in goats and conjugated to Alexa 488 (anti-rabbit Abcam-96883, 
anti-chicken Abcam-96947), Alexa 594 (anti-Rabbit Abcam-96885) or Alexa 647 (anti-
mouse Abcam-150115). The secondary antibodies were used at a standard dilution of 
1:500. The immunohistochemical analyses of GFP expression was conducted using 
Vectastain ABC kit (Rabbit IgG PK-4001 kit, Vector biolabs, Burlingame, CA, USA). We 
used Zeiss CLSM 700 confocal laser scanning microscope for imaging sections of 
different organs after immunostaining (Microscopy services laboratory, UNC). The 
images were stitched, pseudocolored and analyzed on the Zen® Black software.  
 
GuideRNA (gRNA) design. Two gRNAs were designed to detect 98bp Pre-
miR137 flanking region and analyzed by COSMID (crispr.bme.gatech.edu) to check 
potential off-target sites (257). Target sequencing used to make the gRNAs are 
following: mir-137-g1; CGTCACCGAAGAGAGTCAG, mir-137-g3; 
GTAGTCGAGGAGAGTACCAG. For control gRNA, we used a 20bp sequence, which 
recognizes an unspecific backbone region of plasmid DNA (Con-g1; 
GTCGACTCTAGAGGATCCAC). Tandem repeat of U6 promoter-target sequence-
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guideRNA is conjugated with EF1core promoter-tdTomato-P2A-PuroR and subcloned 
into the pTR vector for packaging into AAV.  
 
Droplet digital PCR (ddPCR). PureLink Genomic DNA extraction kit (Thermo 
Fisher Scientific, K182002) was used to obtain DNA from brain and liver tissues. 
Following sequences of primers and probes were used for the ddPCR assay. 
Mmir137L206ddPCR; GCAGCAGTGACAGCGGTAGC, Mmir137R206ddPCR; 
TGGCAACCGGGAGCTTTTAG, Mmir137MTFAMddPCR; /56-
FAM/TCCACCCAA/ZEN/GAATACCCGTCACCG/3IABkFQ/, Mmir137WTHEXddPCR; 
/5HEX/CCCTCCCAG/ZEN/CCCACCAGCTG/3IABkFQ/ 
For ddPCR, 2x ddPCR Supermix for Probes (No dUTP; Bio-rad, 1863023), the QX100 
Droplet generator and reader (Bio-rad) were employed. 10ng genomic DNAs were 
subjected to PCR amplification by C1000 thermal cycler (Bio-rad) with the following 
condition: 95°C 10 min x1, (4°C 30 sec, 65°C 1 min)x40, 98°C 10 minx1; 2°C/sec. 
Obtained data was analyzed by the QuantaSoft software (Bio-rad). 
 
3.4 RESULTS AND DISCUSSIONS 
AAV2g9 and AAV9 display similar spread and transduction efficiencies in 
the CNS. We first carried out neonatal (P0) mouse intracerebroventricular injections 
(ICV) comparing AAV2g9 and AAV9 vectors packaging a self-complementary GFP 
(ScGFP) cassette driven by the ubiquitous chicken β actin hybrid (CBh) promoter. At 2 
weeks post administration (3.5x109 vector genomes (vg)/mouse), diaminobenzidine 
(DAB) immunohistochemistry and confocal microscopy analysis of post-fixed mouse 
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brain sections revealed extensive GFP expression across multiple sections in the 
rostrocaudal axis of the mouse brain for both AAV strains (Fig. 11A). Specifically, we 
observed robust transduction in the olfactory bulb, striatum, hippocampus and cortical 
regions of the mouse brain. To further compare cellular transduction profiles of the two 
vectors, we generated higher magnification confocal micrographs of functionally 
relevant regions of the brain including the cortex, amygdala, hypothalamus and 
hippocampus. Mice injected with AAV9 or AAV2g9 showed comparably robust GFP 
expression in these regions (Fig. 11B). Additionally, we observed that while AAV9 
treatment resulted in GFP+ cells with neuronal or glial morphology, AAV2g9 mediated 
GFP expression was mostly restricted to neurons. We further validated this observation 
using immune co-localization with the neuronal antigen marker, NeuN or glial fibrillary 
acid protein marker, GFAP. These results were further confirmed upon quantitation, 
which revealed a ~4 fold reduction in GFP+ cells with glial morphology for AAV2g9, but 
no significant differences between the two vectors in neuronal populations (Fig. 13A, 
B). Taken together, these results suggest that AAV2g9 spreads efficiently across the 
neonatal mouse brain, while demonstrating a robust and neurotropic transduction profile 
from a single unilateral ICV injection.  
 
AAV2g9 and AAV9 display different cell-type specificities in the CNS. We 
then generated AAV9 and AAV2g9 vectors packaging single-stranded (ss) GFP 
cassettes driven by the neuron-specific human synapsin I (hSyn) or the glia-specific 
glial fibrillary acid protein (GFAP) promoter. Vectors (3.5x109 vg/mouse) were 
administered in postnatal day 0 (P0) mice via the ICV route and post-fixed brain tissues 
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analyzed at 2 weeks post administration by diaminobenzidine (DAB) 
immunohistochemistry, immunostaining and confocal microscopy analysis. Both AAV9 
and AAV2g9 vectors packaging transgene driven by hSyn promoter displayed robust 
transduction across multiple sections of the mouse brain (Fig. 12A). Specifically, we 
observed GFP+ cells colocalizing with NeuN+ cells (yellow) in various regions including 
the striatum, cortex, hippocampus, amygdala and hypothalamus (Fig. 12B). As 
expected, no glial staining was observed for either vector supporting the potential 
application of such neuron-specific promoters for CNS gene therapy studies.  
In contrast to hSyn promoter driven expression, we observed striking differences 
in the patterns of GFP expression mediated by AAV9 and AAV2g9 vectors packaging 
the GFAP promoter driven transgene cassette. Notably, AAV9 injections resulted in 
widespread GFP expression in cells with glial morphology across the entire brain 
parenchyma in multiple brain sections (Fig. 12C). In contrast, mice injected with 
AAV2g9 exhibit spatially restricted GFP expression within close proximity of the site of 
cerebrospinal fluid (CSF) injection (lateral ventricles) or along the immediate point of 
contact between the CSF and brain parenchyma, the inner meninges. To further confirm 
these observations, we co-immunostained different sections of the mouse brain for GFP 
expression (green) with neuronal marker-NeuN or glial marker-GFAP (red) as before. 
High magnification confocal micrographs generated at different brain regions show 
robust GFP+ expression from AAV9 injections in GFAP+ cells, but not NeuN+ cells (Fig. 
12D). These observed patterns of transgene expression were further confirmed by 
quantitative analysis, which revealed ~2.5 fold reduction in glial transduced area 
throughout the brain with AAV2g9 vectors under GFAP promoter activity (Fig. 13C, D). 
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These results demonstrate for the first time that AAV9 vectors packaging GFAP 
promoter driven expression cassettes are excellent candidates for glial gene transfer 
applications, while AAV2g9 appears to more neurotropic and hence suitable for CNS 
gene transfer applications targeting neuronal populations. From the AAV biology 
perspective, AAV2g9 appears to preferentially transduce neurons over glia, while this is 
patently not the case with AAV9. 
 
Heparan sulfate interactions are critical towards preferential neuronal 
transduction by AAV2g9 vectors. The interaction of AAV2 vectors with heparan 
sulfate (HS) proteoglycans is associated with preferential neuronal transduction in the 
immediate vicinity to site of CNS administration (71, 89). Co-administration of soluble 
heparin has been shown to block the ability of AAV2 to bind hep and alter transduction 
profiles in vitro and in vivo (35, 47, 48). Therefore, we compared the CNS transduction 
profiles of AAV2 and AAV2g9 to co-injections of AAV2g9 with 1 g of soluble heparin in 
the neonatal mouse brain. Further, we generated a hep binding mutant, AAV2i8g9, as 
described in earlier studies by our lab (206). Specifically, we injected equal viral titers 
(3.5x109 vg) of AAV2, AAV2g9, AAV2g9 + soluble heparin or AAV2i8g9 packaging CBh-
ScGFP transgene via the ICV route in P0 mice. As shown in Fig. 14A, we observed a 
low level of GFP+ expression as evidenced by DAB immunostaining within the 
hippocampal sections of AAV2 injected mouse brains. Consistent with earlier results, 
AAV2g9 displayed robust and widespread CNS transgene expression supporting the 
notion that the gal footprint enhances transduction efficiency and spread. Further, we 
observed a decrease in GFP+ expression across the brain parenchyma in AAV2g9 + 
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soluble heparin treated animals as well as AAV2i8g9 treated mouse cohorts in 
comparison with AAV2g9 (Fig. 14B-D). 
High magnification confocal micrographs of multiple regions of the mouse brain, 
namely; the somatosensory  cortex (SCT), piriform cortex (PCT), motor cortex (MCT), 
dentate gyrus (DG), amygdala (AMG) and hippocampal CA1, CA2 and CA3 regions 
were then generated. As seen in the top panel of Fig. 14E, we observed sporadic 
expression in neurons and astrocytes in case of AAV2-injected mice. On the other 
hand, extensive and preferential neuronal transduction was observed across these 
regions in case of AAV2g9 as observed earlier (Fig. 14E, second row panel). In 
contrast, loss of hep binding, either by competitive inhibition with soluble heparin or with 
the AAV2i8g9 mutant resulted in a decreased neuronal transduction in multiple brain 
regions (third row and bottom row panels, Fig. 14E). In addition, loss of neuronal 
transduction was accompanied by an increase in GFP+ cells with glial (astrocytic) 
morphology in these cohorts. Taken together, our observations suggest that hep binding 
is critical in determining the preferential neuronal tropism displayed by AAV2g9. 
 
Galactose (gal) binding enhances CNS transduction of AAV vectors 
independent of heparan sulfate (hep) binding interactions.  The exact mechanisms 
by which AAV9 exploits its primary receptor, gal (37) for CNS transduction are yet to be 
determined. We have previously shown that a single point mutation on the VP3 region 
of the AAV9 capsid (W503R) dramatically alters the systemic tropism of the virus by 
disrupting the gal footprint (255, 258). To this end, we compared transduction profiles of 
AAV9 and AAV9W503R packaging CBA-TdTomato (TdTom) fluorescent reporter 
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transgene (3.5x109 vg) in P0 mice via the ICV route. Two weeks post injections; mice 
were sacrificed, fixed and subjected to confocal analysis for TdTom expression. As 
shown in Fig. 15, AAV9-CBA-TdTom (left column) injected mouse brains exhibit robust 
TdTom+ transgene expression (pseudocolored white) across multiple regions of the 
mouse brain, namely: olfactory bulb, cortex, sub-ependymal zone, hippocampus and 
cerebellum. On the other hand, we observed a complete loss of TdTom+ expression in 
the mouse brain injected with AAV9W503R-CBA-TdTom (Fig. 15, right column). This 
result demonstrates the critical role played by gal in mediating the CNS transduction of 
AAV9. A single point mutation attenuating gal interactions (258, 259) on the AAV9 
capsid protein results in a loss of function phenotype within the CNS.  
To further demonstrate the distinct role played by hep and gal in CNS 
transduction by different AAV strains, we engineered the gal footprint (206) onto the 
primate isolate, AAV8 (244). Unlike AAV2, AAV8 does not engage hep as the cellular 
attachment receptor (260). Specifically, we injected equal titers (3.5x109 vg) of AAV8 or 
AAV8g9 packaging the CBh-ScGFP transgene in P0 mice via the ICV route. At 2 weeks 
post vector administration; brains and spinal cords were harvested from the mouse 
cohorts and subjected to immunostaining and confocal analysis. As shown in Fig. 16A, 
we observed that AAV8g9 injected mice showed enhanced spread and efficiency of 
GFP+ transgene expression within multiple sections of the mouse CNS. Further co-
immunostaining with neuronal and glial cellular markers (i.e., NeuN and GFAP, 
respectively) showed that cellular tropisms were unaltered with no preferential 
transduction of either neurons or astrocytes by both AAV8 and AAV8g9 (Fig. 16B). 
These results indirectly support the notion that the robust CNS transduction profile is 
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independent of hep binding. More importantly, these results further corroborate the 
notion that gal binding ability can enhance both CNS transduction efficiency and spread 
without altering the endogenous cellular tropism displayed by a particular AAV capsid 
(natural or engineered).  
 
AAV2g9 and AAV9 display similar transduction profiles in adult mice after 
intrathecal administration. To compare the two strains in adult mice, we carried out 
intrathecal (IT) infusions of AAV9 or AAV2g9 packaging CBh-ScGFP reporter transgene 
into the lumbar CSF space of 8 week old mice. At 3 weeks post administration of 1x1011 
vg/mouse, we subjected postfixed tissues to immunohistochemical analyses and 
confocal imaging as outlined in online methods. As shown in Fig. 17A, IT infusions of 
both AAV9 and AAV2g9 resulted in strong transgene expression in the lumbar, thoracic 
and cervical spinal cord regions. Of note, we observed GFP expression in multiple gray 
and white matter regions of the spinal cord. Further, we compared cellular transduction 
profiles resulting from IT infusions of AAV9/2g9 vectors. Specifically, we focused on 
different regions of the adult CNS, namely: ventral horn (VH), dorsal horn (DH), 
intermediate gray matter region (INT), ventral funiculus (VF), lateral funiculus (LF), 
ventral commissure (VC), and rubrospinal tract (RT). As shown in Fig. 17B, both 
AAV2g9 and AAV9 infused mice exhibit robust GFP expression in these regions of the 
spinal cord. In both AAV9 and AAV2g9 injected mice, we observed that the GFP+ cells 
(green) in the gray matter regions of the spinal cord (VH, DH and INT) extensively 
colocalized with NeuN+ as well as GFAP+ cells. Within the white matter regions of 
spinal cord (VF, LF, VCOM and RT), the GFP+ (green) cells from either injection 
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extensively colocalized with GFAP+ cells (Fig. 17B). Importantly, these observations 
also underscore the potential influence of route of injection on the cellular tropism of 
different AAV vectors.  
 
AAV2g9 and AAV9 display distinct systemic biodistribution and off-target 
transduction profiles following CNS administration. Having established the 
robustness of the rationally engineered AAV2g9 strain, we compared the systemic 
leakage, vg biodistribution and gene expression profiles in peripheral organs resulting 
from ICV or IT injections of AAV9 and AAV2g9 in both neonatal and adult mice. At 3 
days post-administration, we extracted whole genomic DNA from different organs and 
determined vg copies using qPCR in different peripheral organs including the liver, heart 
and spleen. We observed a striking difference between the off-target biodistribution 
profiles of AAV9 and AAV2g9 vectors following ICV or IT injections. As seen in Fig. 
18A-C, in the AAV9 injected neonatal mouse cohort, ~40%, 30% and 3% of the viral 
genomes were recovered from the liver, heart and spleen, respectively, in comparison 
with the brain (normalized to 100%). In contrast, AAV2g9 vg copy numbers ranged from 
~1.4%. 0.7% and 0.003% in these peripheral organs. In the adult mouse cohort, AAV9 
vg copies recovered in the liver, heart and spleen were 188%, 81% and 59%, 
respectively in comparison with vg copies recovered from the spinal cord (normalized to 
100%). In contrast, only ~3%, 4.5% and 10% of vg copies were recovered from these 
systemic organs in the AAV2g9 treated cohort (Fig. 18E-G). These results suggest that 
unlike AAV9, AAV2g9 is sparingly sequestered in off-target, systemic organs following 
CNS administration.  
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To further corroborate the biodistribution results, we harvested different 
peripheral organs from the ICV and IT mouse cohorts treated with either AAV2g9 or 
AAV9 and subjected post-fixed tissue to immunostaining and confocal imaging analysis 
as outlined earlier. We observed robust GFP expression in the heart, liver and spleen of 
both neonatal (ICV) (Fig. 18D) and adult (IT) (Fig. 18H) mice treated with AAV9. 
Consistent with biodistribution data, AAV2g9 treated mice exhibit near background 
levels of GFP expression in both ICV and IT cohorts. Together, these results are also 
consistent with the reduced leakage of AAV2g9 vectors (>100 fold) into the blood 
circulation that was observed in comparison to AAV9 vectors (Fig. 19). Briefly, AAV9 
vector genomes were observed in blood as early as 15 min post-administration and 
continued to decline over two days. These results are consistent with earlier studies 
reported by our lab and others (258, 261). In contrast, AAV2g9 vector genomes 
remained near background levels with a slight increase in copy number observed at the 
24 hr and 48 hr time intervals. Together, our results confirm that unlike AAV9, AAV2g9 
undergoes significantly reduced systemic leakage following CNS administration and 
consequently displays low levels of sequestration and transgene expression in 
peripheral organs. 
 
Brain-restricted deletion of MIR 137 gene using AAV2g9 in CRISPR-Cas9 
knock-in mice. We have established that CNS administration of AAV2g9 results in 
limited systemic exposure and efficient gene transfer within the neural tissue. To 
demonstrate application of this unique property, we produced AAV2g9 vectors 
packaging two gRNAs for targeted disruption of the MIR 137 gene in the brain. 
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Specifically, the gRNAs were designed to recognize both ends of the 85bp pre-miR137 
region. Equal titers of AAV2g9 packaging miR137gRNA or controlgRNA were injected 
into Cas9 transgenic mice (222) via unilateral ICV route. 2 weeks post vector 
administration the mice were sacrificed and organs were harvested. The brain and liver 
tissues were subject to genomic DNA extraction. To evaluate gene disruption events, 
we utilized the droplet digital PCR technique. Briefly, primers were designed to amplify 
206 bp mouse genomic region flanking the miR137 target locus. Fluorescent probes 
were designed to bind miR137gRNA target region (FAM, red) and an unspecific 
downstream locus (HEX, green). Successful disruption of miR137 locus results in 
exclusive excitation of HEX probe alone (green). Whereas both FAM and HEX probes 
are excited (orange) in case of no gene disruption events (Fig. 20A). First, we 
evaluated AAV2g9 vector genome biodistribution by performing QPCR on genomic 
DNA samples obtained from brain and liver tissues of the injected mice. We observed 
significant enrichment of AAV genomes within the brain as compared to the systemic 
liver tissue (Fig. 20B). Next, droplet digital PCR analysis revealed that the frequency of 
miR137 eliminated alleles was significantly higher (green dots) in mice that received 
AAV2g9-miR137gRNA, as compared to AAV2g9-controlgRNA cohort (Fig. 20C, red 
arrow). Correspondingly, quantitative analysis of this phenomenon demonstrated a 
significant increase in mutant allele frequency within the miR137gRNA injected mouse 
brains (Fig. 20D).  
Next, we examined if the gene disruption events were specific to the brain. 
Identical ddPCR analysis conducted on liver DNA extracted from the same mouse 
cohorts displayed near background levels of miR137 elimination in the systemic organ 
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(Fig. 20E). Further quantitation demonstrated negligible mutant allele formation due to 
both AAV2g9-controlgRNA and AAV2g9-miR137gRNA injections in the liver (Fig. 20F). 
Overall, our data demonstrates CNS-restricted gene disruption within the Cas9 
transgenic mouse using ICV administration of engineered AAV2g9 vector. 
Micro RNAs (miRNAs) are one of the largest species of non-coding RNAs that 
employ post-transcriptional silencing mechanisms to control ~60% of host gene 
expression (262). Majority of miRNA expression occurs in the CNS where gene 
regulatory mechanisms within neuronal subpopulations orchestrate states of normalcy 
and disease (263). Large scale GWAS studies conducted across ~40,000 patients 
recently led to the identification of disruption in MIR 137 gene function to have a strong 
correlation with the SZ disease occurrence (248, 264). It is well known that establishing 
a CNS-specific gene delivery system is crucial for developing gene therapy strategies 
and generating disease models of neurological disorders. As miR137 and CAG 
promoter driven Cas9 are both expressed in brain and liver tissue (222, 247), it is safe 
to assume that the brain specific miR137 elimination relies on AAV2g9 vector design. 
To our knowledge, this is the first example of CNS-specific gene disruption using an 
engineered AAV vector. 
Although we successfully demonstrate CNS-restricted gene disruption in this 
study, certain caveats are noteworthy and need to be addressed by future studies. For 
instance, we achieved a modest ~5% frequency of MIR 137 elimination within the 
AAV2g9-miR137gRNA injected Cas9 transgenic mouse brain. It is intriguing to 
speculate that the Cas9 expression within the mouse brain could be mosaic, resulting in 
a smaller subset of CNS cells capable of undergoing CRISPR mediated gene 
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disruption. Moving forward, it is important to evaluate the percentage of cells expressing 
Cas9 within the mouse brain. Additionally, in the current study we utilized rAAV vectors 
packaging single stranded DNA genomes. Packaging the gRNA constructs into a self-
complementary AAV cassette can possibly enhance the gene transfer efficiency and 
subsequently elevate MIR 137 gene disruption frequency. 
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Figure 11. Comparison of transgene (GFP) expression and cellular tropisms 
displayed by AAV9 and AAV2g9 vectors with a ubiquitous promoter after 
ventricular (ICV) injection. Postnatal day 0 (P0) mice were injected with equal viral 
titers (3.5x109 vg) of AAV9 or AAV2g9 packaging a ScGFP transgene driven by a 
ubiquitous chicken  hybrid (CBh) promoter into the left lateral ventricle. At 2 weeks 
post vector administration, the mice were sacrificed and paraformaldehyde postfixed 
brains were sectioned and immunostained as described earlier. (A) Representative 
images of coronal sections obtained from olfactory bulbs, lateral ventricles and 
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hippocampi are shown. Inset images from whole brain sections are shown to the right of 
each section at higher magnification. (B) Top image panel shows higher magnification 
images of DAB staining (GFP expression) in functionally relevant regions of the mouse 
brain namely; somatosensory cortex (SCT), piriform (PCT), motor CT (MCT), dentate 
gyrus (DG), amygdala (AMG), hypothalamus (HTL) and hippocampal CA1, CA2 and 
CA3 are shown. Middle and bottom panels show immuno-colocalization of GFP 
expression (green) with neuronal marker, NeuN or glial marker, GFAP (red). All 
experiments were conducted in triplicate and representative images are shown. 
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Figure 12. Comparison of transgene (GFP) expression and cellular tropisms 
displayed by AAV9 and AAV2g9 vectors with cell type-specific promoters after 
ventricular (ICV) injection. Postnatal day 0 (P0) mice were injected with equal viral 
titers (3.5x109 vg) of AAV9 or AAV2g9 packaging a single-stranded GFP (ssGFP) 
transgene driven by the (A,B) hSyn promoter or the (C,D) GFAP promoter into the left 
lateral ventricle. At 2 weeks post vector administration, the mice were sacrificed and 
paraformaldehyde postfixed brains were sectioned and immunostained. 
Diaminobenzidine (DAB) immunohistochemistry was used to detect GFP expression. 
(A,C) Representative images of coronal sections obtained from olfactory bulbs, lateral 
ventricles and hippocampi are shown. Inset images from whole brain sections are 
shown to the right of each section at higher magnification. (B,D) Representative 
confocal images of coronal tissue sections at higher magnification. Top image panel 
shows higher magnification images of DAB staining (GFP expression) in functionally 
relevant regions of the mouse brain namely; Striatum (STR), piriform CT, Motor CT, 
dentate gyrus (DG), amygdala (AMG), hypothalamus (HTL) and hippocampal CA1, CA2 
and CA3 regions are shown. Middle and bottom panels show  immuno-colocalization of 
GFP expression (green) with neuronal marker, NeuN  or glial marker, GFAP (red) 
obtained using a Zeiss CLSM 700 confocal laser scanning microscope. Co-localized 
cells are pseudocolored yellow (GFP/NeuN or GFP/GFAP overlay). All experiments 
were conducted in triplicate and representative images are shown.  
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Figure 13. Quantitative assessment of transduction following ICV administration 
of AAV9 and AAV2g9 vectors. GFP expression was quantified in representative 
hippocampal sections of the mouse brains treated with AAV9 or AAV2g9 vectors. 
Specifically, GFP+ cells with neuronal (A) or glial (B) morphology were counted in 
different cortical regions including the retrosplenial, posterior parietal, somatosensory, 
auditory and piriform areas. Further, quantitative assessment of GFP expression 
following ICV administration of AAV9 and AAV2g9 vectors driven by (C) human 
synapsin (hSyn) promoter or (D) glial fibrillary acid protein (GFAP) promoter was carried 
out using ImageJ analysis software. Specifically, the mean intensity calculator function 
was applied across multiple sections of the mouse brain including sections of the 
olfactory bulbs, lateral ventricles and hippocampal regions. Data is represented as 
mean ± standard deviation, * represents p<0.05 and n.s. indicates ‘not statistically 
significant’ (p>0.05) as determined by student t-test. All experiments were conducted in 
quadruplicate.  
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Figure 14. Heparan sulfate interactions are critical towards preferential neuronal 
transduction by AAV2g9 vectors. Postnatal day 0 (P0) mice were injected with equal 
viral titers (3.5x109 vg) of AAV2, AAV2g9 or AAV2i8g9 packaging the CBh-ScGFP 
transgene into the left lateral ventricle (ICV). One cohort of mice was co-injected with 1 
g soluble heparin (Hep) per mouse as indicated. 2 weeks post vector administration, 
the mice were sacrificed and the brains were harvested and immunostained for 
comparing transgene (GFP) expression (black). (A-C) Representative images of 
hippocampal sections from AAV2, AAV2g9, AAV2g9+Heparin or AAV2i8g9 injections 
have been shown. (D) Higher magnification images of GFP expression (black) in 
different regions of the mouse brain namely; somatosensory cortex (SCT), piriform CT, 
motor CT, dentate gyrus (DG), amygdala (AMG) and hippocampal CA1, CA2 and CA3 
regions have been shown. The Zeiss CLSM 700 confocal laser scanning microscope 
was used to image stitched images of entire mouse brain and higher magnification 
images of individual regions. All experiments were conducted in triplicate and 
representative images are shown.    
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Figure 15. CNS transduction profile of a gal-binding AAV9 mutant (W503R) and 
AAV9 following ventricular (ICV) administration. Postnatal day 0 (P0) mice were 
injected with equal viral titers (3.5x109 vg) of AAV9 or AAV9W503R packaging a single-
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stranded TdTomato (TdTom) fluorescent reporter transgene driven by CBA promoter 
into the left lateral ventricle. At 2 weeks post vector administration, the mice were 
sacrificed and sagittal sections were obtained from the paraformaldehyde postfixed 
brains. Representative confocal stitches show TdTom reporter gene expression 
(pseudocolored white) in the whole brain (global) and higher magnification images of 
individual regions (i.e. olfactory bulb, cortex, sub-ependymal zone, hippocampus and 
cerebellum). Zeiss CLSM 700 confocal laser scanning microscope equipped with 
555nm excitation filter was used to obtain the global stitches and higher magnification 
images of individual regions of the mouse brain. All experiments were conducted in 
triplicate and representative images are shown. 
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Figure 16. CNS transduction profile and cellular tropisms displayed by AAV8 and 
gal-binding AAV8g9 vectors following ventricular (ICV) injection. Postnatal day 0 
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(P0) mice were injected with equal viral titers (3.5x109 vg) of AAV8 or AAV8g9 
packaging a ScGFP transgene driven by a ubiquitous chicken  hybrid (CBh) promoter 
into the left lateral ventricle. At 2 weeks post vector administration, the mice were 
sacrificed and paraformaldehyde postfixed brains were sectioned and immunostained 
as described earlier. (A) Representative images of coronal sections obtained from 
olfactory bulbs, lateral ventricles and hippocampi are shown. Inset images from whole 
brain sections (arrows) are shown to the right of each section at higher magnification. 
(B) Top image panel shows higher magnification images of GFP expression (green) in 
functionally relevant regions of the mouse brain namely; olfactory bulb (OB), 
somatosensory cortex (ss CT), motor CT (MCT), visual CT (VCT), striatum (STR), 
amygdala (AMG), hippocampal CA1, CA2 and CA3  of the brain and dorsal and ventral 
horn regions of the spinal cord are shown. Middle and bottom panels show immuno-
colocalization of GFP expression (green) with neuronal marker, NeuN or glial marker, 
GFAP (red). All experiments were conducted in triplicate and representative images are 
shown.   
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Figure 17. Comparison of transgene (GFP) expression and cellular tropism 
displayed by AAV9 and AAV2g9 vectors following intrathecal infusion. (A) Spinal 
cord sections showing cervical, thoracic and lumbar regions obtained from 8 week old 
adult C57/BL6 male mice infused with AAV9 or AAV2g9 packaging the CBh-ScGFP 
transgene (1x1011 vg) by lumbar puncture. Mice were sacrificed and the spinal cords 
were postfixed in paraformaldehyde, sectioned at 3 weeks post vector administration. 
Diaminobenzidine (DAB) immunohistochemistry was used to detect GFP expression. 
Inset images from whole spinal cord cross-sections are shown to the right of each 
section at higher magnification. (B) Representative confocal images of immunostained 
sections at higher magnification. GFP expression (top panel, green) in the ventral horn 
(VH), dorsal horn (DH), intermediate zone gray matter (INT), ventral funiculus (VF), 
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lateral funiculus (LF), ventral commissure (VCOM) and rubrospinal tract (RT) regions is 
shown. Middle and bottom panels show  immuno-colocalization of GFP expression 
(green) with neuronal marker, NeuN  or glial marker, GFAP (red) obtained using a Zeiss 
CLSM 700 confocal laser scanning microscope equipped with 488nm, 555nm and 
647nm excitation filters. Co-localized cells are pseudocolored yellow (GFP/NeuN or 
GFP/GFAP overlay). All experiments were conducted in triplicate and representative 
images are shown. 
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Figure 18. Comparison of systemic biodistribution and off-target transgene (GFP) 
expression displayed by ICV/IT injected AAV9 and AAV2g9 vectors. (A-C) Relative 
percentage of vector genome (vg) copy numbers for AAV9 (dark gray bars) and 
AAV2g9 (light gray bars) in systemic organs, i.e., liver, heart and spleen normalized to 
vg copy number in the brain following ICV administration in neonates. (D) Confocal 
micrographs showing GFP expression in systemic organs – liver, heart and spleen 
obtained from neonatal ICV cohorts. (E-G) Relative percentage of vector genome (vg) 
copy numbers for AAV9 (dark gray bars) and AAV2g9 (light gray bars) in systemic 
organs, i.e., liver, heart and spleen normalized to vg copy number in the spinal cord 
following IT administration in adult mice. (H) Confocal micrographs showing GFP 
expression in systemic organs – liver, heart and spleen obtained from adult IT cohorts. 
The vg copy per host genome (vg/cell) was determined by quantitative PCR of extracted 
DNA and normalized to the number of copies of the mouse lamin  gene. Data shown 
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is represented as mean + standard deviation; Statistical significance (* p<0.05) was 
established using student t-test. All experiments were conducted in quadruplicate and 
representative images are shown. 
  
 107 
 
 
Figure 19. Comparison of blood circulation/pharmacokinetic profiles AAV9 and 
AAV2g9 vectors in adult mice post IT administration. 8 week old Balb/C mice were 
injected with equal viral titers (7.8x109vg) of AAV9 or AAV2g9 packaging CBA-Luc 
transgene via intrathecal injections. Approximately 10 µl blood was collected via tail vein 
nicks from adult mice at 15 min, 2 hrs, 6 hrs, 24 hrs and 48 hrs post IT injection. Blood 
samples were immediately mixed with equal volume of sodium citrate (3.8% 
weight/volume) to avoid coagulation. Pharmacokinetic profiles of AAV9/2g9 vectors 
were generated using qPCR to calculate viral genomes in the blood samples with 
primers specific to the luciferase transgene. Data represents mean ± standard error 
mean (s.e.m.) * represents p<0.05 as determined by student t-test. All experiments 
were conducted in quadruplicate. 
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Figure 20. CNS-restricted gene disruption of MIR 137 within Cas9 transgenic 
mouse using AAV2g9. (A) Schematic representation of mouse miR137 locus (mm10, 
chr3:118,433,800-118,434,004). Two gRNAs were designed to generate a 98bp 
deletion within pre-miR137 region. Droplet digital PCR (ddPCR) primers were designed 
to amplify a 206bp region (wild type mir-137) and shorter mutant (mir-137 eliminated) 
genomic DNA. Probes detect unaltered region (HEX probe, green) and a region flanked 
by two miR137gRNAs (FAM probe, red). (B) AAV2g9 vector genome (vg) copy 
numbers (per cell) within the brain (light gray bars) and liver (dark gray bars) tissues, 2 
weeks post ICV administration in neonatal (P0) Cas9 transgenic mice. Scatter plots 
showing results of ddPCR on brain (C) and liver (E) genomic DNA from AAV2g9-
controlgRNA (left) or AAV2g9-miR137gRNA (right) injected mice. Specifically, 
HEX+/FAM+ double positive droplets (Orange) indicate wildtype alleles, while 
HEX+/FAM- droplets (Green; depicted by red arrow) show miR137 eliminated alleles. 
Results from all samples (N=3 or 4) are pooled to generate plots. (D and F) Quantitative 
analyses of ddPCR from controlgRNA (light gray bars) and miR137gRNA (dark gray 
bars). Wild-type or mutant allele were predicted using a 2D dot plot as shown. Graphical 
data represents mean ± standard error mean (s.e.m.) * represents p<0.05, n.s. indicates 
‘not statistically significant’ (p>0.05), as determined by student t-test. All experiments 
were conducted in triplicate.  
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CHAPTER 4: AQUAPORIN 4 REGULATES THE PARAVASCULAR CLEARANCE OF 
AAV VECTORS FROM THE BRAIN 
4.1 Overview 
Adeno-associated viruses (AAV) are currently being evaluated in clinical trials for 
gene therapy of central nervous system (CNS) disorders. However, host factors that 
influence the spread, clearance and transduction efficiency of AAV vectors in the brain 
are not well understood. Recent studies have demonstrated that water flow mediated by 
aquaporin 4 (AQP4) channels located in astroglial endfeet is essential for exchange of 
solutes between interstitial and cerebrospinal fluid. In the current study, we demonstrate 
that AQP4 water transport profoundly affects various aspects of AAV gene transfer in 
the CNS. Mislocalization of AQP4 in aged mouse brains correlated with significantly 
increased retention of AAV vectors in the parenchyma following ventricular 
administration. Within minutes after unilateral administration into the ventricles, AQP4 
knockout mice displayed highly restricted spread of fluorophore labeled AAVs compared 
to WT mice. We observed increased retention and transgene expression when AAV 
vectors were administered into the ventricles (intraCSF) of AQP4-/- mice, as compared 
to WT mice. These results were corroborated by markedly reduced clearance of AAV 
vectors from the brain as demonstrated by reduced transgene expression and vector 
genome accumulation in systemic organs. We postulate that deregulation of AQP4 in 
aged and diseased brains could markedly affect the parenchymal spread, clearance 
and gene transfer efficiency of AAV vectors. Assessment of biomarkers that report the 
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kinetics of CSF flux in prospective gene therapy patients could help understand variable 
treatment outcomes and guide future clinical trial design. 
 
4.2 Introduction 
Tremendous progress is being made towards building a repertoire of viral vectors 
for therapeutic gene transfer in the central nervous system (4, 15, 27, 229). Gene 
therapy approaches for treating diseases such as Spinal Muscular Atrophy 
(NCT02122952), Giant Axonal Neuropathy (NCT02362438), Parkinson’s 
(NCT00229736), Alzheimer’s (NCT00017940) and Lysosomal storage disorders 
(NCT01474343) are being tested in Phase I/II clinical trials. Almost all such therapeutic 
strategies currently utilize AAV biologics for delivering the corrective transgene in the 
disease-affected CNS (4, 266). For instance, clinical trial was conducted on 10 patients 
with early Alzheimer’s disease by administration of AAV2 vectors packaging nerve 
growth factor (NGF). Post-mortem patient brains showed pathological benefits proximal 
to NGF expression in the form of axonal sprouting and cholinergic neuronal hypertrophy 
with no adverse effects for 10 years (238). However, reports from other ongoing clinical 
trials indicate that the efficacy of CNS gene transfer from such strategies often falls 
short of the therapeutic baseline in patient cohorts (164). To this end, techniques like 
convection-enhanced delivery (CED) of AAV vectors are being employed to target a 
larger brain volume from a single intracranial administration (267). Understandably, it is 
crucial to conduct preclinical evaluations of AAV vectors on predictive in vivo systems 
that accurately depict physiological processes and biochemical landscape of the human 
CNS.  
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Interstitial flux of biological fluids is a common mechanism employed by 
mammalian tissues for lymphatic waste clearance (62, 268). Due to lack of a 
conventional lymphatic vasculature in the brain, a combination of CSF and water moves 
via subarachnoid spaces and paravascular compartments to drain extracellular 
depositions like metabolites and proteins (104, 105, 269). Specifically, CSF engages in 
direct exchange of biomaterials with proximal CNS tissue via subarachnoid ducts (63, 
105). Such exchange of cargo within deeper anatomical regions of neural tissue is 
made possible by paravascular water transport through aquaporin-4 (AQP4) channels 
(62, 269). Iliff and colleagues utilized fluorescent CSF tracers and AQP4 knockout 
(AQP4-/-) mice to visualize and elucidate mechanistic aspects of paravascular CSF flux 
and solute clearance in CNS (62, 270). This glial-associated lymphatic clearance of 
brain tissue has been termed ‘glymphatic’ clearance (269, 271).  
Successful CNS spread and infection by viral biologics is a multifactorial cascade 
of events (193). For instance, adeno-associated viral (AAV) vectors overcome 
physiological barriers (e.g. blood-brain/ blood-CSF barrier) and utilize biochemical 
processes (e.g. receptor interactions) to achieve successful CNS gene transfer (25). 
Vector transduction efficiency and cell-specificity are evidently attributed to AAV capsid-
cell surface receptor interactions in vivo (25, 31, 229). However, there is a need for 
better understanding the checkpoints that govern AAV vector spread, accumulation, 
transduction and clearance in the CNS. For this study, we hypothesized that 
transparenchymal CSF flux via glymphatic transport has profound implications on 
aforementioned properties of AAV vectors within the brain. On a molecular level, an 
expanding body of evidence suggests that this paravascular fluid flux is regulated by 
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AQP4 lining at the astrocytic endfeet (62, 269, 272, 273). We demonstrate the effects of 
abnormal AQP4 expression on CNS gene transfer properties of AAV vectors in vivo. 
Specifically two mouse models of dysfunctional AQP4 glymphatic transport were 
studied: a) age dependent mislocalization of AQP4 and; b) genetic knockout of AQP4. 
We show that AQP4 mediated CSF flux dictates multiple aspects of AAV-gene therapy 
of the CNS tissue. 
  
4.3 Materials and Methods 
Recombinant AAV vector production. An updated triple plasmid transfection 
protocol was used to generate recombinant AAV9 vectors (206, 255). All plasmids used 
for AAV production in this study were obtained from the UNC vector core. Specifically, 
HEK 293 cells were transfected with a mixture of (i) the pXR9 helper plasmid; (ii) the 
adenoviral helper plasmid pXX6-80; and (iii) pTR-CBh-ScGFP or pTR-CBA-Luc 
plasmids encoding the green fluorescent protein (GFP) or luciferase (Luc) reporter 
genes driven by the chicken β hybrid (CBh) or chicken β actin (CBA) promoter and 
flanked by inverted terminal repeats (ITRs) derived from the AAV2 genome. Iodaxinol 
gradient ultracentrifugation was used to purify AAV vectors. Fluorophore labeled AAV 
vectors were generated using an Alexa-647 labeling kit (Thermofisher-A20006) by 
following the protocol provided by the kit manufacturer. Following fluorophore labeling, 
the AAV vectors were dialyzed against 1X PBS for 2 overnight cycles using a 12-14 kDa 
MWCO dialysis column (Millipore-71505-3). Finally, quantitative PCR (QPCR) 
(Lightcycler® 480, Roche Applied Sciences, Pleasanton, CA) was used to calculate 
vector genome (vg) titers with primers designed to selectively bind AAV2 ITRs (forward, 
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5’- AAC ATG CTA CGC AGA GAG GGA GTG G -3’; reverse, 5’- CAT GAG ACA AGG 
AAC CCC TAG TGA TGG AG -3’) (IDT Technologies, Ames, IA).  
 
Animal Experiments: The constitutive aquaporin-4 knockout (AQP4-/-) mouse 
model was provided by Dr. Alan Verkman in University of California in San Diego. All 
animal experiments reported in this study were conducted on AQP4-/- or C57/Bl6 mice 
bred and maintained in accordance to NIH guideline as approved by the UNC 
Institutional Animal Care and Use Committee (IACUC) protocol number 15-109.  
 
Intracerebroventricular (ICV) administration. Postnatal day 0 (P0) mouse 
pups which were rapidly anesthetized on ice for 2 min followed by 
intracerebroventricular (ICV) injections using a stereotaxic apparatus. AAV vectors (< 3 
µl total volume for ICV and < 1 µl total volume for ISTR) packaging the CBh-ScGFP 
transgene cassette were injected into the left lateral ventricle with a Hamilton 700 series 
syringe and 26s gauge needle (Sigma-Aldrich, St. Louis, MO), attached to a KOPF-900 
small animal stereotaxic instrument (KOPF instruments, Tujunga, CA). Ventricular 
injections were performed at the following stereotaxic coordinates - 0.5mm relative to 
the sagittal sinus, 2mm rostral to transverse sinus and 1.5mm deep. Mice were revived 
under a heat lamp and rubbed in the bedding after AAV injections before being placed 
back with the dam. The mouse brains were harvested, post-fixed and immunostained 2 
weeks post vector administrations (P14). The immunostaining procedure has been 
described in detail below. For visualizing AAV spread within the mouse brains, Alexa-
647 tagged AAV vectors were mixed with 0.1% dextran (10 kDa) (5mg/ml) 
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(Thermofisher-D22910) reconstituted in 1XPBS prior to ICV injections. 45 min later, 
injected mouse pups were rapidly anesthetized using hypothermic shock, perfused with 
1XPBS followed by 4% paraformaldehyde. The neonatal mouse brains were harvested 
and postfixed for 3 days prior to vibratome sectioning, staining and confocal 
microscopy. 
 
Vector genome biodistribution. Mouse Cohorts used for biodistribution studies 
were sacrificed 3 days post vector administration via the ICV route. The genomic DNA 
was extracted from the tissue lysates and blood using the DNeasy® kit (Qiagen, 
Valencia, CA). Viral genome copy numbers were calculated by performing QPCR 
(Lightcycler® 480, Roche Applied Sciences, Pleasanton, CA) using primers specific to 
luciferase transgene 5’-AAAAGCACTCTGATTGACAAATAC-3’ and 5’-
CCTTCGCTTCAAAAAATGGAAC-3’. The vector genome copy numbers were 
normalized to mouse lamin B2 locus as the housekeeping gene using the primers 5’-
GGACCCAAGGACTACCTCAAGGG-3’ and 5’- AGGGCACCTCCATCTCGGAAAC-3’. 
The vector biodistribution was represented as the ratio of vector genomes per cell 
recovered in the peripheral organs to the CNS site of injection (brain).    
 
Tissue processing and immunostaining. Mouse cohorts used for gene 
expression (GFP) studies, were sacrificed 2 weeks post vector administration via ICV 
route. Mouse cohorts used for visualizing viral spread were sacrificed 45 min after 
fluorescent AAV injections. The mice were overdosed with tribromoethanol (avertin) (0.2 
ml/10 g of 1.25% solution) via the intraperitoneal route. This was followed by 
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transcardial perfusions of PBS and 4% paraformaldehyde in 1xPBS. The organs were 
removed and post-fixed for 24 hr prior to sectioning. Briefly, 50 μm thick sections were 
obtained using a Leica VT 1200S vibrating blade microtome (Leica Biosystems, IL). The 
sections of mouse organs from various treatments were blocked in 10% goat serum 
(Sigma-Aldrich, St. Louis, MO) and 1% Triton X (Sigma-Aldrich, St. Louis, MO) in PBS 
for 1 hr. This was followed by overnight incubation with primary monoclonal antibodies 
at 4˚C. The primary antibodies utilized as a part of this study are as follows: Rabbit anti-
GFP (Life-Technologies- G10362, 1:750), rabbit anti-AQP4 (Millipore-AB3594, 1:750). 
Secondary antibodies were raised in goats and conjugated to Alexa 488 (anti-rabbit 
Abcam-96883 or Alexa 594 (anti-Rabbit Abcam-96885). The secondary antibodies were 
used at a standard dilution of 1:500. The immunohistochemical analyses of GFP and 
AQP4 expression was conducted using Vectastain ABC kit (Rabbit IgG PK-4001 kit, 
Vector biolabs, Burlingame, CA, USA). 
 
Microscopy and Image processing: We used Zeiss CLSM 700 confocal laser 
scanning microscope (Microscopy services laboratory, UNC) or Aperio Slide scanner 
(Leica Biosystems, IL) (Translational pathology laboratory, UNC) for imaging 
immunostained mouse tissue sections. Quantitation of fluorescence intensities was 
carried out using the ImageJ image analysis software. For calculating AAV/dextran 
fluorescence, the mean pixel intensity function was applied across identical regions of 
interest (ROI) and threshold settings in specific anatomical regions of the mouse brain. 
For calculating subpial AQP4 expression profiles, individual fluorescence intensity 
values were recorded at 0-200 pixel positions starting from the pial surface of every 
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mouse brain. For calculating perivascular AQP4 polarity, fluorescence intensity values 
were recorded at 50 pixel positions across 4-5 major cortical blood vessels in the mouse 
brain. The procedure for quantitation of perivascular AQP4 polarity was adopted from a 
previous study (273). Confocal images were stitched, pseudocolored and analyzed on 
the Zen® Black software.  
 
4.4 Results 
AAV vectors readily accumulate within the aging mouse CNS. The aging 
brain is susceptible to increased parenchymal depositions of biomolecules such as 
metabolic wastes. We hypothesized that CNS administration of AAV vectors in aging 
mice will result in enhanced viral accumulation in the neural tissue. AAV serotype 9 
(AAV9) is currently being evaluated in Phase I clinical trials for treating neurological 
disorders-spinal muscular atrophy and giant axonal neuropathy (Clinical trial identifiers 
NCT02122952, NCT02362438). To verify our hypothesis, we performed intracranial 
injections of AAV9 into juvenile (3 months old) and aging (>18 months old) mouse 
brains. In order to visualize viral particles within the brain, we generated fluorophore 
labeled AAV9 vectors. Additionally, prior to intracerebroventricular (ICV) injections, 
labeled AAVs were mixed with 10kDa fluorescent dextran tracer as an internal control 
for injections and microscopy. Specifically, equal mixtures of Alexa-647 labeled AAV9 
vectors (1.75x109 vector genomes (vg)/mouse) and (0.1%) Alexa-488 labeled dextran 
were administered. 45 min post injections, the mice were rapidly anesthetized and the 
brains were harvested after cardiac perfusions with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde (PFA). Postfixed brains were sectioned on a 
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vibratome and Zeiss 700 confocal microscope was used to obtain whole brain stitches 
of the ventricular slices. We observed restricted fluorescence (red) from AAV9 vector 
particles at close proximity to ventricular site of administration in the juvenile mouse 
cohort (Fig. 21A, AAV9). On the other hand, identical injections performed on aging 
mice resulted in dramatically enhanced fluorescence (red) in deeper anatomical regions 
across the brain parenchyma (Fig. 21B, AAV9). A similar increase in fluorescence 
signal (green) was also observed due to dextran tracer injections in the aging mice (Fig. 
21B, AAV9/Dex) as compared to juvenile mice (Fig. 21A, AAV9/Dex). This suggests 
that increase in parenchymal accumulation is not specific to AAV vectors. To further 
demonstrate AAV accumulation in the aging brain, we generated high magnification 
confocal micrographs of six brain regions i.e. lateral ventricles (LV), corpus callosum 
(CC), cortex (CT), piriform cortex (PCT), thalamus (THL) and hypothalamus (HTL). We 
observed fluorescence from AAV vectors and dextran tracers restricted to LV and CC 
regions of the juvenile mouse brain (Fig. 21C, AAV9 & AAV9/Dex). On the other hand, 
fluorescent signal was observed in all the six anatomical regions in the aging mouse 
brain (Fig. 21D, AAV9 & AAV9/Dex). Quantitation of fluorescence intensities due to 
AAV9 vectors shows a significant increase CC, CT, PCT, THL and HTL of the aging 
mice as compared to the juvenile mice (Fig. 21E and F, regions 2-6). It should be noted 
that difference in AAV fluorescence in the two groups was not-significantly different in 
the area surrounding the lateral ventricle site of injection (Fig. 21E, region 1). A similar 
overall enhancement in fluorescence signal was also observed due to dextran 
administration within different anatomical regions of the aging mouse brain (Fig. 21G 
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and H). Overall, our results show increased parenchymal accumulation of AAV vectors 
and dextran tracers, minutes after intracranial administration into the aging CNS.  
Altered AQP4 localization correlates with AAV deposits in the aging brain. 
Loss of perivascular AQP4 polarity is one of the histological hallmarks that indicate 
impairment of CSF penetration through the brain parenchyma (273). To assess whether 
altered localization of AQP4 plays a role in accumulation of AAV vectors within the aged 
mouse brain, we analyzed AAV capsid accumulation and AQP4 expression profiles in 
juvenile and aging mouse brains. Fluorescently labeled AAV9 particles were injected 
through the intraCSF route in juvenile (3 months) and aged (18 months) mouse brains. 
At 45 min post-administration, animals were sacrificed and post-fixed in 4% PFA. High 
magnification confocal micrographs of cortical regions (Fig. 22D and E) revealed that 
the fluorescent signal from AAV9 particles (red) was strikingly elevated and appeared 
as deposits in the aged mouse brain (Fig. 22B) as compared to the juvenile cohort (Fig. 
22A). Quantitation of this phenomenon shows a significant increase in fluorescence 
signal associated with AAV capsids within cortical regions of aged mouse brains 
compared to juvenile mice (Fig. 22C).  
Next, to compare perivascular AQP4 polarity, we generated high magnification 
confocal micrographs of AQP4 expression within juvenile and aged mouse brains. 
Specifically, we compared AQP4 localization on penetrating large blood vessels 
(arterioles) within the cortex (Fig. 22D and E, red boxes and insets). When compared to 
juvenile mice (Fig. 22D, inset), we observed a striking increase in AQP4 expression 
(green) immediately surrounding the blood vessels in the aged mice (Fig. 22E, inset). 
These results are consistent with loss of AQP4 polarity as reported earlier in the 
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literature (273). To quantify this phenomenon, we measured fluorescence intensities in 
pixel positions across the blood vessel walls (Fig. 22D and E, insets, red dotted lines). 
In juvenile mice, we observed a noticeable increase in AQP4 expression within the 
blood vessel architecture with low, background level fluorescence signal in the 
surrounding tissue (Fig. 22F). However, AQP4 expression was mislocalized and 
broadly distributed in areas adjacent to the blood vessels of the aging mice (Fig. 22F). 
Taken together, these results suggest a potential correlation between altered AQP4 
expression in aged mouse brains and increased parenchymal accumulation of AAV 
vectors.  
AAV vectors exhibit significantly reduced spread within the AQP4 knockout 
mouse CNS. Our previous results establish a strong correlation between loss of AQP4-
mediated CSF flux and increased accumulation of AAV vectors within the brain. To 
further delineate the role of AQP4 in other aspects of AAV mediated CNS gene transfer, 
we utilized the constitutive AQP4 knockout (AQP4-/-) mouse model (274). Successful 
knockout was ensured by detecting loss of AQP4 expression with 
immunohistochemistry on wildtype (WT) and AQP4-/- mouse brain sections (Fig. 26). 
First, we hypothesized that AAV vectors utilize AQP4-CSF flux to spread within the 
CNS. To verify, we compared spread of fluorescently labeled AAV vectors within the 
WT and AQP4-/- mouse brain. Specifically, we injected equal titers (1.75x109 
(vg)/mouse) of Alexa-647 labeled AAV9 mixed with equimolar concentrations (0.1%) of 
Alexa-488 labeled 10kDa dextran-tracer into the postnatal day 0 (P0) mouse brains. 
The mice were sacrificed 45 min post ICV injections following which the brains were 
harvested and postfixed in 4% PFA.  
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To evaluate differences in viral spread from a global standpoint, we employed the 
histograph functionality (Zen Black image analysis software, Zeiss 700 confocal 
microscope) on whole brain confocal stitches (Fig. 23, top row). Briefly, white peaks on 
the surface of coronal brain sections indicate positions of the fluorescent AAV9 vector 
particles. ICV administration of AAV9 in WT mice resulted in numerous fluorescent 
peaks distributed across both hemispheres of the brain (Fig. 23A, WT, top row, AAV). 
Additionally, dextran tracer injection in the WT mouse resulted in similarly diffuse 
fluorescent peaks across the brain parenchyma (Fig. 23B, WT, top row, Dextran). On 
the other hand, ICV administration of AAV9 vectors in the AQP4-/- mice resulted in a 
large concentration of fluorescent peaks restricted to the immediate vicinity of the 
ventricular site of injection (Fig 23A, AQP4-/-, top row, AAV). Similarly, we observed 
noticeable increase in fluorescent peaks surrounding the ventricles and within the extra 
parenchymal CSF space due to dextran injections in AQP4-/- mice (Fig. 23B, AQP4-/-, 
top row, Dextran). In order to further demonstrate change in the spread of AAV9 vectors 
within the AQP4-/- brain, we generated high magnification confocal micrographs of the 
lateral ventricles. In comparison to WT mice (Fig. 23A, WT, middle row, AAV), AAV9 
injections in the AQP4-/- mice resulted in increased fluorescence (red) surrounding the 
ventricles (Fig. 23A, AQP4-/-, middle row, AAV). A similar increase in the fluorescent 
signal (green) was also observed due to dextran injections in the AQP4-/- mice (Fig. 
23B, AQP4-/-, middle row, Dextran) as compared to WT mice (Fig. 23B, WT, middle 
row, Dextran). Furthermore, to evaluate the numerical change in the spread of AAV and 
dextran particles, we quantified the fluorescence intensities in WT and AQP4-/- mouse 
brains after various treatments. We observed significant increase in fluorescence signal 
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due to AAV (~3 fold) and dextran (~6 fold) injections in the AQP4-/- mice as compared 
to WT mice (Fig. 23C & D). Our results demonstrate that during conditions of reduced 
transparenchymal CSF penetration, AAVs show restricted mobility within the brain. In 
other words, AAV vectors employ AQP4-mediated CSF flux to spread within the brain.  
AAV transduction is significantly altered in the brains of AQP4-/- mice. To 
further delineate the role of AQP4 in other aspects of AAV mediated CNS gene transfer, 
we utilized the AQP4 knockout (AQP4-/-) mouse model (274). Complete loss of AQP4 
expression was confirmed by immunohistochemical analysis of wildtype (WT) and 
AQP4-/- mouse brain sections (Fig. 26). We then compared transduction profiles of 
AAV9 vectors injected unilaterally into the ventricular CSF space (ICV injections). 
Specifically, we injected neonatal P0 mice with AAV9 vectors packaging a self-
complementary GFP (scGFP) cassette driven by a hybrid chicken β actin (CBh) 
promoter. At 2 weeks post-administration, 50 m vibratome brain sections were subject 
to diaminobenzidine (DAB) immunohistochemistry to visualize transgene (GFP) 
expression. AAV9 injections in the WT mice resulted in broad GFP expression across 
the brain parenchyma (Fig. 24A). Interestingly, ICV administration of AAV9 in AQP4-/- 
mice resulted in dramatically enhanced GFP expression in the CNS (Fig 24A). 
Specifically, we observed a significant increase in GFP+ cells in representative regions 
of the contralateral hemisphere after unilateral ICV injections in the AQP4-/- mice (Fig. 
24A, boxes and insets). We measured pixel intensities to quantify GFP expression 
across different brain regions, specifically, the motor, somatosensory, auditory and 
piriform cortices as well as striatum and hippocampus. A significant increase in pixel 
intensities within the aforementioned regions in AQP4-/- mouse brain when compared to 
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the WT brain was observed (Fig. 24B). These results indicate that AAV vectors 
administered directly into the CSF are likely subject to rapid clearance. Reduced 
clearance of solutes due to lack of AQP4 function could result in retention of AAV 
vectors and consequently improved gene expression. Taken together, these results can 
possibly be explained by severely impaired parenchymal transport within the brain and 
CSF clearance of AAV vectors from the brain in AQP4-/- mice.  
CNS-administered AAV vectors utilize AQP4 for systemic leakage and 
peripheral organ gene transfer. AQP4 mediated brain interstitial fluid flux shunts 
parenchymal cargo into CSF compartments where they drain into peripheral lymphatics 
or systemic blood circulation. An important safety concern raised during CNS injections 
of clinical vector candidates like AAV9 is systemic leakage resulting in off-target gene 
transfer. We hypothesized that transportation of AAV vectors from CNS tissue to 
peripheral organs is an AQP4 dependent process. To verify, we injected AAV9 vectors 
into WT and AQP4-/- mouse brains via the ICV route. 3 days post vector administrations 
we sacrificed one cohort of mice and carried out biodistribution studies to calculate 
vector genome accumulation in off-target organs. ICV injections of AAV9 results in 
heavy viral genome leakage (~150 fold) into peripheral organs like heart and liver (Fig. 
25B, WT) resulting in strong off-target transgene expression (Fig. 25A, WT). Crucially, 
under identical conditions of AAV9 CNS administration, the AQP4-/- mouse cohort 
displayed near background levels of off-target vector genome biodistribution (Fig. 25B, 
AQP4-/-). Correspondingly, this resulted in dramatically reduced transduction (GFP 
expression) in the heart and liver tissue (Fig. 25A, AQP4-/-). Overall, for the first time, 
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our results indicate that AQP4 mediated CSF flux is the underlying phenomenon driving 
systemic leakage and off-target transduction of CNS injected AAV vectors. 
 
4.5 Discussion 
AAV vectors are being evaluated as clinical vector candidates for CNS maladies 
such as Alzheimer, Parkinson and Frontotemporal dementia (4, 15, 27, 229). A common 
hallmark of such diseases is the parenchymal accumulation of misfolded proteins and 
erroneous metabolic byproducts such as alpha-synuclein, hyperphosphorylated tau etc. 
Aging brains are more susceptible to such depositions of senile plaques (275, 276). 
Correspondingly, these neurocognitive disorders are more prevalent among the geriatric 
demographic (277). In the aging mouse brain (>18 months), both glymphatic CSF flux 
and transparenchymal solute clearance have been demonstrated to be severely 
impaired (273). In the current study, we first hypothesized that CSF flux plays a major 
role in retention of clinically relevant biomaterials like AAV vectors in the CNS. Our 
results in Figure 21 confirm that accumulation of AAV vectors and dextran tracer 
increase dramatically in the aging mouse brain. As shown in Figure 22, AQP4 lines the 
major blood vessels (arteries and veins) and microvasculature (capillaries) in the brain. 
Furthermore, dysregulated AQP4-fluid flux is a common occurrence during conditions of 
ablated interstitial clearance in the CNS such as aging, Alzheimer’s disease and 
dementia (270-273, 278). Correspondingly, Figure 22 also confirms that increased 
parenchymal AAV accumulation is accompanied by indications of dysfunctional AQP4-
glymphatic clearance. It is therefore tempting to speculate that the older patient 
demographic offers a CNS landscape that allows for increased retention of AAV vectors 
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within the brain. Future gene expression studies done on aging animals might uncover 
the effect of dysfunctional AQP4 on other aspects of therapeutic AAV gene transfer 
such as dosage and efficacy.  
To directly investigate if the absence of AQP4 water channel protein affects AAV 
vector functioning in the brain, we compared WT mice with constitutive AQP4 knockout 
mouse model (AQP4-/-) generated by Verkman and colleagues (274). AQP4-/- mice 
have reduced glymphatic water transport resulting in slower clearance of parenchymal 
accumulations such as Amyloid- in the CNS (269). Accordingly, intraventricular 
administration of fluorophore labeled AAV vectors in the AQP4-/- mice resulted in 
restricted spread and increased fluorescence from accumulating AAV vector particles 
(Fig. 23). Intriguingly, we observed differences in spread and accumulation of AAV 
vectors depending upon the level and functional status of AQP4 in the brain. 
Specifically, while Figure 21 and 22 depict the dysregulated status of the AQP4 
channel protein in the aging brain, in Figure 23 AAV particles were exposed to a CNS 
environment lacking AQP4 altogether. Both conditions resulted in enhanced retention of 
AAV particles in the brain. Interestingly however, while AAV vectors successfully spread 
within the aging brain (Fig. 21), knocking out AQP4 restricts the viral mobility (Fig. 23). 
These results demonstrate that fluid flux via AQP4 channels is crucial for AAV vector 
spread in the parenchyma.  
In addition to the implications on AAV vector retention and spread within the 
CNS, the AQP4 glymphatic flux also has a significant effect on AAV transduction and 
systemic leakage. Interestingly, intraCSF administration of AAV9 resulted in a 
significant increase in transduction efficiency within the AQP4-/- mice (Fig. 24). Similarly 
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dramatic effects were also observed with respect to the systemic leakage of AAV9 
particles from the CNS. Specifically, AQP4-/- mice injected with equal concentrations of 
AAV9 underwent a significantly reduced systemic leakage. Thus resulting in diminished 
biodistribution and gene expression in peripheral organs such as heart and liver (Fig. 
25). 
 Overall, our study suggests that AQP4-glymphatic flux has critical implications 
on determining parameters of AAV-mediated CNS gene transfer. Moving forward, 
kinetic-biomarkers of CSF flux can be used to devise the right combination of AAV 
capsid, dosage and injection strategies to ensure therapeutic gene transfer for treating 
CNS dysfunctions (279).  
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Figure 21. Comparison of AAV vector accumulation within juvenile and aging 
mouse brains. 3 month and 18 month old mice were injected with equal viral titers 
(1.75x109 vg per animal) of Alexa-647 tagged fluorescent AAV9 vectors mixed with 
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0.5% Alexa-488 tagged fluorescent 10 kDa dextran tracer (5 mg/ml) into the left lateral 
ventricle. 45 min post injections, the mice were anesthetized and sacrificed for organ 
harvests. Paraformaldehyde fixed brains were sectioned on a vibratome and Zeiss 700 
confocal microscopy was used to generate fluorescence images of the mouse brains. (A 
and B) Representative confocal stitches of coronal sections containing the lateral 
ventricular site of injection. Top row shows accumulation of fluorophore labeled AAV9 
(red). Bottom row shows merge of AAV (red) and dextran (green) fluorescent signals. 
Additionally, 6 brain regions: i.e. lateral ventricles (LV), corpus callosum (CC), cortex 
(CT), piriform cortex (PCT), thalamus (THL) and hypothalamus (HTL) have been 
numbered 1-6 as positional cues to higher magnification images below. (C and D) 
Higher magnification confocal micrographs show regions of interest in juvenile (C); and 
aging (D) mouse cohorts. Images show differences in fluorescence signal due to AAV 
(top row, red) and AAV/dextran merge (bottom row, red/green). Quantitation of 
fluorescence intensities from AAV (E and F) and dextran (G and H) channels within 
regions 1-6 have been shown. Graphical data shown is represented as mean + 
standard deviation. P values were calculated by unpaired, 2 tailed student t-test. ‘n.s.’ 
indicates not statistically significant; ‘*’ indicates statistically significant (p<0.05). All 
experiments were conducted in triplicate, representative images are being shown. 
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Figure 22. Aged mice display abnormal AAV accumulation and altered AQP4 
localization in the brain. (A and B) Comparison of accumulation of fluorophore 
labeled AAV9 vector particles (red) 45 min after ICV injections in the 3 month and 18 
month old mouse brain. (C) Quantitation of fluorescence intensities from AAV9 
accumulation within cortical regions of 3 month and 18 month old mice. Graphical data 
shown is represented as mean + standard deviation. P values were calculated by 
unpaired, 2 tailed student t-test. ‘*’ indicates statistically significant (p<0.05). (D and E) 3 
month and 18 month old mouse brains injected with fluorescent AAV9 vectors (Fig. 1) 
were immunostained for AQP4 expression (green). Red boxes indicate positions of 
large blood vessels (arterioles) shown in higher magnification within the insets on the 
left. White boxes indicate cortical regions where AAV accumulation was compared (F) 
Fluorescence intensity (green) of AQP4 expression was measured as a function of 
distance (in pixels) across 4-5 large blood vessels (red boxes, D and E) per mouse (red 
dotted line, insets within D and E). Error bars on the graphs represent 95% confidence 
interval of fluorescence intensity calculated at every pixel position across the blood 
vessel (F). All experiments were conducted in triplicate, representative images are 
being shown. 
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Figure 23. Comparison of AAV vector spread within wildtype and aquaporin-4 
knockout mouse CNS. Postnatal day 0 (P0) wildtype (WT) and aquaporin-4 knockout 
(AQP4-/-) mice were injected with equal viral titers (1.75x109 vg per animal) of Alexa-
647 tagged fluorescent AAV9 vectors mixed with 0.1% Alexa-488 tagged fluorescent 10 
kDa dextran tracer (5 mg/ml) into the left lateral ventricle. 45 min post injections, the 
mouse pups were anesthetized and sacrificed for organ harvests. Paraformaldehyde 
fixed brains were sectioned on a vibratome and Zeiss 700 confocal microscopy was 
used to generate fluorescence images of the mouse brains. (A and B) Top row- 
Histograph functionality (ZEN black image analysis software for Zeiss 700 laser 
scanning microscope) was applied across whole brain confocal stitches of AAV+dextran 
injected mouse brains. White peaks within the histographs represent positions of 
fluorescent AAV or dextran particles within mouse brains. Bottom row- higher 
magnification fluorescence images of the lateral ventricles show differential 
accumulation of AAV vectors (red) and dextran tracers (green) at the site of injection in 
WT and AQP4-/- mice. (C and D) Quantitation of fluorescence intensities due to AAV9 
(C) and dextran (D) administration into WT and AQP4-/- mouse brains. Graphical data 
shown is represented as mean + standard deviation. P values were calculated by 
unpaired, 2 tailed student t-test. ‘n.s.’ indicates not statistically significant; ‘*’ indicates 
statistically significant (p<0.05). All experiments were conducted in triplicate, 
representative images are being shown.  
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Figure 24. Comparison of AAV transduction efficiency following intraCSF 
administration in WT and AQP4-/- mouse brains. Postnatal day 0 (P0) mice were 
injected with equal viral titers (3.5x109 vg per animal) of AAV9 packaging the self-
complementary GFP transgene driven by hybrid chicken  actin promoter (CBh) into the 
left lateral ventricle. 2 weeks post vector administration the mice were sacrificed and the 
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brains were harvested, postfixed and vibratome sectioned. (A) Diaminobenzidine (DAB) 
immunohistochemistry was used to visualize GFP expression (brown) within the WT 
and AQP4-/- mouse brains. Boxes indicate the positions of higher magnification insets 
adjacent to the whole brain coronal stitches. (B) Quantitation of pixel intensities from 
GFP expression within motor cortex (MCT), somatosensory cortex (SCT), auditory 
cortex (ACT), piriform cortex (PCT), striatum (STR) and hippocampal (HC) regions of 
WT (red) and AQP4-/- (grey) mice injected with AAV9 vectors. Graphical data shown is 
represented as mean + standard deviation. P values were calculated by unpaired, 2 
tailed student t-test. ‘n.s.’ indicates not statistically significant; ‘*’ indicates statistically 
significant (p<0.05). All experiments were conducted in triplicate, representative images 
are being shown.  
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Figure 25. Comparison of off-target transduction and biodistribution of AAV 
vectors following intracranial administrations in WT and AQP4-/- mice. Postnatal 
day 0 (P0) WT or AQP4-/- mice were injected with equal viral titers (3.5x109 vg per 
animal) of AAV9 packaging the self-complementary GFP transgene driven by hybrid 
chicken  actin promoter (CBh) into the left lateral ventricle. 2 weeks post vector 
administration the mice were sacrificed and peripheral organs were harvested, postfixed 
and vibratome sectioned. (A) Vector genome (vg) copy numbers within the heart and 
liver of WT and AQP4-/- mice injected with AAV9 vectors (normalized to vg in the brain) 
via ICV injections. The vg copy per host genome (vg/cell) was determined by QPCR of 
extracted genomic DNA and normalized to the number of copies of the mouse lamin  
gene. (B) Confocal micrographs showing GFP expression (green) in heart and liver, 
following brain injections of AAV9. Graphical data shown is represented as mean + 
standard deviation. P values were calculated by unpaired, 2 tailed student t-test. ‘n.s.’ 
indicates not statistically significant; ‘*’ indicates statistically significant (p<0.05). All 
experiments were conducted in quadruplicate, representative images are being shown.  
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Figure 26. Comparison of AQP4 expression in WT and AQP4-/- mouse brain. 2 
week old WT and AQP4-/- mice were harvested, postfixed and vibratome sectioned. (A 
& B) Diaminobenzidine (DAB) immunohistochemistry was used to compare AQP4 
expression (brown) in the whole brain stitches of WT and AQP4-/- mice. (C & D) 
Comparison of AQP4 expression in functionally relevant anatomical regions of the 
mouse brains. Specifically, high magnification images of six anatomical regions- 
striatum, motor cortex, piriform cortex, hippocampal CA1, thalamus and hypothalamus 
have been shown. All experiments were conducted in quadruplicate, representative 
images are being shown. 
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Chapter 5: SYNOPSIS AND FUTURE DIRECTIONS 
5.1: The Big Picture 
AAV gene therapy has come a long way since the initial discovery of the wildtype 
virus as a contaminant in adenoviral stocks. The combination of comprehensive 
understanding of AAV biology and some significant achievements in AAV vector 
engineering has equipped us with technology to generate recombinant AAVs (rAAVs) 
(24, 172, 280). Using rAAV vector technology, any ssDNA within the packaging capacity 
(~4.7kb between AAV ITRs) can be encapsidated as an AAV serotype of choice. Such 
flexibility has enabled scientists to characterize an arsenal of natural and engineered 
AAVs as gene transfer vectors towards research and therapeutic applications.  
From the vantage point of CNS gene therapy, AAV vectors offer the following 
attractive features - (a) there is no conceivable evidence correlating AAV serotypes with 
pathogenicity/disease in animal models or human patients; (b) unlike many other 
viruses, AAV is not highly immunogenic, with the immune response being usually 
restricted to generation of anti-capsid neutralizing antibodies (281); (c) upon host 
nuclear entry, the genomic contents of AAV predominantly exist in an episomal form 
and utilize the cellular machinery for gene expression (16, 188, 189). It is important to 
mention that a small percentage of AAV genomes have been reported to undergo highly 
specific insertion at the AAVS1 locus of human chromosome 19 (186). In contrast, host 
genome integration is an integral part of the life cycles of other viral vectors like 
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lentiviruses, adenoviruses and herpes viruses (187). Such events are often associated 
with insertional and frame shift mutageneses, sometimes resulting in carcinogenic 
outcomes for the host cells. (d) AAVs transduce both dividing and non-dividing 
mammalian cells. This is especially important for CNS transduction where a majority of 
cells stop dividing once complete maturity is attained. (e) Lastly, direct brain 
administrations of different AAV serotypes result in distinctive patterns of cellular and 
regional gene expression in the CNS (53, 71, 72, 89-91, 114, 267, 282). Such variations 
in AAV transduction profiles have been attributed to capsid-receptor interactions in 
different hosts (172). For instance, AAV serotype 9 (AAV9) binds N-terminal galactose 
residues on the mammalian cell surfaces and shows extensive neuronal as well as glial 
transduction in animal models (37, 94). On the other hand, AAV2, which utilizes 
Heparan sulfate as the primary receptor demonstrates neuronal tropism and minimal 
spread from the injection site in the mammalian brain parenchyma (71, 182). Another 
unique example is AAV4, which binds sialic acid and displays exclusive tropism for 
astrocytes at the injection site of the mammalian brain (34, 77).  
Numerous genetic disorders exhibit distinct manifestations in the CNS. Viral 
vectors, especially Adeno-associated viruses (AAV) have emerged as the vehicle of 
choice for supplying healthy cargo of therapeutic genes for such CNS indications (4, 15, 
27). The past few decades have witnessed consistent progress towards 
characterization and preclinical evaluations of AAV vectors in small/large animals and 
non-human primates (NHPs) (283). Such efforts enable us to make informed decisions 
regarding parameters like viral serotype, route of administration, immune response, 
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dosage and biosafety; and employ AAV vectors for therapeutic gene transfer in the 
clinic. 
Continuous efforts in vector design have resulted in an ever increasing toolkit of 
novel AAV vectors. The key areas requiring vector design and improvement include-
transduction efficiency, cell/tissue specificity, packaging capacity and antibody evasion. 
My doctoral thesis in Asokan Lab in part was focused on developing a deeper 
understanding of the physiological and biochemical checkpoints that control AAV 
biologics in the CNS. The interesting phenotypes were often uncovered during 
screening of multiple AAV variants in vivo. The findings showcased in this thesis were 
the consummation of a systematic sequence of tests conducted on in vitro and in vivo 
platforms to unravel the underlying biology of specific phenomena pertaining to AAV 
vectors in the CNS. To this end, I was fortunate to be working in a laboratory that 
offered the bandwidth to produce an extensive portfolio of natural and engineered AAV 
vectors to be tested within the mammalian CNS landscape.  
 Given the bench-to-bedside nature of the field, it is absolutely crucial that 
preclinical evaluation of AAV biologics be carried out in predictive in vivo systems that 
mimic the patient CNS. To this end, my research work spanned the use of mouse 
models in neonatal, juvenile and geriatric demographics displaying varying physio-
chemical statuses. In the following chapter, I have proposed follow up studies that have 
the potential to answer questions pertinent to the theme of my PhD work. 
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5.2: Future Directions 
In the first project, we focused on the African green monkey isolate, AAV 
serotype 4. AAV4 utilizes O-linked sialic acid for cellular attachment. Systemically 
administered AAV4 results in highly targeted gene transfer in heart and lung tissue. In 
the CNS, cerebral ventricular system constitutes the ductal connectivity of CSF deep 
within the brain parenchyma. In addition to the ventricular system, the CSF maintains 
contact with the CNS tissue via subarachnoid ducts, foramena in the cerebellum and 
spinal cavity. The key advantage of administering AAV biologics into the CSF space is 
the ability to target maximal CNS tissue from a single injection. In the context of 
ventricular administration, AAV4 shows highly specific transduction of the ependymal 
cells. Although, the underlying glycan receptor interaction of AAV4 is well known, we 
discovered the biochemical requirement for the virus to traverse the brain parenchyma 
further. We focused on AAV spread, transduction and cellular tropism for this study. 
The formation of functional neurons and glia from the initial pool of neural stem 
cells (NSCs) is thought to be due to expression of time-sensitive molecular signatures 
that trigger migration and differentiation (284, 285). For instance, olfactory neurogenesis 
in mammals is characterized by the migration of a subset of ependyma-derived 
neuronal progenitors from the sub-ependymal zone (SEZ) via the rostral migratory 
stream (RMS). These neuroblasts radially differentiate into interneurons of the granular 
and periglomerular layers in the olfactory bulb (OB), while cells of radial glial lineage 
differentiate to form glial tubes that guide these migratory processes (284). In addition to 
rostral migration, a subpopulation of the subependymal progenitors migrate in the 
caudal direction towards the hippocampal boundary (286). This migration is almost 
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exclusively gliogenic and gives rise to astrocytes and oligodendrocytes in the neocortex 
and white matter regions of the brain (287, 288). The ability of such precursor cells to 
continuously migrate, differentiate and replenish neuronal subpopulations makes them 
attractive candidates for therapeutic gene delivery in treating neurodegenerative 
diseases. 
Currently available techniques to label or manipulate various aspects of 
progenitor cell migration during postnatal neurodevelopment include injection of equine 
infectious anemia viruses or retroviruses packaging fluorescent transgenes directly into 
adult sub-ventricular zone; DNA analog mediated cell lineage tracking; cell type-specific 
promoters; transgenic mouse models; or immunohistological analyses (211, 289-292). 
In addition to these tools, different viral vectors derived from rabies virus, herpes 
simplex virus and lentiviruses have enabled efficient gene transfer to the mammalian 
central and peripheral nervous systems (110, 293, 294). Despite this broad spectrum of 
tools and reagents, targeted genetic manipulation of specific subsets of neuronal 
progenitors in vivo remains a daunting challenge.   
Migration and differentiation of neuronal precursors in the developing brain is a 
carefully orchestrated event. The cell surface biomarker, polysialic acid (PSA) is known 
to regulate neural plasticity and plays an indispensable role in embryonic and adult 
neurogenesis (210). In my first project, we reported a novel, engineered AAV4.18 that 
displays a switch in glycan receptor specificity from sialic acid (SA) to PSA and 
consequently, acquires the ability to target migrating progenitors in the developing brain. 
The new AAV strain spreads throughout the brain parenchyma following 
intracerebroventricular administration, but selectively transduces a subset of ependyma-
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derived neuroblasts in the subventricular zone, rostral migratory stream and olfactory 
bulb (295). Engineering viral tools to exploit molecular signatures could enable selective 
reprogramming of progenitors to understand and repair damaged CNS tissue.  
The engineered AAV4.18 strain has several possible applications. Packaging 
genome editing tools such as the CRISPR/Cas9 nucleases (296) within AAV4.18 can 
facilitate targeted ablation of genetic factors that drive neural stem cell recruitment and 
differentiation during development or trauma (288, 297, 298). For instance, ependymal 
cells lining the spinal canal have been shown to give rise to neuroblasts and astrocytes 
in response to stroke (298). Manipulating different mechanisms to maintain an 
undifferentiated quiescent state or activate normally quiescent cells in order to promote 
the expansion and migration of progenitors might enable lineage tracing (299). In 
addition, the highly selective tropism for migrating neuroblasts also make the 
engineered AAV4.18 strain a promising vector for manipulating the stem cell niche by 
overexpressing dominant negative transgene cassettes to model neurodevelopmental 
disorders (300) or deliver neural stem cell reprogramming factors (301, 302).  
For my second project, we evaluated a dual glycan binding AAV2g9 vector that 
harbors the ability to bind both HS and Gal on mammalian cell-surfaces. From the AAV 
biology perspective, our study provides new insights into the role of capsid-glycan 
interactions in determining CNS spread and systemic leakage. Earlier studies in our lab 
and others have demonstrated that the diverse cellular tropisms and biodistribution 
profiles of different AAV strains are intricately linked to their glycan receptor binding 
profiles (38, 172). For instance, intracranial injection of the heparan sulfate binding 
strain, AAV2 shows restricted, neuronal gene expression (71). This preferential 
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neuronal tropism of AAV2 appears to correlate with the higher concentration of heparan 
sulfate proteoglycans (HSPGs) on the surface of neurons compared to glia (42). 
 However, as a caveat to this neurotropic bias, the ability of AAV2 to bind HS with 
high affinity also restricts vector spread and the effective volume of CNS tissue 
transduced (89). In contrast, the galactose binding strain, AAV9, shows both neuronal 
and glial transduction as well as efficient CNS spread (55, 56). Consistent with the latter 
attributes, AAV9 capsids also appear to be prone to systemic leakage and transduction 
in the liver and other organs following CNS administration (94, 235, 246). In our current 
study, we demonstrated that the dual glycan binding AAV2g9 strain inherited traits from 
both parental AAV serotypes, i.e., neurotropism from AAV2 and robust CNS spread and 
transduction from AAV9. 
Our study demonstrates that the interplay between capsids and cell surface 
glycans can determine CNS spread and transduction efficiency of AAV vectors 
administered into the cerebrospinal fluid. However, it is also known that viruses can 
travel large anatomical distances within the CNS using synaptic connections or axonal 
transport (303, 304). Viral entry into the neuronal cell body (soma) leading to 
dissemination at the axonal projections represents anterograde transport, while the 
opposite scenario is termed retrograde transport. In this regard, AAV strains have been 
shown to employ axonal transport to undergo single or bidirectional movement within 
the brain parenchyma (112, 118, 120, 305). In particular, hep binding AAV2 particles 
have been shown to exclusively move in the anterograde direction (115), whereas sialic 
acid binding AAV1 or gal binding AAV9 particles appear to shuttle in both directions 
(117, 118, 120). Exactly how each glycan receptor influences the axonal transport of 
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different natural AAV isolates as well as engineered strains, such as the dual glycan 
binding strain AAV2g9 reported here remains to be determined. 
 From the vector development perspective, our studies have important 
implications for gene therapy, silencing and editing. First, it should be noted that the 
CNS transduction efficiency and systemic gene expression from a single ICV/IT dose of 
AAV9 is particularly striking. Although, not ideal for CNS-specific indications due to the 
systemic leakage profile, AAV9 could serve as an optimal vector candidate for treatment 
of lysosomal storage disorders and other such diseases, which are characterized by 
multi-organ involvement in addition to the CNS. On the other hand, AAV2g9 displays 
favorable attributes for therapeutic applications targeting neuronal populations within the 
CNS. Further, the features displayed by the engineered AAV2g9 strain exemplify the 
feasibility of making rational improvements to AAV vector design with the goal of 
imparting favorable biodistribution profiles. When combined with cell-specific elements 
such as the hSyn promoter, as established in the current study or miRNA targeting 
elements (235, 246), such approaches can help to efficiently restrict transgene 
expression to neuronal populations within the CNS and reduce systemic exposure. 
Crucially, we demonstrate that therapeutic delivery of gene editing nucleases using 
AAV2g9 helps mitigate the risk for off-target effects at the organ level. 
Conventional treatments for mental illnesses like attention deficit hyperactivity 
disorder (ADHD), bipolar disorder (BD) and schizophrenia (SZ) are exclusively designed 
to ameliorate psychosomatic symptoms. Interestingly, diseases like SZ and BD display 
strong genetic predispositions in patient cohorts (306). Understandably, devising the 
next generation of therapeutic interventions for such disorders requires development of 
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animal models with underpinning disease genetic signature. The AAV2g9 vector offers 
the unprecedented advantage of CNS contained CRISPR/Cas9 gene disruption using 
capsid engineering. As shown in Fig. 20, chapter 3, we demonstrate ~5% mutant allele 
formation in the brain using this approach. Understandably, future studies can be 
designed to achieve improvement of gene editing efficiency. The availability of smaller 
Cas9 species e.g. from Staphylococcus aureus offers the unique possibility of 
packaging both CRISPR endonuclease and the targeting gRNAs within the single AAV 
cassette. Such a strategy also offers the ability to perform targeted gene editing in any 
animal model and circumvents the need for using transgenic Cas9 mice. Nevertheless, 
optimization of the site(s) of CNS administration, AAV dosage and promoter usage; and 
use of self-complementary AAV cassettes are all viable targets to pursue for improving 
the gene editing efficiency with AAV2g9 in the CNS. 
In the third study, we studied glymphatic flux mediated by AQP4-water transport 
as an important parameter that governs various aspects of AAV gene transfer within the 
CNS. More importantly, animal testing of clinical conditions like traumatic brain injury 
(TBI) have revealed significant loss (~60%) in AQP4-mediated glymphatic water 
transport (270). Correspondingly, the risk of developing neurodegenerative disorders 
stemming from parenchymal aggregations of neurofibrillary tangles such as Alzheimer’s 
and dementia are significantly higher in the post-TBI demographic (278, 307-310). It is 
intriguing to speculate with our data that CSF administration of AAV vectors in post-TBI 
patient cohort, will display inherently reduced vector spread within the CNS.  
As shown in Figure 24, in chapter 4, the increase in viral residence within CNS 
also translated to enhanced gene transfer efficiency from CSF injections of AAV vectors 
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in AQP4-/- mice. Interestingly, a reverse phenotype was observed in case of 
transduction efficiency from parenchymal administration of AAV vectors (data not 
shown). Specifically, AAV9 administration into the neonatal mouse striatum transduces 
significantly smaller area within the AQP4-/- mouse. It is known that AAV9 successfully 
employs axonal transport in both retrograde and anterograde directions to travel long 
distances within the brain (118-120, 311). We speculate that under conditions of ablated 
CSF flux in the AQP4-/- brain, AAV vectors are unable to “hit” all the neuronal 
projections with the same efficiency, from a single parenchymal injection. Conversely, 
AAV2 is only able to travel in the anterograde direction in the CNS (114, 115). 
Supporting our hypothesis regarding the role of axonal transport, we do not see 
reduction in transduced area from intrastriatal injections of AAV2 within the AQP4-/- 
mouse cohort (data not shown). Taken together, ablation of AQP4 fluid flux negatively 
affects transduction of bidirectional axonal transporters like AAV9 possibly due to 
diminished levels of axonal transport. In future, studies with unidirectional transporters 
like AAV2 (anterograde) and AAV6 (retrograde), can further juxtapose the roles of CSF 
flux and axonal transport on AAV transduction within the CNS. 
In addition to viral spread, retention and transduction, we also proposed that 
AQP4 fluid flux plays a major role in systemic leakage of interstitial deposits such as 
AAV vectors. Accordingly, we saw a significant reduction of off-target biodistribution and 
gene expression in peripheral organs from intracranial administration of AAV9 vectors in 
the AQP4-/- mice (Fig. 25). To our knowledge, this is the first demonstration of AQP4 
fluid flux as the biological flushing mechanism that clears AAV vectors into the systemic 
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circulation/organs. Accordingly, in the absence of AQP4, AAV vectors are effectively 
contained within the CNS.  
Events like aging, neurological storage disorders and traumatic brain injuries can 
have direct implications on AQP4 function and therefore glymphatic solute clearance 
(270-273, 278). We believe that future preclinical evaluations of CNS gene therapy 
strategies can benefit from results obtained from predictive in vivo systems like AQP4-/- 
condition and aged mice. Additionally, biomarkers of CSF flux can be made an integral 
part in the recruitment process of patient candidates with neurological disorders towards 
therapeutic AAV gene transfer (279).  
The success of CNS gene therapy hinges on a thorough understanding of 
successes achieved and challenges faced during experimental, preclinical and clinical 
administrations of therapeutic gene transfer strategies. In this regard, although AAV 
vector mediated gene transfer in the CNS has demonstrated safe and successful 
replenishment of proteins, the efficacy of gene therapy reported in the last decade of 
clinical trials has not met the expectations of researchers and clinicians. There remains 
a critical need for predictive in vivo models of neurodegenerative disorders; establishing 
correlation between preclinical studies conducted in rodent and primate animal models, 
and recruitment of representative patient cohorts for clinical trials. Moving forward, it is 
particularly important to invest time and effort towards various aspects of AAV vector 
design, development of biomarkers and animal models to overcome the existing 
roadblocks. 
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